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ABSTRACT 
 
Increase in body temperature is a major factor limiting endurance performance in the 
heat and it is shown in this thesis that the effects of raised body temperature on 
performance, perception and neuroendocrine response to exercise are mediated by an 
interaction of body temperatures. Prolactin has been used as an indicator of 
hypothalamic activity and the pathways regulating its release have been investigated 
using pindolol as a 5-HT1A antagonist. The prolactin response to a buspirone 
challenge has been shown to be approximately 50% serotonergic and 50% 
dopaminergic, but with a wide inter-subject variation.  Passive heating is a potent 
stimulus for prolactin release and it was shown that 5-HT1A stimulation plays virtually 
no part in this process, raising the possibility that prolactin release during 
hyperthermic exercise may also be largely due to withdrawal of dopamine inhibition. 
A comparison of exercise tolerance in the heat and the sensitivity of central 
serotonergic and dopaminergic pathways further indicates the importance of 
dopamine in central fatigue. The action of caffeine in enhancing endurance 
performance has been shown not to involve the hypothalamus and this draws attention 
to other pathways that may be involved in central fatigue including the basal ganglia 
and limbic system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
It doesn't matter what temperature the room is; it's always room 
temperature.  
Steven Wright  - US comic
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Chapter 1 
 
Fatigue, Thermoregulation and the Brain 
 2
1.1 Fatigue during exercise 
 
Fatigue is defined in the Oxford English dictionary as; a) Lassitude or weariness 
resulting from either bodily or mental exertion; b) a condition of muscles, organs, or 
cells characterized by a temporary reduction in power or sensitivity following a period 
of prolonged activity or stimulation.  These two definitions correspond quite well with 
what, in the physiological world, have come to be known respectively as, central and 
peripheral fatigue.  Another term sometimes used is ‘objective fatigue’ (Layzer, 1998) 
which is seen as a deterioration of performance, either during a specific type of 
competition or as a task is repeated from one day to another. 
 
Edwards (Edwards, 1983) described the major possible causes of fatigue in relation to 
the chain of command for voluntary muscle activations (Figure 1.1). The separation of 
these possible causes into peripheral and central effects occurs at the level of the 
motoneurone.  A failure of transmission along the peripheral nerve, at the 
neuromuscular junction or within the muscle itself is therefore considered peripheral 
fatigue and is the main problem during short duration high intensity exercise. Many 
studies have addressed the biochemical mechanisms of peripheral fatigue and while 
the details have yet to be elucidated, there is broad agreement that the loss of force 
and power is due to decreased calcium release and slowing of cross bridge cycling 
consequent upon metabolic changes within the muscle fibre (Allen et al., 1995; Jones, 
1999). 
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Figure 1.1 The chain of command for voluntary contractions and the major causes for fatigue. From 
(Edwards, 1983). 
 
Endurance (i.e. the time to volitional fatigue) during exercise is negatively related to 
the exercise intensity during both dynamic and static contractions (Sahlin, 1992). The 
relationships are not linear but have a strong curvilinear appearance (Figure 1.2). 
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Figure 1.2 Estimated endurance time during cycle ergometry in relation to work intensity, from 
(Sahlin, 1992). 
 
1.1.1 Prolonged exercise 
 
The very short durations of exercise at intensities greater than 100% maximal 
oxygen uptake, are clearly limited by the inability of the muscle to supply energy 
at a sufficient rate to meet the demands and  will lead to peripheral failure.  
However, for exercise below 100% maximal oxygen uptake, the mechanism of 
fatigue is not so clear.  The energy demands are within the aerobic capacity of the 
body and, in theory, exercise should continue until the fuel supply is exhausted 
and, at low intensity, where energy is supplied mainly by fatty acid oxidation, this 
could continue for days.  At higher workloads in well-fed subjects, carbohydrate 
stores could support exercise for several hours.  When the stores of oxidative fuels 
are depleted, anaerobic sources will be called upon and metabolic failure will 
occur within minutes.  However these upper limits of endurance are achieved only 
by some individuals and in some circumstances, notably by experienced and 
trained subjects exercising at moderate intensities in cool conditions.  It appears, 
therefore, that there may be at least two mechanisms limiting submaximal 
exercise.  One is a peripheral mechanism related to the exhaustion of energy 
reserves, while the other is of less obvious origin. 
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1.1.1.1  Peripheral Fatigue 
 
At exercise intensities between 60 and 90% of maximal oxygen uptake, fatigue has 
been associated with depleted stores of muscle glycogen (Saltin & Karlsson, 1972). 
Depletion of muscle glycogen poses a metabolic problem for the muscle but it also 
puts a strain on the liver and, consequently, on blood glucose levels and 
hypoglycaemia also has a detrimental effect on exercise. Many studies have 
manipulated muscle glycogen content through diet. Elevation of pre-exercise muscle 
glycogen has generally been found to be of benefit only in events lasting longer than 
60-90 minutes where delays in fatigue of ~20% have been reported (Hawley et al., 
1997).    
 
Feeding carbohydrate during exercise is one way of counteracting the reduction in 
muscle and liver glycogen during exercise and maintaining blood glucose. This has 
been demonstrated to improve exercise performance and time to fatigue in a large 
number of studies, to the extent that the relationship between improved performance 
and carbohydrate feeding can be considered true (Jeukendrup & Jentjens, 2000).  
However even with carbohydrate feedings perceived exertion still increases during 
exercise, and fatigue cannot be delayed indefinitely. 
 
The hints and suggestions of central fatigue mechanisms during prolonged exercise 
under thermo- neutral conditions are much more evident when exercise is carried out 
in hot and/or humid conditions.  Perceived exertion is higher and fatigue occurs 
before carbohydrate levels become limiting (Galloway & Maughan, 1997, 2000) 
during exercise in the heat.  It is likely, therefore that fatigue during exercise in the 
heat is largely due to central factors whereas in cooler environments peripheral 
mechanisms of fatigue are more important (see section 1.3). 
 
1.1.1.2  Perceived exertion and central fatigue 
 
Whether we perceive exercise as easy or hard depends on many factors, only some of 
which are related to the physical or mental demands, while others depend on our 
interest and motivation.  The perceived difficulty of a task is continuously monitored 
and if this increases there is a natural tendency to reduce the demands by slowing 
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down or stopping.  The perception of muscular effort is not an absolute physical 
reality but something that is modulated by a multitude of internal and external factors.  
Internal factors may be the sensitivity with which afferent information is perceived 
and processed; external factors might include distractions, rewards or threats.  An 
example of heightened perception of exercise is the disorder of chronic fatigue 
syndrome whose suffers, in the extreme case, find even the mildest activity 
demanding and tiring and yet have no impairment of muscle function (Lloyd et al., 
1991; Gibson et al., 1993).  At the other extreme, highly motivated athletes competing 
for the highest prizes will endure conditions that most would find intolerable.  
 
These internal and external considerations seem to set the overall gain or sensitivity of 
the processes linking perception and motivation.  But, no matter what the absolute 
level of perception, all subjects report an increase in the perception of exertion as 
exercise continues even when the exercise is constant and apparently non-fatiguing, as 
judged by the signs that normally signify peripheral fatigue (e.g. Robertson, 1982; 
Borg et al., 1987; Robertson et al., 1990; Maw et al., 1993; Glass et al., 1994; Travlos 
& Marisi, 1996; Marvin et al., 1997; Garcin et al., 1998; Szmedra & Bacharach, 
1998; Held & Marti, 1999; Utter et al., 1999; Nielsen et al., 2001; Nybo & Nielsen, 
2001c). 
 
It would appear, therefore, that there is some factor that accumulates during exercise 
and increases the perception of exertion.  This factor, or factors, could be the 
accumulation of some metabolite or product of activity such as heat, it may be the 
summation of some constant signal, such as stretch of tendon organs, or an increasing 
signal from inflamed or damaged receptors in muscles, tendons or joints.  There is one 
further possibility, and that is the summation of feed-forward efferent drive from the 
motor cortex or from the cardiovascular and respiratory centres. 
 
Electrical stimulation was first used by Merton (1954) to determine whether it is 
possible to fully activate skeletal muscles by a voluntary effort and the technique of 
twitch superimposition or " twitch occlusion" was further developed for experimental 
and clinical applications by a number of groups (Bigland-Ritchie et al., 1978; 
Rutherford et al., 1986 and see Gandevia, 2001 for review).  Most of these studies 
have been concerned with high force isometric contractions, primarily because it is 
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technically difficult to stimulate and record from a muscle that is moving although 
James et al (1995) and Beelen et al (1995) managed to use the technique during 
isokinetic knee extension and cycling, respectively.   In these cases electrical 
stimulation was applied to the peripheral nerve or branches within the muscle which 
means that it is not possible to distinguish failure at the motoneurone from failure at 
high centres. 
 
The introduction of transcranial magnetic stimulation (TMS) has allowed the 
techniques to be safely extended to the motor cortex to assess muscle activation 
(Hollge et al., 1997).  Liepert et al (1996) compared TMS and peripheral electrical 
stimulations after fatiguing finger abduction exercise in controls and patients suffering 
from central nervous system (CNS) lesions and subjective fatigue.  The authors 
concluded that the fatigue resulting from the exercise could not be attributed to either 
intramuscular processes or to a reduced spinal excitability, but that it probably 
reflected a supraspinal, probably cortical, phenomenon.  Gandevia et al (1996) 
stimulated different levels of the motor pathway during prolonged fatiguing 
contractions.  They found no limitation to maximum voluntary contraction (MVC) 
occurred in the motor cortex, α–motoneurones or within the muscle fibres.  The one 
area that may be involved in the genesis of central fatigue during repetitive exercise is 
an inadequate neural drive ‘upstream’ of the motor cortex (Gandevia et al., 1996; 
Gandevia, 1999) although the cause of this inadequate drive is unknown (Taylor et 
al., 2000).  So far, studies using TMS, as with electrical stimulation, have 
concentrated on single muscle groups of the upper body primarily looking at high 
force contractions and have not been applied to prolonged exercise. 
 
Nybo & Nielsen (2001a) assessed the ability of subjects to maintain activation of 
voluntary isometric contractions following cycling exercise in thermoneutral and 
hyperthermic conditions and showed that hyperthermic subjects had difficulty fully 
activating their muscles.  Interestingly this difficulty applied both to the quadriceps, 
the major muscle group used in the exercise, but also to handgrip strength, which 
presumably was not heavily used.  This implies a global reduction in motor activation 
rather than specific inhibition of the working muscles. 
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A recent study looked at the effects of an ultramarathon (65 km) on neuromuscular 
function (Millet et al., 2002).  The authors found that both MVC and maximal 
voluntary activation decreased significantly after the ultramarathon and suggested that 
these changes were mostly due to central fatigue, possibly resulting from changes in 
intracortical excitability or some effect of afferent feedback from the muscle.   
 
Another technique that has been used to assess changes in the motor output of the 
brain with exercise is the measurement of brain EEG.  Several studies have looked at 
changes in activity during prolonged sub-maximal exercise (Kubitz & Mott, 1996; 
Nielsen et al., 2001; Nybo & Nielsen, 2001c) and found increases towards the end of 
exercise suggesting that a greater central drive was required to maintain the same 
motor output. 
 
Whilst it still remains difficult to obtain direct evidence of central fatigue during 
prolonged dynamic exercise, the evidence strongly suggests that, as exercise 
continues, a greater central effort is required to generate the same output from the 
motor cortex. This increased drive to the motor cortex may well impinge on 
consciousness, increasing the sense of effort through a feed-forward mechanism and 
eventually resulting in fatigue. 
 
1.1.1.3  Summary 
 
The literature suggests that fatigue during prolonged endurance exercise has a 
significant central component as is apparent during constant load exercise when 
perceived exertion increases steadily long before muscle glycogen or other causes of 
peripheral fatigue become limiting.  Central fatigue is unlikely to be the only cause of 
loss of performance in every situation since the relative importance of central and 
peripheral factors will vary with the type and intensity of exercise and the physical 
and psychological characteristics of the subjects.  It is evident, however, that central 
fatigue can be an important factor limiting performance and, moreover, the extent of 
the problem and the underlying mechanisms are poorly understood in comparison to 
peripheral muscle fatigue that has been the subject of considerable research over the 
last 50 years. 
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1.2 The neuroendocrine system and fatigue 
 
The inability to continue exercising in some circumstances may be due to a loss of 
central drive or motivation and changes in brain motor activity, as discussed above. 
The role of changes in central neurotransmission in fatigue and the loss of motivation 
during prolonged sub maximal exercise has recently become the subject of a great 
deal of interest. It was suggested by Newsholme and colleagues (1987) that changes 
in plasma amino acid concentrations could play a role in central fatigue by altering the 
synthesis, concentration and release of neurotransmitters and, in particular, 5-
Hydroxytryptamine (serotonin, 5-HT) in the brain.  Although Newsholme’s ideas 
about the role of fatty acids and branch chain amino acids regulating tryptophan entry 
into the brain have been largely discounted as a result of the careful experiments of 
Van Hall et al (1995) and Struder et al (1996b), his original idea that 5-HT has a role 
to play in the genesis of central fatigue still excites considerable interest (see section 
1.2.1.3 below) 
 
5-HT is not the only neurotransmitter that is of interest in central fatigue. A possible 
role of dopamine (DA), which is heavily involved in motor control, has recently 
arisen and there is increasing evidence to support this idea.  
 
To establish a clear role of 5-HT/DA in a fatigue of a central nature during prolonged 
exercise a number of tests might be applied: 
(i) Do brain 5-HT/DA concentrations and activity change during exercise in such 
a way that they could produce a central fatigue? 
(ii) Do manipulations of brain 5-HT/DA activity alter exercise performance? 
(iii) Do differences in brain 5-HT/DA activity that occur between individuals 
reflect differences in exercise ability? 
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1.2.1 The serotonergic system and exercise 
 
Interest in 5-hydorxytryptamine (serotonin) as a neurotransmitter dates from 1953 
when Gaddum (1953) found that lysergic acid diethylamide (LSD) acted on 5-HT 
receptors in peripheral tissues and suggested that its central effects may likewise be 
due to a serotonergic action. 5-HT is known to have a multitude of actions within the 
brain.  It is involved in the control of arousal, sleepiness and mood (Jacobs & Fornal, 
1993) and might therefore be linked to fatigue during prolonged exercise, possibly 
through an inhibitory influence on motor neurones.  An increase in voluntary drive 
necessary to overcome this inhibition would result in an increased perception of 
effort.  Conversely, there is evidence that an increase in serotonin in certain areas of 
the brain is beneficial to exercise (Jacobs & Fornal, 1993).  It is also interesting to 
note that there is a substantial evidence to suggest that 5-HT also plays a role in the 
control of thermoregulation (see section 1.4). 
 
1.2.1.1  Central serotonergic pathways 
 
Serotonergic neurones are widely distributed throughout the brain. The earliest maps 
of serotonergic neurones and fibres were produced using the formaldehyde-induced 
fluorescence method and, together with newer methods such as autoradiography, have 
given a good understanding of the extent of the serotonergic projections within the 
brain.  In their pioneering studies, Dahlstrom and Fuxe (1964) described nine 5-HT 
containing cell groups in the rat CNS, which they designated B1-B9.  The largest 
collection of 5-HT neurones is found in the dorsal raphe nuclei in the lower brain stem 
and in humans is estimated to contain about 165,000 cells which have projections to 
all areas of the brain (Figure 1.3).  5-HT neurons concentrated in the midline raphe 
nuclei in the pons and medulla project diffusely to the cortex, limbic system, 
hypothalamus and spinal cord. 
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Figure 1.3 5-HT neurones and major pathways in the brain. The location of the main groups of cells 
bodies and fibre tracts is in solid black. Light shaded areas show the location of serotonergic terminals. 
(Am – Amygaloid nucleus; C – cerebellum; Hip – hippocampus; Hyp – hypothalamus; Sep – septum; 
SN – substantia nigra; Str – striatum; Th – thalamus.) 
 
There are a number of receptor subtypes that mediate the central and peripheral 
actions of 5-HT.  There are seven types of receptor (5-HT1-7) with further subtypes 
(A-D) of 5HT1 and 5HT2.  5-HT1 receptors occur mainly in the CNS and, in the case 
of 5-HT1D, in some blood vessels (see Table 1.1). The general actions of the 5-HT1 
receptor group are neural inhibition and vasoconstriction.  5-HT2 and 5-HT3 receptors 
occur in greater number outside the CNS than do the 5-HT1 group and the effects of 
these groups are generally excitatory (see Table 1.1). 
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Receptor Location Main Effects 
1A CNS Neuronal inhibition 
Behavioural effects: sleep, feeding, 
thermoregulation, anxiety 
1B CNS Presynaptic inhibition 
Behavioural effects 
1D CNS 
Blood vessels 
Cerebral vasoconstriction 
Behavioural effects: locomotion 
2A CNS 
PNS 
Smooth Muscle 
Platelets 
Neuronal excitation 
Behavioural effects 
Platelet aggregation 
Smooth muscle contraction 
Vasoconstriction / vasodilatation 
2B Gastric Fundus Contraction 
2C CNS 
Choroid plexus 
CSF secretion 
3 PNS (GI tract) 
CNS 
Neuronal excitation 
Emesis 
Behavioural Effects: Anxiety 
 
Table 1.1 5-HT1/2/3 receptor subtypes and their main effects. For more detail see (Barnes & Sharp, 
1999). 
 
The precise localisation of the 5-HT neurons in the brain has allowed their electrical 
activity to be studies in detail. From this it has been found that in vertebrates certain 
behavioural and physiological functions relate to 5-HT pathways, namely: various 
behavioural responses; control of mood and emotion; control of sleep/wakefulness; 
control of sensory transmission; control of body temperature, (Rang et al., 1999). 
 
1.1.1.2  Control of 5-HT synthesis and release 
 
Serotonin is an indolealkylamine whose chemical designation is 3-(2-
aminoethyl)indol-5-ol, but usually goes under the name 5-hydroxytryptamine (5-HT).  
The chemical structure of 5-HT closely resembles that of its precursor the amino acid 
tryptophan (TYP).  5-HT is synthesised from TYP in a two step process catalysed by 
the enzymes tryptophan hydroxylase and aromatic L-amino acid decarboxylase 
(Figure 1.4) 
 
A number of control mechanisms regulate 5-HT synthesis and some involve 
alterations to the active state of tryptophan hydroxylase.  There is considerable 
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evidence that an increase in the rate of firing of serotonergic neurones leads to an 
increase in the activity of this enzyme.  Conversely a suppression in firing rate 
through the action of somatodendritic 5-HT1A autoreceptors has been shown to be 
consistent with a reduction in the Vmax of tryptophan hydroxylase (Fernstrom et al., 
1990).  There is no real evidence of a direct inhibitory action of 5-HT itself on the 
enzyme. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Synthesis and catabolism of serotonin. Serotonin (5-HT) is synthesised from tryptophan in 
two enzyme-catalysed steps by the enzymes tryptophan hydroxylase and aromatic L-amino acid 
decarboxylase. Serotonin is initially catabolised by the enzyme monoamine oxidase to 5-
hydroxyindoleacetaldehyde, which is rapidly converted to 5-hydroxyindolacetic acid by the enzyme 
Aldehyde dehydrogenase. The cofactors for each enzyme are also shown. 
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The regulation of 5-HT release by inhibitory autoreceptors is similar to that which 
occurs with many neurotransmitters.  5-HT neurones possess both somatodendritic 
and presynaptic autoreceptors.  Somatodendritic autoreceptors suppress cell firing, 
probably through hyperpolarization, and are also thought to have a role in collateral 
inhibition of 5-HT neurones (Aghajanian, 1981).  This leads to reductions in 5-HT 
synthesis and release in the areas to which the neurones project.  Presynaptic 
autoreceptors are not thought to influence cell firing but do inhibit 5-HT release 
(Sawada & Nagatsu, 1986), probably by altering some aspect of the neurotransmitter 
stimulus-secretion coupling.  Whether activation of presynaptic autoreceptors inhibits 
5-HT synthesis is still uncertain (Sawada & Nagatsu, 1986). 
 
5-HT autoreceptors seem to respond to chronic changes in extracellular 5-HT. 
Repeated administration of 5-HT reuptake inhibitors has been shown to cause a 
functional desensitisation of both autoreceptor types (Chaput et al., 1986; Moret & 
Briley, 1990). 
 
Under resting conditions there may be little role for these autoreceptors since 5-HT is 
rapidly removed by the synaptic reuptake system (Wolf & Kuhn, 1990).  However the 
autoreceptor system may well come into play with the behavioural and physiological 
changes that occur during exercise and other challenges. 
 
Termination of the effects of 5-HT release is mainly through an active reuptake 
process.  This process is saturable, Na+ dependent and requires ATP (Graham & 
Langer, 1992), it is specific for 5-HT selectively and can therefore be inhibited by a 
number of drugs such as the reuptake inhibitors used in the treatment of depression. 
 
In the nervous tissue 5-HT is broken down to 5-hydroxyindoleacetic acid (5-HIAA) 
that is considered to be the primary metabolite of 5-HT.  In this two-step process 5-
HT is first converted to 5-Hydroxyindoleacetaldehyde through oxidative deamination 
and then oxidised (Figure 1.4). 
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An obvious rate-limiting step in the formation of any compound is the availability of 
its precursors.  Studies in rats have shown that under normal conditions tryptophan 
hydroxylase is not saturated with TYP (Fernstrom & Wurtman, 1971).  This is 
strongly supported by studies that have shown that increasing TYP availability 
increases both the synthesis and release of 5-HT both in animals (Lookingland et al., 
1986; Diksic et al., 1991; Westerink & De Vries, 1991) and humans (Gillman et al., 
1981).  
 
1.2.1.3  5-HT and exercise  
 
Brain serotonergic activity changes with exercise. In vivo electrophysiological studies 
of serotonergic neurones have found that firing rates of the dorsal raphe neurones in 
animals are regular and highest when they are awake and walking on a treadmill and 
almost completely abolished during REM sleep (Jacobs & Fornal, 1993).   
 
Newsholme and colleagues (1987) first suggested that during prolonged exercise the 
increased brain serotonergic activity might produce lethargy and a loss of drive and 
motivation to exercise, thereby producing a central fatigue (discussed in greater detail 
below, section 1.2.1.3). This idea is supported by the observations that serotonergic 
pathways project into the brain limbic system which is associated with motivation and 
fatigue (Jacobs & Azmitha, 1992) and increases in brain 5-HT can have effects on 
arousal, lethargy, sleepiness and mood linked to altered perceptions of effort (Young, 
1986). The original mechanism that Newsholme and colleagues (1987) proposed 
related to changes in peripheral amino acid concentrations affecting brain TYP 
concentration and subsequently 5-HT synthesis (see section 1.2.1.3b) and since this 
time there has been a growing interest in the role of 5-HT in central fatigue. 
 
1.2.1.3a Changes in brain 5-HT with exercise 
 
To support a role for 5-HT in fatigue during prolonged exercise it is necessary to 
observe increases in brain 5-HT activity and concentrations and this can only be 
carried out directly in animals.  Numerous studies in rats have shown exercise-
induced increases in brain 5-HT at fatigue (see Chaouloff, 1989; Meeusen & De 
Meirleir, 1995) and there is growing (albeit indirect) evidence to suggest that 
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increases in brain 5-HT activity occurs in humans during prolonged exercise (Struder 
& Weicker, 2001b). 
 
5-HT is a prominent excitatory neurotransmitter for PRL release (Struder & Weicker, 
2001a) and changes in PRL levels in the blood have therefore been used as a marker 
for changes in central 5-HT activity.  Data from a range of human and animal studies 
suggests that the serotonergic neurones of the dorsal raphe nuclei project to 
hypothalamic sites to stimulate prolactin (PRL) secretion (see Figure 1.5) through 
activation of 5-HT receptors (Van de Kar et al., 1996).  However PRL release is also 
under the control of dopaminergic neurones (Figure 1.5) and so care must be taken 
when interpreting changes in PRL as an indicator of changes in central 5-HT activity. 
 
There have been many studies of the effects of exercise on blood PRL concentrations 
in humans (Frewin et al., 1976; Brisson et al., 1981; Christensen et al., 1985; De 
Meirleir et al., 1985b; Smallridge et al., 1985; Brisson et al., 1986; Brisson et al., 
1987; Luger et al., 1988; Melin et al., 1988; Brisson et al., 1989; Knudtzon et al., 
1989; Saini et al., 1990; Brisson et al., 1991; Ferrari et al., 1991; Luger et al., 1992; 
Boisvert et al., 1993; Kraemer et al., 1993; Struder et al., 1996a; Struder et al., 1996b; 
Elias et al., 1997; Struder et al., 1997; Pitsiladis et al., 1998; Bridge et al., 1999; 
Struder et al., 1999; de Vries et al., 2000; Vigas et al., 2000).  The common finding 
being that blood PRL concentrations increase with prolonged exercise, although this 
increase is, to some extent, dependent on the intensity of the exercise.   
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Figure 1.5 Control of prolactin release from the anterior pituitary gland (after Feldman et al., 1997).  
Serotonergic pathway activation exerts a stimulatory effect on release, whereas dopaminergic 
tuberohypophyseal pathway activation inhibits release. 
5-HT neurones project from the raphe nuclei to central hypothalamic areas and the hypothalamus, 
thereby inducing 5-HT dependent prolactin release through activation of 5-HT1A and/or 5-HT2A/2C 
receptors (Van de Kar et al., 1996).  Receptor activation results in the secretion of prolactin releasing 
factors (PRF) into the perivascular spaces of the primary capillary plexus of the hypothalamic-
hypophyseal portal system.  These PRF then travel to the anterior lobe of the pituitary and act on 
lactotrophs to stimulate prolactin secretion. 
DA is also released from the axons of the tuberohypophyseal pathway into the perivascular spaces of 
the primary capillary plexus and travels to the anterior pituitary gland where to acts on lactotrophs to 
inhibit PRL secretion.  Numerous other substances also affect prolactin release to a lesser degree (e.g. 
oestrogen, thyroid hormones, vitamin D and glucocorticoids). 
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Brisson and colleagues (1981) found exercise at 55% maximal oxygen uptake to 
reduce serum PRL concentrations whilst bouts of exercise at 70% and 85% of 
maximal oxygen uptake both increased serum PRL.  This is in agreement with the 
findings of Luger and colleagues (1988; 1992) who found no increase in serum PRL 
at 50%, a slight increase at 70% and a large increase at 90% maximal oxygen uptake.  
It is interesting to note that the apparent threshold of around 70-75% maximal oxygen 
uptake is similar to that considered necessary to increase the concentration of TYP in 
the brain (Struder et al., 1997).  
 
It has been suggested that PRL release is related to anaerobiosis and lactate formation 
(De Meirleir et al., 1985a; Luger et al., 1992).  The first of these studies (De Meirleir 
et al., 1985a) reported that one-hour of sub-maximal cycle ergometry at a workload at 
which blood lactic acid remained below 4mmol.l-1 was accompanied by a decrease in 
plasma PRL levels.  However PRL levels were shown to increase promptly and 
significantly when the anaerobic threshold was reached in a maximal exercise test (De 
Meirleir et al., 1985a).  The exercise intensity resulting in a blood lactate level below 
4mmol.l-1 corresponded to an oxygen uptake of 44-55% of maximal so in view of 
previous reports (Brisson et al., 1981; Luger et al., 1988; Luger et al., 1992) it is not 
surprising that PRL was not released at this intensity. Luger and colleagues (1992) 
have also looked at the role of lactic acid accumulation in PRL release during 
exercise.  Exercise-induced levels of PRL were not achieved by L-lactate infusion at 
doses resulting in similar blood lactate concentrations to those seen at 70 and 90% 
maximal oxygen uptake.  The authors therefore suggested that while lactate cannot be 
totally excluded it does not appear to play a major role. 
 
1.2.1.3b Manipulating brain 5-HT during exercise through diet 
 
Tryptophan, the precursor of 5-HT, is an essential amino acid that must be supplied in 
the diet.  Since the administration of TYP has been shown to alter both the synthesis 
and release of 5-HT, it might be expected that manipulation of TYP in the diet would 
lead to changes in 5-HT metabolism.  However when fasted rats were given a meal 
that increased the level of TYP in the plasma, brain tryptophan and 5-HT 
concentrations did not rise (Fernstrom & Wurtman, 1972).  Further experiments found 
this to be due to competition for a blood-brain barrier transporter (the L-system) that 
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TYP shares with a group of amino acids called the large neutral amino acids (LNAA) 
including the branched chain (BCAA) amino acids, valine, leucine and isoleucine.  
The rate-limiting step in the synthesis of 5-HT may be the transport of TYP across the 
blood-brain barrier and when TYP is given in combination with other amino acids 
competition prevents the extra TYP from entering the brain.  Hence it is not only the 
concentration of TYP in the blood stream that is important, but also the BCAA, which 
make up roughly 75% of the LNAA, that determines TYP transport into the brain 
(Figure 1.6).  
 
Another important factor regulating the transport of TYP into the brain is that TYP is 
the only amino acid that binds to plasma albumin and an equilibrium between bound 
and free TYP (f-TYP) exists (Figure 1.6).  At rest only about 10% of TYP is free in 
the plasma and it is thought that the concentration of f-TYP governs the rate of uptake 
into the brain.  This idea is supported by studies in animals that have shown a 
relationship between f-TYP and the concentration of TYP in the brain, whilst no such 
relationship has been shown for total plasma TYP concentration.  
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Figure 1.6 Effects of prolonged exercise on plasma concentrations of free tryptophan (f-TYP) free fatty 
acids (FFA) and branched chain amino acids (BCAA). TYP binds to Albumin (A) in competition with 
FFA.  Increases in plasma FFA with prolonged exercise results in FFA binding to albumin (A) 
displacing TYP and increasing the plasma f-TYP concentration. This along with reductions in plasma 
BCAA results in an increased f-TYP/BCAA ration and increases in blood brain TYP transport and 5-
HT synthesis (after Davis & Bailey, 1997). 
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The concentration of f-TYP in the plasma during exercise is mainly influenced by 
changes in plasma free fatty acids (FFA) which are also transported bound to albumin 
and compete for the same binding site. A release of FFA from adipose tissue during 
exercise results in an increase in plasma FFA which can displace TYP from albumin 
thereby elevating plasma f-TYP concentration (Figure 1.6).  Several factors such as 
hormonal levels, a low blood glucose and reduced muscle glycogen content at the 
start of exercise are known to stimulate the release of FFA from adipose tissue. As a 
result of these changes, and a reduction in plasma BCAA due to muscle BCAA uptake 
(van Hall et al., 1996), an increase in the f-TYP/BCAA ratio is found after exercise 
and a recent study by Strüder et al (1997) suggests that increases in the ratio during 
prolonged (~5 hour) exercise may be dependent upon exercise intensity. An increase 
in the ratio was found during the final hours of exercise at 75% of maximal oxygen 
uptake whereas no significant elevation in the ratio was found at 50% of maximal 
oxygen uptake.  
 
If the mechanism described above does regulate TYP entry into the brain and thus the 
synthesis of 5-HT then manipulation of the f-TYP/BCAA ratio during exercise should 
influence the onset of fatigue (Figure 1.6).  Several studies have looked at the effects 
of feeding BCAA during exercise to maintain a low f-TYP/BCAA ratio and have 
claimed improvements in performance (Blomstrand et al., 1991; Blomstrand et al., 
1997; Mittleman et al., 1998) although there are doubts about the experimental design 
in some cases.  Blomstrand et al., (1991) looked at two groups of male subjects 
running a marathon. One group was given 16g of BCAA in four separate aliquots 
during the race whilst the control group received only water. In addition to this the 
subjects were allowed any other drink provided during the race (including 
carbohydrate drinks). No difference was found in marathon times between groups 
unless the subjects were divided into groups of fast and slow runners. This resulted in 
a small but significant reduction in marathon time in slow runners. Problems that arise 
with this study are: (i) the BCAA and control groups were not matched for marathon 
performance; (ii) the carbohydrate intake and nutritional status should have been 
controlled and should have been the same in each group; (iii) the arbitrary division of 
runners in to fast and slow groups based upon a set marathon time is not an acceptable 
statistical procedure.  Also in the same study no effect of BCAA supplementation was 
found in cross-country runners participating in a 30km race.  In the other study by 
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Blomstrand et al (1997) seven cyclists were given a either a BCAA drink containing 
90mg.kg body weight-1 (6-8g) of BCAA or a flavoured placebo during one hour of 
cycle ergometry at 70% of maximal oxygen uptake followed by 20 minutes at 
maximum.  The evening before the ride the subjects performed a bout of exercise to 
reduced muscle glycogen levels. This was to achieve amore rapid rise in f-TYP during 
the test the following morning.  The authors found that ratings of perceived exertion 
and mental fatigue were lower during exercise with BCAA supplementation when 
compared to placebo.  However the authors did not look at the effects of the BCAA 
supplementation on exercise time to fatigue and used only the amount of work done in 
the 20 minutes of maximal exercise as a measure of performance and found no 
differences between trials.  Additionally, lowering muscle glycogen levels the 
previous day may have affected muscle metabolism so that BCAA could have been 
used as an additional fuel (Wagenmakers et al., 1989; Weicker & Stobel, 1994).  
 
The third of these studies (Mittleman et al., 1998) was carried out during exercise in 
heat. The authors found that time to exhaustion increased from 137 to 153 minutes 
with BCAA supplementation.  However the exercise intensity used in this study was 
very low (40% maximal oxygen uptake) whereas it has been suggested that intensities 
near 75% maximal oxygen uptake are where significant increases in the f-TYP/BCAA 
ratio occur (Struder et al., 1997).  
 
In contrast to the studies discussed above, others have found no positive effects on 
performance (Wagenmakers & van Hall, 1995; Struder & Weicker, 2001b).  In one 
such study attempts were made to both increase and decrease TYP entry into the brain 
(Struder et al., 1996b).  To increase the f-TYP, an oral soy oil solution was given to 
elevate plasma triglycerides, followed by an infusion of heparin during exercise which 
liberates FFA, increasing f-TYP and thus the f-TYP/TYP ratio. To decrease TYP 
entry LNAA were infused to prevent the decline in plasma LNAA, usually seen with 
exercise and thus maintain the plasma f-TYP/LNAA (BCAA) ratio compared to the 
placebo trial. However, in neither instance was there any significant difference 
between trials in perceived exertion or plasma PRL and subjects completed the 90 
minute exercise period in both trials.  
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It is interesting to note in this study that in the early stages of the exercise significant 
increases in plasma FFA, f-TYP and f-TYP/LNAA ratio did not increase plasma PRL 
concentration. However at the end of exercise when athletes were beginning to fatigue 
(90 minutes running) plasma FFA, f-TYP and f-TYP/TYP ratio were similar to those 
at the start and yet plasma PRL was significantly increased.  These results indicate 
that whatever role TYP uptake has to play, some other mechanism must play the 
major part in the regulation of PRL release. 
 
Another strategy used to manipulate the f-TYP/BCAA ratio during exercise is to feed 
BCAA together with carbohydrate.  It is well known that the ingestion of 
carbohydrates during exercise can delay fatigue, probably by maintaining blood 
glucose levels and the supply of energy when muscle glycogen levels are low.  
However, it is possible that carbohydrates may also affect central fatigue by altering 
the f-TYP/BCAA ratio.  The intake of carbohydrates before or during exercise 
reduces that exercise-induced increase in plasma FFA (Jeukendrup et al., 1999) 
probably by stimulating insulin secretion, which is known to inhibit lipolysis (Snow et 
al., 2000).  Additionally, carbohydrate ingestion delays the rise in plasma FFA and the 
rise in f-TYP during sustained exercise although, if exercise continues for longer than 
2-3 hours, there is an increase in the plasma concentration of FFA and f-TYP whether 
or not carbohydrates are consumed (Davis et al., 1992; McConell et al., 1999).  
Several studies have investigated the effect of BCAA and carbohydrate on exercise 
and found no difference in performance between the ingestion of BCAA with 
carbohydrates and carbohydrates alone (Blomstrand et al., 1995; Davis et al., 1999; 
van Hall et al., 1995).  The latter authors also question whether f-TYP is as important 
to the transport process as is generally supposed and point out that the ammonia 
production associated with the metabolism of large doses of BCAA may itself cause 
problems since ammonia is known to be very toxic. 
 
The final way to alter the f-TYP/BCAA ratio is through the ingestion of TYP which 
would be expected to reduced performance.  Van Hall et al (1995) found no effect of 
TYP ingestion on exercise to exhaustion at 70-75% maximal oxygen uptake, although 
the reproducibility of the exercise times to exhaustion in this study was very large.  
Other studies that have given TYP before exercise have found contrasting results 
(Segura & Ventura, 1988; Stensrud et al., 1992).  In the first of these studies twelve 
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male subjects ran to exhaustion at 80% maximal oxygen uptake either with or without 
TYP supplementation (Segura & Ventura, 1988).  Subjects were given 300mg of TYP 
the night before, at breakfast, lunch and one hour before the test to increase brain TYP 
levels.  Unexpectedly exercise time to fatigue was increased by 49.4% after TYP 
administration and this was accompanied with lower ratings of perceived exertion.  In 
the second study (Stensrud et al., 1992) twenty-four male subjects ran to exhaustion at 
100% maximal oxygen uptake. In the TYP trial they were given 240mg the night 
before the test, 360mg in the morning, 240mg at lunch and 360mg one hour prior to 
the test. However no change in time to exhaustion was found between trials.  
 
One practical difficulty with experiments attempting to manipulate brain 5-HT 
synthesis by diet or infusion, is that there seems to be a reduced control of central 5-
HT synthesis by TYP during exercise (Chaouloff et al., 1987).  A second conceptual 
problem is to assume that a global increase in TYP or 5-HT will have a single 
behavioural outcome.  As emphasised before, 5-HT pathways are widely distributed 
throughout the brain and whilst some may be involved with inhibition, others may 
well be beneficial in facilitating motor output during exercise (Jacobs & Fornal, 
1993).   
 
1.2.1.3c Effects of Drugs 
 
There are a wide range of drugs which affect 5-HT metabolism or action.  Some of the 
best known are the monoamine oxidase inhibitors which were the first 
pharmacological treatment to be developed for depression.  As their name implies 
they inhibit the first step in 5-HT breakdown and thus, presumably, increase brain 
levels.  More recently popular interest has centred on drugs such as Prozac, selective 
5-HT re-uptake inhibitors (SSRI), which are the newer drugs used to treat depression.  
In general, drugs that work presynaptically alter the synthesis, metabolism or reuptake 
of the transmitter while post-synaptic actions can be as full agonists, partial agonists 
or antagonists.   
 
5-HT re-uptake inhibitors, given acutely, have been shown to increase fatigue and/or 
perceived exertion during exercise in humans (Wilson & Maughan, 1992; Davis et al., 
1993; Struder et al., 1998). Blockade of 5-HT reuptake by SSRI treatment increases 
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synaptic 5-HT concentrations and thereby stimulates many behavioural and 
physiological adaptations mediated by the transmitter.  
 
Wilson & Maughan (1992) were the first to use the SSRI paroxetine and reported a 
decrease in time to fatigue which they attributed to an increase in serotonergic 
activity. They did not measure PRL which is thought to be indicative of hypothalamic 
5-HT activity.  A more recent study, using time to fatigue as the end-point, involved 
ten male cyclists with, and without, administration of 20mg of paroxetine.  Time to 
exhaustion was significantly reduced after paroxetine administration (Struder et al., 
1998) but surprisingly there was no difference in PRL release between placebo and 
paroxetine treatments.  It is possible that a single low dose (20mg paroxetine) of the 
SSRI used in both these studies may have had a 5-HT antagonist effect through 
activation of inhibitory 5-HT1A autoreceptors (Artigas et al., 1996) of the pathway 
controlling PRL release. 
 
Two studies have used 5-HT agonists or antagonists to alter brain serotonergic 
activity during exercise (Marvin et al., 1997; Meeusen et al., 1997). Meeusen and 
colleagues  (Meeusen et al., 1997) used the 5-HT2A/2C receptor antagonist ritanserin 
during exercise to fatigue at 65% of the maximal aerobic power output.  The authors 
gave 0.3mg.kg-1 of ritanserin or a placebo twenty-four hours, and immediately, before 
the test but no differences were found in time to fatigue between trials and prolactin 
was not measured.  The other study to pharmacologically alter brain 5-HT in humans 
during exercise used the 5-HT1A receptor agonist buspirone (Marvin et al., 1997).  
Subjects exercised to fatigue at 80% of maximal oxygen uptake after ingesting 
buspirone (45mg) or a placebo one hour prior to exercise.  Ratings of perceived 
exertion and plasma PRL during exercise were increased after buspirone ingestion 
whilst time to fatigue was reduced.  This study provides the only clear evidence so far, 
in humans, that alteration in central 5-HT activity, as shown by change in plasma 
PRL, result in changes in exercise tolerance. 
 
Whilst the human experiments in this area are rather limited, there is a large volume 
of work carried out on animals which shows that the pharmacological modulation of 
central 5-HT activity influences fatigue during endurance exercise.   For example, 
application of quipazine dimaleate (5-HT agonist), m-chlorophenylpiperazine (5-
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HT2/2C receptor agonist) and LY-53,857 (5-HT antagonist) respectively reduced and 
increased endurance, while xylamidene tosylate, a 5-HT antagonist with only a 
peripheral action, had no effect (Bailey et al., 1993a, b; Davis, 1995).  
 
1.2.1.3d Effects of training status 
 
Several studies have reported differences in measures of 5-HT function between 
trained and sedentary individuals. Reduced resting PRL concentrations have been 
found in male distance runners and endurance athletes compared to sedentary controls 
(Wheeler et al., 1984; Weicker & Struder, 2001).  Six weeks of endurance training led 
to a reduced resting PRL (Marvin et al., 1999a) and other authors have found reduced 
resting PRL after 3 weeks of moderate training (Weicker & Struder, 2001).  In 
contrast, other studies have not found changes in resting prolactin levels after training 
(Hurley et al., 1990; Pitsiladis et al., 1999; Dwyer & Flynn, 2002) or between trained 
and sedentary individuals (Pitsiladis et al., 1999). 
 
The azapirone derivative, buspirone, has a high affinity for 5-HT1A receptors (Eison & 
Temple, 1986) and has been widely used to probe serotonergic function in humans, 
acting as a neuroendocrine challenge (Meltzer et al., 1983; Anderson & Cowen, 1992; 
Bakheit et al., 1992; Jakeman et al., 1994; Sharpe et al., 1996; Bridge et al., 2001).  
The technique involves giving the agonist and following the appearance of PRL in the 
blood over the next 2-3 hours. 
 
Jakeman and colleagues (1994) found elite endurance athletes to have a decreased 
sensitivity (reduced PRL response) to a 5-HT1A agonist challenge with buspirone 
which they suggested might be a training adaptation associated with increased 
exercise tolerance in these individuals.  This was not, however, found by Pitsiladis 
and colleagues using the same 5-HT1A agonist (Pitsiladis et al., 1999).  Contrasting 
findings to those of Jakeman (1994) have also been shown in a study that looked at 
postsynaptic 5-HT2 function using d-fenfluramine (Strachan & Maughan, 1999). 
These authors found no difference in the PRL response to drug administration 
between trained and untrained subjects.  A recent study by Marvin and colleagues 
(1999a) found that the PRL response to buspirone was not altered after training, and 
Dwyer and Flynn, (2002) came to a similar conclusion. 
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Although the evidence seems to be against a training-induced effect on the 
neuroendocrine response to a buspirone challenge the major reservation about all 
these studies  is that although significant improvements in aerobic fitness were seen 
the levels reached were well below those of the elite endurance athletes studied by 
Jakeman and colleagues (1994) (maximal oxygen uptake 43±5 (Pitsiladis et al., 1999) 
; 50±8 (Marvin et al., 1999a) & 45±3 (Dwyer & Flynn, 2002) compared with 74±1 
ml.kg.min-1 (Jakeman et al., 1994)).  It may be that it requires far longer and more 
rigorous training to modify the serotonergic pathways involved in PRL release.  
 
Strachan and Maughan (1998) hypothesised that one way in which the synaptic 
concentration of 5-HT could be reduced through training is through an increase in 
number or activity of neuronal 5-HT transporters.  They measured platelet 5-HT 
transporter density in red blood cells and found the density was greater in endurance 
trained males compared to sedentary controls.  Whether this peripheral measure 
reflects central 5-HT transport density and whether such differences in transporter 
density would be sufficient to affect synaptic 5-HT clearance remains to be seen. 
 
At the opposite end of the spectrum to elite athletes are patients suffering from 
chronic fatigue syndrome, which includes post viral fatigue syndrome, and seriously 
affects aerobic exercise capacity (Maffulli et al., 1993).  Such patients have been 
found to have a greater sensitivity to buspirone than healthy controls (Bakheit et al., 
1992; Sharpe et al., 1996; Sharpe et al., 1997).  A recent single case study of a patient 
suffering from CFS who substantially recovered over a period of 18 months found 
that as exercise tolerance increased, and subjective measures of fatigue and anxiety 
improved, the response to buspirone returned to the normal range, having been very 
high when first examined (Sharma et al., 2001).  
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1.2.1 The dopaminergic system and exercise  
 
It was not until the late 1950s that dopamine (DA) was shown to be present in the 
brain. DA is both a precursor for adrenaline and noradrenaline as well as having its 
own explicit functions within the body and is thought to constitute as much as 80% of 
the total brain catecholamine content.  In rats an intimate relationship has been shown 
between DA production and all aspects of motor behaviour, speed, and posture (Freed 
& Yamamoto, 1986) and an influence of a decrease or increase in brain DA function 
can be correlated with exercise capacity in rats (Heyes et al., 1985).  Changes in brain 
DA with exercise should also be considered in relation to DA linked behavioural 
responses such as motivation and emotion (Scheel-Kruger & Willner, 1991). 
 
1.2.2.1  Central dopaminergic pathways 
 
In their classic mapping of the brain Dahlström and Fuxe (1964) designated 
noradrenaline and dopamine cell groups with the letter A and the current 
nomemclature spans A8-A15.  Dopamine containing cells are found in relatively 
rostral parts of the brain (i.e., the midbrain, hypothalamus, and olfactory bulbs; Figure 
1.7).   
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Figure 1.7 DA neurones and major pathways in the brain. The location of the main groups of cells 
bodies and fibre tracts is in solid black. Light shaded areas show the location of serotonergic terminals. 
(Ac – Nucleus accumbens; Am – Amygaloid nucleus; C – cerebellum; Hip – hippocampus; Hyp – 
hypothalamus; P – pituitary gland; Sep – septum; SN – substantia nigra; Str – striatum; Th – thalamus.) 
 
Dopamine neurones form three main systems within the brain (Figure 1.7). These are; 
the nigrostriatal pathway, with the cell bodies in the substantia nigra and the axons 
terminating in the corpus striatum; the mesolimbic/ mesocortical pathway whose cell 
bodies occur in groups in the midbrain and project to parts of the limbic system, 
nucleus accumbens, the amygdaloid nucleus and to the cortex; and, finally, the 
tuberohypophyseal system which is a group of neurones with axons that run from the 
hypothalamus to the pituitary gland, the secretions of which regulate PRL. 
 
Two types of dopamine receptor (D1 and D2) were originally distinguished by 
pharmacological and biochemical techniques and further subtypes (D1-D5) have been 
revealed by gene cloning. The distribution and function of these receptors is shown in 
Table 1.2.  The receptors are grouped into two main families D1 and D2 which have 
their actions linked to stimulation and inhibition of adenylate cyclase respectively. 
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  D1 type D2 type 
  D1 D5 D2 D3 D4 
Distribution Functional Role      
Cortex Arousal, mood ++ - ++ - - 
Limbic system Emotion, 
stereotypic 
behaviour 
+++ - +++ + + 
Basal ganglia Motor control ++ + +++ + + 
Hypothalamus Autonomic and 
endocrine control 
++ + - - - 
Pituitary gland Endocrine control - - +++ - - 
Action  Mainly postsynaptic 
inhibition 
Pre- and postsynaptic 
inhibition 
Stimulation/inhibition of 
hormone release 
 
Table 1.2 DA receptor subtypes and the functions, + indicates degree of importance (Rang et al., 1999). 
 
The functions of the dopamine pathways divide broadly into three categories; motor 
control (nigrostriatal system), behavioural effects (mesolimbic and mesocortical 
systems), endocrine control (tuberohypophyseal system) 
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Figure 1.8 Synthesis and metabolism of dopamine. Dopamine (DA) is synthesised from tyrosine in two 
enzyme catalysed steps by the enzymes tyrosine hydroxylase and aromatic L-amino acid 
decarboxylase. The cofactors for each, tetrahodrobiopterin, Fe2+ ,O2 and pyridoxal phosphate, are also 
shown.  Dopamine is metabolised to homovanillic acid (HVA) through oxidative deamination with 
monoamine oxidase (MAO) or with O-methylation by catechol-O-methyltransferase (COMT).  The 
cofactors fro each enzyme are also shown flavin adenine dinucleotide (FAD), S-adenosyl-methionine 
(SAM), and Mg2+. 
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Aromatic L-amino 
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1.2.2.2  Control of DA synthesis and release 
 
The rate-limiting step in the biosynthesis of dopamine is the hydroxylation of tyrosine 
(TYR) to dihydroxyphenylalanine (DOPA) by the enzyme TYR hydroxylase (Figure 
1.8).  Activity of this enzyme can be inhibited by catecholamines suggesting a 
feedback inhibitory mechanism. DOPA is decarboxylated to dopamine by the enzyme 
dopa-decarboxylase.  In normal physiological conditions dopamine is first 
metabolised to 3,4-dihydroxyphenylacetic acid (DOPAC) by monoamine oxidase and 
aldehyde oxidase. DOPAC is further metabolised into homovanillic acid by catechol-
O-methyltransferase (see Figure 1.8). 
 
As in the serotonergic system, there are presynaptic dopaminergic autoreceptors, 
activation of which inhibits both dopamine synthesis and release (Feldman et al., 
1997).  The somatodendritic dopamine autoreceptors cause a reduction in cell firing 
which in turn causes a reduction in release in terminal areas (Santiago & Westerink, 
1991). 
 
1.2.2.3  DA and exercise 
 
1.2.2.3a Changes in brain DA with exercise 
 
Recent advancements in positron emission tomography (PET) scanning are starting to 
allow the measurement of changes in brain neurotransmitters in humans pre and post 
exercise. One such study found no change in brain DA concentration 5-10 minutes 
after 30 minutes of treadmill exercise (Wang et al., 2000) although it would have been 
more interesting had the exercise been continued to fatigue.  
 
DA neurones are critical components of the motor system, there are a number of 
studies of the effects of exercise upon the dopamine synthesis and metabolism in 
animals (see Meeusen & De Meirleir, 1995). Most studies find an increase in brain 
DA and/or DOPAC levels during exercise but when animals are taken to fatigue 
decreased or unchanged brain DA/DOPAC levels were found in the hypothalamus 
(Meeusen & De Meirleir, 1995).  Hoffmann et al (1994) found decreased DA and 
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DOPAC levels in the limbic forebrain at exhaustion suggesting a decreased level with 
no change in turnover. 
 
Bailey et al., (1993a) found elevated levels of brain DA and DOPAC in rats after one 
hour of exercise but which then decreased, returning to resting levels at fatigue. 
Administration of quipazine dimaleate, a general 5-HT agonist, blocked the increase 
after one hour and LY53857, a 5-HT antagonist, prevented DA and DOPAC decrease 
at fatigue. The authors point out that there is clearly an interaction between 
serotonergic and dopaminergic pathways during exercise.   
 
Bailey et al (1992) have argued that the effects of 5-HT activity on fatigue may be 
through the impairment of DA synthesis and this may be mediated by increased levels 
of 5-HT. This idea is based on the finding that the 5-HT1C agonist m-
chlorophenylpiperazine (m-cpp) reduced brain DA and DOPAC in rats exercising to 
fatigue. Support for this idea comes from the work of Spaminato et al (1985) who also 
showed that the 5-HT agonist m-cpp reduces DA synthesis in rats. 
 
Heyes et al (1988) suggested that time to exhaustion in rats is influenced by the 
activity of nigrostriatal dopaminergic neurones, and that central dopaminergic activity 
modulates performance. A possible dopaminergic pathway linking the limbic cortex 
and pre-motor areas, through the limbic striatum and sensorimotor striatum has been 
suggested by Smith and Bolam (1990).  They envisage that the limbic brain may 
‘gate’ information through the sensorimotor striatum, linking emotion and motivation 
with motor control. The existence of such a pathway suggests that DA may play a role 
in central fatigue through a coupling of motivation and motor control. 
 
1.2.2.3b Effects of drugs 
 
Heyes et al., (1985) administered the dopamine agonist apomorphine to rats with 6-
hydroxydopamine (destroys DA nerve terminals) induced lesions of the central 
dopaminergic pathways to determine the influence of central dopaminergic activity on 
exercise.  Lesioned rats, without apomorphine administration, ran for a shorter time 
before exhaustion than control rats, while administration of apomorphine resulted in 
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lesioned rats running significantly longer than control rats.  The authors suggest that 
increasing central dopaminergic activity increases time to fatigue. 
 
Increases in brain TYR have been shown to affect TYR hydroxylase activity (Carlson 
& Lindquist, 1978) and augmented neuronal dopaminergic responses to TYR have 
been shown to occur in previously activated neurones (Sved, 1983).  Strüder et al., 
(1998) administered 10mg of L-TYR, the precursor of dopamine, to endurance trained 
cyclists before exercise to exhaustion at a workload that resulted in a blood lactate 
concentration of 2mmol.l-1. No changes were found in endurance times between trials 
although plasma PRL was significantly elevated above resting and placebo levels after 
30 minutes of exercise following TYR administration. It might have been expected 
that an increase in brain DA would lead to a reduction in blood PRL concentration 
through increased inhibition of secretion.  A reduction in PRL has previously been 
seen in rats injected with TYR (Sved et al., 1979) however this only occurred after 
prior activation of DA neurones by reserpine administration (reserpine blocks 
neuronal DA reuptake and storage) and other studies support the idea that TYR 
administration only enhances DA release from activated neurones (Sved, 1983). Since 
PRL release was enhanced after DA administration in the experiments of Strüder et 
al., (1998) other factors may have reduced dopaminergic neural activity during 
exercise. One factor could have been 5-HT as there is a suggestion that 5-HT can 
influence fatigue through inhibition of the DA system during exercise (Bailey et al., 
1993a).  
 
Intracerebral infusion of the DA precursor L-DOPA has been shown to enhance motor 
activity in rats (Vogt, 1973) and is well known for its beneficial effects on motor 
activity in Parkinson's patients.  Meeusen et al., (1997) administered L-DOPA to male 
subjects before exercise to fatigue at 65% of the workload corresponding to maximal 
oxygen uptake.  L-DOPA was given in combination with carbidopa (4mg.kg-1) which 
prevents peripheral decarboxylation of L-DOPA.  Time to exhaustion did not differ 
from that of the placebo trial. The dose used had previously been shown to increase 
plasma and brain DA level in rats (Sarre et al., 1992) although whether this also 
applies to humans is unknown. There is some evidence that although L-DOPA was 
given in conjunction with a peripheral decarboxylation inhibitor in this study, at least 
some partial peripheral metabolism of L-DOPA occurred since there were higher 
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plasma DA levels after L-DOPA administration. Whether there was a significant 
effect of administration on central DA levels is unclear. 
 
More direct manipulation of brain DA can occur through administration of 
amphetamines. Amphetamines have been shown to be potent brain DA releasers 
(Adams et al., 2002) and re-uptake inhibitors (Azzaro et al., 1974) and increase 
exercise capacity in humans (Wyndham et al., 1971; Chandler & Blair, 1980; Laties 
& Weiss, 1981).  It is possible that there may be an additional peripheral effect of 
amphetamines, however no differences in maximal oxygen uptake or heart rate have 
been found in humans (Wyndham et al., 1971). 
 
Caffeine is well known to improve exercise capacity in humans (Graham & Spriet, 
1995).  Though the mechanisms for this improvement are not clear.  It was originally 
thought that caffeine led to a shift in substrate metabolism away from carbohydrate 
towards fat oxidation and glycogen sparing, but this seems largely to have been 
disproved (Graham et al., 2000).  There is the possibility that as caffeine acts as a 
calcium releasing substance in muscle in vitro may have a similar action on muscle in 
vivo.  (Wiles et al., 1983) found no evidence for an action of aminophylline, a more 
potent methyl xanthine, affecting either the contractile properties or fatigability of 
human muscle in vivo. There have, however, been reports of caffeine improving 
stimulated muscle performance in tetraplegics patients which supports a peripheral 
action (Mohr et al., 1998). Caffeine is known to cross the blood brain barrier and the 
possibility exists that its action may have a large central component.  Caffeine has 
been shown to have a major protective effect against the development of dopamine 
depletion related Parkinson’s symptoms in human populations (Ross et al., 2000a; 
Ross et al., 2000b; Ascherio et al., 2001; Ross & Petrovitch, 2001) and in 
experimental animal models (Ross & Petrovitch, 2001).  In trials that have shown 
improvements in exercise capacity and performance with caffeine ingestion it may 
well be that this is the result of an enhanced brain DA activity. 
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1.2.2.3c Effects of disease and training 
 
It has been suggested that the predominance of African middle and long distance 
runners is related to differences in their DA systems compared to Caucasians (Gilbert, 
1995) although the evidence for this is sketchy at best. More direct evidence for DA 
being important in motor control and performance comes from Parkinsonian patients. 
In the early 1960s investigators started to find that there was a depletion of DA 
neurones in post mortem brain tissues of patients with Parkinson’s disease (see 
Hornykiewicz & Kish, 1986 for review).  These large losses (>80%) were found to be 
in all DA cell groups in the brain but particularly in the substantia nigra pars compacta 
(Feldman et al., 1997).  The classic symptoms of the disease include resting tremor, 
bradykinesia, rigidity and postural disturbances that are largely attributed to the 
damage to DA innervation in the neostriatum, which forms a complex loop between 
the basal ganglia and the neocortex (Feldman et al., 1997).  Although the basal 
ganglia itself does not initiate motor commands it plays a critical role in co-ordinating 
and synchronising such commands and is important for the execution of smooth, co-
ordinated and repetitive movements.  Parkinson's patients report increased sense of 
effort or fatigue during motor tasks (Ziv et al., 1998) and it has been suggested that 
this is a consequence of patients having to use other pathways to effect complex 
motor commands, a little like learning a new skill, every time a routine movement is 
carried out (Berardelli et al., 2001). Administration of the DA precursor levodopa (L-
DOPA) produces a reduction in symptoms (Shan et al., 2001) and about 20% of 
patients are restored to normal motor function, at least in the early years of the 
disorder. 
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1.2.3 Interaction between 5-HT and DA in fatigue and during exercise 
 
In the work reviewed so far concerning serotonergic and dopaminergic systems there 
have been a number of suggestions that they may interact in regulating motor activity, 
and there are numerous studies which have addressed this point.  In general it appears 
brain 5-HT increases and DA decreases at fatigue (Meeusen & De Meirleir, 1995) and 
it has been suggested that this is more than coincidence and implies some reciprocal 
control and interaction of the two systems (Spampinato et al., 1985; Meltzer, 1992; 
Ferre et al., 1994; Huttunen, 1995; Wong et al., 1995; Iyer & Bradberry, 1996; Kapur 
& Remington, 1996; Howell et al., 1997; Thorre et al., 1998). It has been suggested 
that a major site of these interactions is the serotonergic dorsal raphe nuclei (Thorre et 
al., 1998). 
 
Davis & Bailey, (1997) have hypothesised that central fatigue is the result of changes 
in the ratio of 5-HT and DA.  They suggest that a low 5-HT/DA ratio favours 
improved performance, through increased arousal, motivation and optimal muscular 
coordination, whilst increased in the 5-HT/DA ratio results in decreased performance. 
This latter mechanism would constitute a central fatigue.  
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1.3 Fatigue during exercise in the heat 
 
Many studies have shown that high ambient temperatures reduce exercise capacity in 
man and increase ratings of perceived exertion (e.g. Febbraio et al., 1996; Galloway 
& Maughan, 1997; Nybo & Nielsen, 2001c). Except when carried out at low intensity 
or in cold conditions, endurance exercise is associated with a steady increase in core 
temperature that can be detrimental to performance.  To combat this increase in 
temperature the body activates several thermoregulatory responses to dissipate the 
heat. 
 
A redistribution of blood to the skin occurs to facilitate heat loss and it is possible that 
this may divert blood away from the working muscles (Fink et al., 1975).  However, 
there is both indirect and direct evidence that this is not a serious problem.  If blood 
supply to working muscles was restricted they would be working under potential 
anaerobic conditions and this should be evident as a high blood lactate, but there is no 
such evidence of metabolic crisis.  Blood lactate, although tending to be higher than 
when working in cool conditions, does not show any large or rapid increase as 
subjects fatigue in the heat (Galloway & Maughan, 1997).  
 
It is possible that excessive sweating coupled with inadequate fluid intake may lead to 
dehydration and reduced blood flow (Gonzalez-Alonso et al., 1998). However, the 
reduction in muscle blood flow that is seen does not cause fatigue by compromising 
muscle metabolism or oxygen delivery to the active muscle (Gonzalez-Alonso et al., 
1999a) since the oxygen extraction by working muscles increases to compensate for 
the reduced flow. 
 
The influence of temperature on enzymic rates (Q10 effect) is well known and it is 
possible that exercise in the heat may increase metabolic rate and the rate of 
carbohydrate depletion.  Fink et al., (1975) were the first authors to demonstrate an 
effect of temperature on substrate utilisation. They found increased glycogen usage 
during one hour of intermittent exercise at 41°C compared to the same exercise at 
9°C.  Since this time other authors have found that exercise in the heat results in 
increased intramuscular carbohydrate oxidation compared to cooler environments 
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(Febbraio et al., 1994a; Febbraio et al., 1994b; Hargreaves et al., 1996; Galloway & 
Maughan, 1997). This increase in oxidation appears only to be present during 
submaximal exercise and if a marked increase in body temperature occurs (see 
Febbraio, 2000). Increased carbohydrate oxidation and glycogen depletion might lead 
to earlier fatigue but, Galloway & Maughan, (1997) calculated the total carbohydrate 
oxidation during exercise to fatigue at different ambient temperatures and found the 
total was lowest (90±6g) at fatigue during exercise at 31°C compared to trials at 4°C 
(168±20g), 11°C (166±19g) and 21°C (149±11g).  Clearly depletion of endogenous 
carbohydrate stores cannot be the explanation of the more rapid fatigue seen in the 
heat. 
 
Whilst some effect of redistribution of blood and increased carbohydrate oxidation 
cannot be ruled out it has been suggested that the major factor limiting exercise in the 
heat is body temperature itself (Bruck & Olschewski, 1987).  An upper limit to core 
temperature has been described at which athletes fatigue (Nielsen et al., 1993; Nielsen 
et al., 1997; Gonzalez-Alonso et al., 1999b) for reasons that are not related to 
metabolic or cardiovascular changes.  This suggestion arises from the observation that 
during exercise in the heat, fatigue occurs at a relatively fixed core temperature and 
the duration of exercise can be prolonged or shortened by respectively reducing or 
raising core temperature before the start of exercise.  The time to fatigue is thereby 
determined by the time it takes for core temperature to reach the critical temperature 
(Lee & Haymes, 1995; Teller et al., 1998; Gonzalez-Alonso et al., 1999b). 
 
Recently, Nybo and Nielsen, (2001a) have shown that subjects made hyperthermic by 
exercise in the heat were unable to fully activate their quadriceps and that this effect 
was accompanied by changes in their electroencephalogram.  These observations add 
weight to the suggestion that raised core temperature gives rise to central fatigue 
rather than affecting peripheral muscle function (Nielsen et al., 1997; Nybo et al., 
2001; Nybo & Nielsen, 2001b, a, c). 
 
Nybo and Nielsen, (2001b) found reductions in middle cerebral artery blood flow with 
hyperthermia and fatigue in the heat.  The same authors (Nybo & Nielsen, 2001c) also 
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looked at brain EEG activity during exercise in the heat and found a strong correlation 
between core temperature, brain EEG activity and perceived exertion.   
 
Hirata et al., (1987) found that ratings of perceived exertion during handgrip exercise 
in hyperthermic conditions were reduced by facial fanning and this also increased 
time to fatigue.  The fanning had no effect on oesophageal temperature while 
tympanic temperature was reduced.  It is most unlikely that fanning had any effect on 
peripheral muscle metabolism, suggesting a central action.  Further support for a 
central temperature-related component of fatigue in the heat comes from a study by 
Marvin et al., (1999b).  They found that cooling the head by fanning and spraying 
water reduced the perception of exertion and increased time to fatigue, during cycle 
ergometry at 31°C suggesting that core temperature may not be the only aspect of 
body temperature that is important.   
 
There is, therefore, strong evidence to suggest that the cause of fatigue in the heat is 
related to high core temperatures leading to changes in brain activity and increases in 
perceived exertion.  It is of particular interest to see how this mechanism may be 
related to the changes in serotonergic and dopaminergic pathways discussed in 
previous sections.   
 
1.3.1 Neuroendocrine responses to exercise and heat 
 
There are few studies that have looked at the direct effects of hyperthermia on 5-HT 
and DA activity.  Hyperthermia is generally found to increase rat brain 5-HT 
concentrations (Mohamed & Rahman, 1982; Sharma & Dey, 1987; Sharma et al., 
1992; Dey et al., 1993) and, likewise DA has been found to increase in the rat 
striatum (Zhao et al., 2001) and hypothalamus (Kao et al., 1994; Hasegawa et al., 
2000).  
 
It is possible to assess human brain activity in response to hyperthermia by indirect 
means, such as following the release of neuroendocrine hormones.  Passive heating 
has been shown to stimulate PRL release (Mills & Robertshaw, 1981; Christensen et 
al., 1985) and blood PRL concentrations have been reported to be linearly related to 
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core temperature during exercise (Brisson et al., 1986; Melin et al., 1988).  PRL 
levels remain low and relatively unchanged during exercise at around 70% maximal 
oxygen uptake at cool ambient temperatures, however blood levels rise 4-5 fold 
towards the point of volitional fatigue during exercise in the heat (around 35oC), 
which typically occurs between 30 and 60 minutes in reasonably fit young subjects 
(Pitsiladis et al., 1998).  It has been suggested that one of the main stimuli for 
increases in PRL release during exercise is a thermic stress (Brisson et al., 1986) and 
PRL release has been shown to be more clearly related to heat stimuli than changes in 
other possible releasing factors such as β-endorphin, vasoactive intestinal peptide or 
thyrotropin (Brisson et al., 1991).  The greater release of PRL in hot environments is 
indicative of changes in central hypothalamic activity responding to raised circulating 
blood temperature.  However core temperature may not be the only factor controlling 
PRL release since skin temperature rises in hot environments and cooling the head 
and face during exercise has been found to attenuate PRL responses as wells as 
ratings of perceived exertion (Brisson et al., 1989; Marvin et al., 1999b). 
 
Increases in blood PRL concentration with passive exposure and exercise in the heat 
may be due to changes in either, or both, 5-HT and DA.  Changes in brain levels of 
both have been reported (see above) but there is a conundrum in that whilst increases 
in 5-HT activity is known to stimulate PRL release, increased DA is generally 
regarded as being inhibitory and there are clearly complex interactions between the 
pathways controlling thermoregulatory responses and those involved in PRL release 
and, possibly, central fatigue. 
 42
1.4 Thermoregulatory control 
 
Animals have two basic strategies for dealing with excessive heat loads, the first is 
behavioural thermoregulation in which the animal seeks to minimise or avoid the 
source of the heat.  This is a fundamental response and can seen at every level of 
evolution from unicellular organisms moving away from heat, to amphibians and fish 
seeking cooler water, to mammals seeking shade and cool water to drink. The neural 
networks involved probably evolved long before autonomic thermoregulation.  
Evidence of behavioural thermoregulation can be seen in experiments in which the 
POAH is lesioned. These lesions have been shown to impair autonomic 
thermoregulation but do not prevent an animal from performing an operant response 
to maintain a constant body temperature.  Rats with lesions of the POAH that are 
placed in a cold chamber will press a bar to turn on a heat lamp (Carlisle, 1969) and 
those in a warm environment will turn on a fan (Satinoff & Rutstein, 1971). It must 
also be remembered that an important source of heat is physical exercise and, while 
muscle may be more efficient than many mechanical devices, still about 75% of the 
energy appears as heat.  Reducing the level of physical activity is an important 
component of behavioural thermoregulation.   
 
The second form of thermoregulation, autonomic thermoregulation, is largely under 
the control of pathways located in the preoptic area and anterior hypothalamus 
(POAH).  This involves the activation of thermoregulatory heat loss and heat gain 
mechanisms (e.g. sweating, vasodilatation, shivering) in response to changes in body 
temperature. The POAH is at least one area in the brain that integrates behavioural 
and autonomic thermoregulation. 
 
1.4.1 The preoptic area and anterior hypothalamus 
 
The importance of the POAH in thermoregulation has been demonstrated in many 
studies largely carried out on animals.  Satinoff, (1964) showed that rats would press a 
bar to provide heat when the POAH is cooled directly by an implanted thermal probe. 
Conversely, if hypothalamic temperature is raised rats have also been shown to turn 
on a fan to provide cooling or to press a bar to cool the temperature of water perfusing 
a hypothalamic thermonode (Corbit, 1969).  These studies support the notion that 
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hypothalamic temperature is a most important factor in subjective thermal comfort.  A 
recent study in humans using PET scanning has shown that in response to whole body 
heating a significant increase in hypothalamic metabolism occurs (Nunneley et al., 
2002), providing some indirect evidence of an increased neuronal activity.  
 
The POAH contains many thermosensitive neurones that detect changes in internal 
temperature and initiate the appropriate thermoregulatory responses.   Preoptic 
warming of anaesthetised animals has been shown to induce panting (Hellstrom & 
Hammel, 1967; Jacobson & Squires, 1970; Boulant & Gonzalez, 1977), sweating 
(Schonung et al., 1971), increase skin blood flow (Jacobson & Squires, 1970; 
Schonung et al., 1971) and, in non anaesthetised animals, it elicits behavioural 
changes that increase heat loss (Adair, 1977).  These responses, and those that are 
related to heat conservation and production mechanisms, are subject to a classic error-
system feedback control in which the temperature of the POAH is compared to a set 
point and appropriate adjustment of heat loss and heat gain are made in response to 
the error signal.  
 
The POAH is populated by temperature sensitive neurones. The response of these 
neurones to changes in POAH temperature and skin temperature has been studied in 
individual neurones using microelectrodes to record changes in firing rate activity.  
The hypothalamic sensitivity of thermoregulatory responses is the change in response 
for each degree change in POAH temperature away from the set point (Boulant, 1981, 
Figure 1.9a). The hypothalamic thermosensitivity of a single neurone is the slope of 
the change in POAH temperature against the impulses per second that a neurone fires 
(Figure 1.9b). 
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Figure 1.9 a) Hypothalamic sensitivity of a thermoregulatory heat loss response or the change in that 
response for every degree change in POAH temperature above the set point.  b) Hypothalamic 
thermosensitivity of a warm-sensitive neurone. The different lines indicate different skin temperatures 
and how they affect the response. 
 
There are two types of temperature sensitive neurone located in the POAH; warm-
sensitive and cold-sensitive.  About 30% of POAH neurones are sensitive to warm 
temperatures; they increase their firing rates in response to increases in TPOAH and 
decrease when TPOAH decreases.  Generally a hypothalamic neurone must have a 
sensitivity of at least 0.8 impulses per second per degree Celsius to be considered 
warm-sensitive (Boulant, 1981). Many warm-sensitive neurones have a threshold, or 
set point temperature, and are only thermosensitive over a certain temperature range.  
A very small (often <5%)  proportion of POAH neurones are classified as cold-
sensitive (Boulant, 2000). These cold-sensitive neurones increase their firing rate as 
POAH temperature falls and decrease as temperature rises.  A hypothalamic neurone 
must have a negative thermosensitivity of at least –0.6 impulses per second per degree 
Celsius to be considered cold-sensitive (Boulant, 1981). In addition to these 
temperature sensitive neurones there are other neurones that are temperature 
insensitive and these make up the majority of hypothalamic neurones (>60%). The 
temperature insensitive neurones tend to fire at a very slow rate and show little change 
in their firing rate in response to changes in TPOAH.  The majority of local excitatory 
and inhibitory inputs within the POAH come from these temperature insensitive 
neurones which may provide tonic synaptic input to ‘interneurones’ such as the cold-
sensitive neurones shown in Figure 1.10.  Such ‘interneurones’ may compare synaptic 
inputs from temperature insensitive neurones and inputs from temperature-sensitive 
neurones and in this way may appear to be warm or cold-sensitive. 
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Single-unit studies have shown that the temperature sensitive neurones of the POAH 
receive a large afferent input from cutaneous thermoreceptors and from deep body 
thermoreceptors, such as those in the spinal cord (Boulant & Hardy, 1974). Cutaneous 
thermoreceptors are stimulated when the skin is warmed or cooled and this afferent 
information ascends through the anterolateral tract of the somatosensory system. A 
major pathway in this system is the lateral spinothalamic tract which conveys 
information to various nuclei in the brain stem reticular formation.  From here this 
somatosensory information is relayed to the thermosensitive neurones of the POAH. 
In this way the rostral hypothalamus serves as an integrator of thermal information 
comparing peripheral and central temperature information. The integration of thermal 
information from the cutaneous thermoreceptors is an important factor determining 
subjective comfort in humans (Frank et al., 1999).  In one study that recorded thermal 
comfort while core and skin temperatures were altered independently, it was found 
that core and skin temperature contributed equally to thermal comfort whilst core 
temperature predominated in the autonomic regulation of thermoregulatory responses 
of vasodilation and reduced heat production (Frank et al., 1999).  
 
Despite the evident importance of the hypothalamus there is some evidence from 
clinical studies of patients with hypothalamic lesions that reflex thermoregulatory 
pathways can function independently of the hypothalamus (Johnson et al, 1990) and 
this is in keeping with suggestions that the hypothalamus may not receive peripheral 
temperature information (Berner & Heller, 1998).  These authors concluded that 
consideration should be given to integration of skin temperature lower in the 
neuroaxis. Their idea is supported by studies in patients with spinal cord injuries who 
have the ability to respond to changes in skin and core temperature even though there 
is no afferent feedback to the brain (Downey et al., 1976; Huckaba et al., 1976; Attia 
& Engel, 1983) although the control of body temperature involved was not as precise 
as in intact subjects.  
 
Areas other than the hypothalamus have also been found to be thermosensitive. One 
of these is the midbrain through which peripheral thermoreceptors send afferent 
information to the POAH via the reticular formation. The neurones of the midbrain 
have been shown to be sensitive to changes in temperature (Hori & Harada, 1976; 
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Sato, 1984).  Many years of studies using brain lesions led Boulant, (1996) to 
conclude that no single neural area acts as the thermoregulatory control centre. Instead 
there seems to be a hierarchy of structures extending through the hypothalamus, brain 
stem and spinal cord.  The brain stem and spinal cord are capable of crudely sensing 
body temperature changes and implementing some thermoregulatory responses but 
when the POAH is included, temperature is regulated more precisely and the CNS is 
more sensitive to changes in central and peripheral temperature (Boulant, 2000).  
Interestingly, neurones in the midbrain can respond to changes in hypothalamic 
temperature, suggesting that the POAH can send information back to the brain stem 
(Sato, 1984). This pathway through the median forebrain bundle to the lower brain 
stem has been shown to be important in transmitting effector signals to areas 
controlling changes in skin blood flow (Kanosue et al., 1994).  
 
These observations have lead to the suggestion that thermal information is integrated 
at various levels of the neuroaxis in a hierarchically organised fashion; spinal cord, 
brain stem and hypothalamus. Presumably an integrator exists at each of these levels 
receiving input and transmitting output signals.  The hypothalamus is the highest of 
these centres and the question arises as to how it organises the various thermal inputs 
it receives in order to activate the thermoregulatory responses to heat and cold. 
 
Numerous neuronal models have been proposed to explain how the CNS can maintain 
a balance between heat production and heat loss.  The first model was presented by 
Hammel, (1965) who suggested that it is the comparison of excitatory and inhibitory 
synaptic inputs from warm-sensitive and temperature insensitive neurones that 
provides the basis for responses to changes in body temperature.  Our current 
understanding is based on the model of Boulant (Figure 1.10, Boulant, 1996). 
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Figure 1.10 The neuronal model of thermoregulation proposed by Boulant (Boulant, 1996) in which 4 
types of thermosensitive neurones are depicted: warm (W) neurones (a, b and c) and cold (C) neurons 
and in addition temperature insensitive neurones (I). 
 
The model consists of 4 different types of thermosensitive neurones; three are warm-
sensitive (W) and one is cold-sensitive (C), together with temperature insensitive 
neurones (I). Warm sensitive neurone ‘a’ has a low spontaneous firing rate and 
responds only when the animal is hyperthermic. It is postulated that these neurones 
are most likely to control heat loss (sweating or panting).  The low firing rate is 
attributed to inhibition from peripheral cold-receptors and/or limited input from 
peripheral warm-receptors. Warm-receptors labelled ‘b’ vary their firing frequency in 
a range around normal hypothalamic temperature and are most likely to control skin 
blood flow and behavioural thermoregulatory responses.  These neurones receive 
moderate inputs not only from ascending sensory pathways but also have links to the 
limbic system.  This linkage is potentially very important for understanding central 
fatigue as it provides a link between the central processing of thermal information and 
the higher centres controlling emotions, behaviour and learning.  Interestingly it also 
provides a pathway linking skin blood flow to emotional state (e.g. “hot and bothered” 
and flushing under emotional stress).  Warm-sensitive ‘c’ neurones have the highest 
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firing rates, attributed to the fact that they receive the largest afferent excitatory input 
and may have a greater sensitivity to endogenous factors including testosterone and 
estradiol, osmolality, decreased glucose etc.  Because they have such a high firing 
rate, it is unlikely that they would increase their firing rate during hypothalamic 
warming and Boulant (1996) suggests that these neurones act primarily to inhibit 
cold-sensitive neurones, and therefore inhibit shivering and non-shivering 
thermogenesis. 
 
The major part of the peripheral input to the POAH impinges on neurones ultimately 
controlling heat production rather than heat loss.  Cold-sensitive neurones receive 
direct input from cutaneous cold-receptors and indirect input from cutaneous warm-
receptors through warm-sensitive neurones (c).  The latter neurones inhibit POAH 
cold-sensitive neurones. Thus with a cold skin, cold-sensitive neurones are doubly 
activated because of positive input from cutaneous cold-receptors and the removal of 
negative input from cutaneous warm-receptors.  This model fits well with studies of 
animals and humans showing that changes in skin temperature are 2 to 3 times more 
effective in activating heat production than heat loss (Benzinger & Kitzenger, 1963; 
Hellstrom & Hammel, 1967).  
 
Most of the local excitatory and inhibitory inputs within the POAH come from 
temperature insensitive neurones and their function is not at all clear.  The 
temperature sensitive neurones may not fire spontaneously, but could be driven by the 
temperature insensitive neurones, one of which is shown in Figure 1.10 innervating a 
cold-sensitive neurone.  The output neurones (a, b, c plus the cold sensitive neurone in 
Figure 1.10) would thus be driven tonically by temperature insensitive neurones and 
their output modulated by hypothalamic temperature and direct and indirect inputs 
from peripheral warm and cold receptors. 
 
If the hypothalamus controls thermoregulatory responses as suggested by Boulant, 
(1996) and illustrated in Figure 1.10, then it would be expected that changing the 
temperature of the hypothalamus and/or skin would not only affect thermoregulatory 
responses but also the ability or desire to exercise, as part of the behavioural response. 
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Isolated heating and cooling of the head have been shown to affect sweating rates 
(McCaffrey et al., 1975).  Subjects sat in an environmental chamber maintained at an 
ambient temperature of 40°C and their heads were then exposed to heating or cooling 
(70°C or 29°C) for 30 min.  Head heating resulted in increases in head skin, tympanic 
and oral temperatures whilst rectal temperature remained stable and oesophageal 
temperature rose slower than tympanic and oral temperature.  Mean sweating rate 
increased rapidly as head and skin temperature increased and continued to increase in 
parallel with tympanic and oral temperatures after head skin temperature had 
stabilised.  During head cooling, mean sweating rate fell whilst rectal and oesophageal 
temperatures were unchanged but tympanic and oral temperatures declined.  It was 
assumed by the authors that head heating and cooling altered the temperature of the 
hypothalamus and they concluded that brain temperature is the most important 
stimulus for thermoregulatory responses which are primarily designed to maintain 
brain temperature (McCaffrey et al., 1975).  Head cooling has been shown to increase 
core temperature during exercise whilst brain temperature remains precisely regulated 
and constant (Cabanac & Caputa, 1979b) and the preliminary findings of Marvin et 
al., (1999b) showed a similar trend. 
 
Cabanac and Caputa, (1979a) sat subjects in a warm bath at 38.6-38.7°C who reported 
their ratings of body temperature. Oesophageal and tympanic temperatures rose to a 
similar extent and subjects found the warm water immersion to be unpleasant.  Facial 
fanning was described as a pleasant stimulus and was accompanied by a reduction in 
tympanic temperature whilst oesophageal temperature continued to rise.  The authors 
conclude that brain temperature is an important factor determining temperature 
sensation and comfort. 
 
In the studies just described it is generally assumed that tympanic temperature gives a 
good indication of brain and, probably, hypothalamic temperature.  However whether 
selective cerebral cooling occurs in humans is still a matter of considerable contention 
(see Brengelmann, 1993; Cabanac, 1993 for review).  Tympanic temperature is a 
difficult measure to make and can quite easily be contaminated by cold skin 
temperature in and around the ear.  In addition, measurements of conduction velocity 
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in the auditory nerve, which should give a direct indication of the temperature of the 
brain, failed to show any change with head cooling (Nielsen & Jessen, 1992) 
 
Changing head temperature certainly has marked effects on thermoregulation and 
thermal comfort and if this is not the result of cooling the brain then cooling a 
relatively small area of skin on the head must have a considerable influence on central 
brain activity. 
 
1.4.2 Neuroendocrine control of thermoregulation 
 
Since the mid-1960s there have been numerous studies in which a wide variety of 
substances have been injected peripherally or directly into the brain and changes in 
body temperature observed (Clark, 1979). The monoamine theory of 
thermoregulation, proposed by Feldberg and Myers (1964) proposed that the two 
main neurotransmitters governing heat loss and heat gain in the hypothalamus were 
norepinephrine and 5-hydroxytryptamine respectively.  Since that time there has been 
a large volume of work, almost exclusively in animals, that has looked at the role of 
various putative neurotransmitters in the control of thermoregulation in the 
hypothalamus.  This search illustrates a common tendency to equate a single function, 
e.g. heat loss, to a single pathway and transmitter.  However it is now widely 
appreciated that most, if not all, functions are coded by multiple neurotransmitters, 
hormones, neuromodulators, and the interaction of diverse neural circuits (Brezina & 
Weiss, 1997; Segovia et al., 1997). 
 
In this vein, Feldberg and Myers, (1964) proposed that a balanced release between 
serotonin and noradrenaline could serve as the neurochemical basis for the control of 
temperature. Shortly thereafter, acetylcholine was proposed as an inhibitory 
neurotransmitter mediating heat gain or heat loss (see Cox & Lomax, 1977 for 
review), and peptides were suggested as neuromodulators (see Ruwe et al., 1983 for 
review). Today a long list of neurotransmitters and neuromodulators has been 
reported to change body temperature when injected into the cerebral ventricles or 
directly into the brain. However, evidence supporting a role for any of these 
substances transmitting specific thermal information among neurones in the CNS is 
equivocal (Blatteis, 1981; Myers & Lee, 1989).  Differences in methodology, animal 
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species, route of drug administration, dose, anaesthetics, restraint and ambient 
temperature have seriously complicated the interpretation of the data collected.  
Furthermore, in the majority of studies changes in body temperature alone were 
measured which could simply be a secondary response to activation of another 
autonomic physiological system.  For serious progress to be made, direct 
measurements are required of thermoregulatory effector mechanisms (e.g., sweating, 
vasodilation, panting) in response to endogenous release of putative neurotransmitters. 
 
Since the late 1960s the most consistent thermoregulatory responses have been 
elicited by central stimulation with 5-HT and DA. However, even these responses 
vary between species.  
 
1.4.2.1  5-HT and thermoregulatory control 
 
Since 1960 it has been known the raphe nuclei receive collateral input from the 
ventral spinal tract, where information about skin temperature and pain travels 
upwards and it has been suggested that the ascending raphe nuclei have a role in 
thermoregulatory function (Hillegaart, 1991). Furthermore, the raphe nuclei are the 
only source of serotonin-containing neurones in the brain and these serotonin 
neurones project widely in a rostral direction to areas that include the preoptic area of 
the hypothalamus (Fuxe, 1965). It has also been known for sometime that 
microinjections of 5-HT into the preoptic area can cause changes in the body 
temperature of an animal, although the evidence about the direction of these changes 
has been conflicting. The extensive microinjection study of Komiskey & Rudy, 
(1977) showed there are two distinct hypothalamic regions sensitive to serotonin: an 
anterior one that drives heat loss and a posterior one that drives heat gain.  
 
Clearly one possibility that would fit these observations is that raphe nuclei receive 
input from cutaneous warm and cold receptors and relay this information to the 
preoptic area, with serotonin as the likely transmitter (Hellon, 1981).  Dickenson, 
(1977) found that changing the skin temperature of the rat could specifically drive a 
large proportion of the neurones in the raphe nuclei as shown by microelectrode 
recordings. Injections of LSD, a specific serotonin blocker, caused a reversible 
inhibition of these cells, which also lost their sensitivity to skin temperature changes 
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(Hellon, 1981).  It is possible that afferent neurones of skin thermoreceptors may also 
project directly to the preoptic area of the hypothalamus but this is not proven. 
 
5-HT innervation of the hypothalamus comes from fibres arising from cell bodies 
located in the raphe dorsalis, raphe magnus and raphe centralis superior, or groups 
B7-B9, to use the original terminology of Dahlstrom and Fuxe, (1964).  Many 
pharmacological experiments have shown that 5-HT injected ICV or directly into the 
POAH at certain doses produces hyperthermia.  However at other doses it produces 
hypothermia.  Myers (1980), using push-pull perfusion found an increase in 5-HT in 
perfusates from the POAH when the animals were cooled, but not when they were 
heated suggesting a role of 5-HT in heat conservation and production. 
 
Single unit recordings have also reported contradictory results: 5-HT seems to 
produce non-specific effects. In fact Watanabe et al., (1986) reported that of the total 
number of warm-sensitive neurones recorded in the hypothalamus, 91% were 
activated by 5-HT.  37% of hypothalamic neurones that were thermally insensitive 
were also excited by 5-HT, presenting a confused picture of 5-HT’s role in 
thermoregulation. 
 
Woolf et al., (1975) have suggested the 5-HT increases inhibitory input from central 
thermosensors to effector neurones leading to an increase in vasoconstriction and 
thermoregulatory heat production in the rabbit.  White et al., (1985) have also 
suggested a role for 5-HT in heat conservation but this time through excitation of 
effector neurones leading to vasoconstriction.  In contrast Bruck and Zeisberger, 
(1990) looked at changes in the guinea pig and rat and found increased heat loss and 
reduced heat production as the result of activating the 5-HT system. To confuse the 
issue further, in the anterior hypothalamus of the cat, most of the warm-sensitive, 
cold-sensitive and thermoinsensitive neurons are inhibited by 5-HT (Jell, 1974). 
 
Obviously one of the major problems with the discussion above is that there are 
considerable differences between species. Additionally it is unlikely that 5-HT is the 
sole mediator of thermal information in hypothalamic pathways. It seems very likely 
that thermal information does reach the hypothalamus via the mid brain and this 
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involves 5-HT, but the precise role that 5-HT plays in thermoregulatory control by the 
POAH remains unclear. 
 
1.4.2.2  DA and thermoregulatory control 
 
DA is another prominent amine thought to participate in hypothalamic temperature 
regulation. Lee et al., (1985) reviewed the literature in this area and concluded that in 
rats, rabbits and other species, including humans, DA plays a role in the 
thermoregulatory pathways mediating heat loss.  Microinjections of DA in both 
ventricles and POAH reduce body temperature in the rat (Lee et al., 1985). There are 
a few electrophysiological studies of the effects of DA on firing rates of the 
temperature sensitive neurones of the hypothalamus. In the cat Sweatman and Jell, 
(1977) showed that DA microiontophoretically applied to cold-sensitive neurones 
decreased their spontaneous firing rate, suggesting that the effects of DA may be 
through an inhibition of heat production mechanisms.  This hypothermic effect is 
further supported by in vitro electrophysiological recordings from tissue slices 
obtained from the hypothalamus of the rat. Perfusing the preparations with DA 
reduced the activity of cold-sensitive neurones but increased that of the warm 
sensitive neurones in the hypothalamus (Scott & Boulant, 1984). The results of this 
study rule out the possibility that DA may depress the firing of all hypothalamic 
temperature sensitive neurones in a non specific manner whilst at the same time 
strengthening the evidence for the role of DA in thermoregulation by mediating heat 
dissipation 
 
The evidence discussed so far has suggested that there is a role for DA in 
thermoregulation, although most of the studies discussed have introduced DA into the 
brain through injections.  Strong evidence for endogenous DA in the normal control 
of body temperature comes from studies by Cox et al., (1978) and Cox and Lee 
(1980). In these studies rats were placed under a heat lamp to stimulate heat 
dissipation mechanisms consisting of vasodilatation of blood vessels in the tail.  In 
experimental rats treated with either a DA antagonist or 6-OHDA, the vasodilation 
was significantly reduced and the rats were less able to control their core temperature, 
indicating that DA initiates heat loss mechanisms.  Similar conclusions can be drawn 
from the work of Ohara et al., (1972) who reported that hypothalamic DA content 
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declines when rats are placed under heat stress.  An experiment, in cats, in which the 
endogenous stores of DA and NE were labelled within the anterior hypothalamic pre-
optic area showed that DA but not NE was released at catecholamine sensitive sites of 
the POAH when ambient temperature was increased to the point at which heat loss 
mechanisms were activated (Ruwe & Myers, 1978). At sites outside the POAH only 
NE was released showing a specificity of DA activity when heat loss mechanisms are 
activated (Myers, 1980). 
 
DA microinjected into other areas of the brain, particularly in areas involved in motor 
behaviour, also affects temperature regulation.  For example, injecting DA into the 
caudate putamen produced hypothermia that can be antagonised by DA-receptor 
blockers (Lee et al., 1985).  In the substantia nigra, another area of motor control, 
microinjections or apomorphine (DA receptor agonist) produced a dose-dependent 
hypothermia that was also antagonised by a specific DA receptor blocker (Lee et al., 
1985). This hypothermia was associated with increased heat loss and decreased heat 
production, and it was independent of ambient temperature. Furthermore, the same 
dose of apomorphine injected into the POAH produced similar hypothermic effects 
(Lee et al., 1985). 
 
The significance of the basal ganglia affecting hypothalamic function is not clear but 
it could be an example of integration of function, an anticipatory activation of 
thermoregulatory control mechanisms in advance of changes in body temperature 
during exercise.   
 
Support for a role of the nigrostriatal pathway is also obtained from clinical reports in 
humans.  Parkinson’s patients suffer from degeneration of the nigrostriatal pathways 
and exhibit abnormalities in heat dissipation and thus become heat intolerant.  In a 
series of experiments between 1981 and 1985 Lin and colleagues presented evidence 
for the nigrostriatal dopaminergic pathway being involved in thermoregulation in rats. 
Lesions of DA neurons within the substantia nigra produced by 6-OHDA were found 
to interfere with thermoregulation (Lin et al., 1981).  Intrastriatal administration of 
apomorphine decreased metabolism and resulted in hypothermia, whereas haloperidol 
produce the opposite effects in rats in the cold (Lin et al., 1982).  It was also found 
that cold sensitive neurones in the striatal area were inhibited by apomorphine but 
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excited by haloperidol (Lin & Tsay, 1985).  A few years after these experiments the 
same authors found that stimulating the substantia nigra could inhibit both heat 
production and heat loss mechanisms in the rat (Lin et al., 1992) depending on the 
ambient temperature. Below an ambient temperature of 22°C, stimulation led to a 
decrease in core temperature, whereas at an ambient temperature of 30°C stimulation 
lead to a hyperthermia and cutaneous vasoconstriction a finding that seems almost 
counter-intuitive.   
 
The above series of experiments, although confusing, demonstrate an involvement of 
the nigrostriatal DA pathways in thermoregulation although the precise role is still not 
fully understood. 
 
Lee et al (1985) have proposed a scheme depicting possible components of central 
dopaminergic systems that interact to influence thermoregulation (Figure 1.11) 
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Figure 1.11. Hypothetical scheme of components of central dopaminergic systems interacting to 
influence heat loss, adapted from Lee et al (Lee et al., 1985). 
 
This scheme was proposed from a review of the evidence pointing to a role for DA in 
thermoregulation.  The authors have proposed a link between the substantia nigra and 
the preoptic area of the anterior hypothalamus but whether this pathway actually 
exists within the brain is uncertain.  There is certainly some evidence to support its 
existence, although it may be that the substantia nigra functions independently of the 
preoptic area receiving thermal signals through a thermosensitive structure which is 
currently unknown (Lee et al., 1985). 
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1.5 Central fatigue as part of an integrated response to exercise in the heat:  
outline of the work presented in subsequent chapters. 
 
The experimental approach described in the following chapters has been stimulated by 
previous work in four main areas.   
 
The first concerns the role of serotonin in limiting endurance exercise, largely 
initiated by Newsholme and continued with important work in animals demonstrating 
the involvement of serotonergic and dopaminergic systems.  This was pioneering 
work which not only drew attention to the reality of central fatigue but also gave a 
theoretical framework that stimulated intense interest in the actions of central 
pathways and their influence on exercise.  The difficulty with much of the work is that 
it is basically a biochemical approach and it treats the brain as a homogeneous tissue, 
regulated by levels of different hormones. Often the conclusions are somewhat 
simplistic i.e. increases in serotonin are bad for continued exercise.  One way forward 
in this area is to try and identify the central pathways involved and in this respect 
measurement of pituitary hormones provide an indication of hypothalamic activity 
and much of the work described in this thesis uses prolactin for this purpose. 
 
The second major influence has been the work of Nielsen and colleagues in the last 
ten years, who have shown that increases in body temperature and central fatigue is a 
major limitation for exercise in the heat.  In the absence of a simple test for central 
fatigue during dynamic exercise, Nielsen and co-workers have systematically 
demonstrated that peripheral explanations for fatigue, such as reductions in blood 
flow to working muscles, do not explain the loss of performance.  More recently this 
group has begun to provide more direct evidence in terms of EEG changes and 
assessment of their subjects' ability to activate limb muscles under hyperthermic 
conditions.  The one area that this group has not explored is the neuropharmacology 
of the fatigue processes they have been studying. 
 
In attempting to understand the behavioural, endocrine and thermoregulatory 
responses to exercise it is essential to have some broad theoretical model of the 
interaction of neural pathways against which to test ideas and design experiments. The 
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work of Boulant has been especially important in defining these interactions in the 
hypothalamus and demonstrating how central and peripheral thermoreceptors can 
combine to provide multiple outputs that cover behavioural changes (which could be 
construed as central fatigue) as well as the more obvious thermoregulatory responses 
of sweating and shivering. 
 
Finally, the work of Brisson has been very influential in developing many of the ideas 
explored in this thesis.  Although not primarily concerned with questions of fatigue, 
Brisson and colleagues provided much stimulating and important information about 
the control of hypothalamic function by core and skin temperature.  The implications 
of this work for fatigue mechanisms have been elaborated in the present series of 
experiments.  Chapters 2 and 3 are concerned with these points and describe how core 
and skin temperature interact to modify the perception of exertion, endurance and 
prolactin secretion (Chapter 2) and how other stress hormones (GH and Cortisol) are 
affected by body temperature. 
 
When using prolactin as a marker of hypothalamic function it is important to know 
how its release is controlled, since both increased 5-HT and decreased DA are known 
to be potential mechanisms.  In Chapter 4 the specific 5-HT1A antagonist pindolol has 
been used to separate out these two mechanisms when prolactin release is stimulated 
with Buspirone, a drug that has been used as a neuroendocrine challenge to test the 
sensitivity of putative serotonergic pathways involved in fatigue mechanisms.  The 
results show that it is possible to use buspirone in combination with pindolol to assess 
the sensitivity of both serotonergic and presumed dopaminergic pathways in the 
hypothalamus. 
 
This modified neuroendocrine challenge was used in the experiments described in 
Chapter 5 to look for correlates between the sensitivity of hypothalamic serotonergic 
and dopaminergic pathways and exercise tolerance in the heat. 
 
It would be most interesting to know how prolactin release during exercise is 
controlled, whether it is primarily by serotonergic stimulation or the withdrawal of 
dopaminergic inhibition.  In theory, exercise in the presence of pindolol should 
answer this question, but in practice the beta antagonist properties of pindolol mean 
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that it is impossible to exercise at a sufficient intensity to release prolactin.  However, 
much of the work described here, and elsewhere, indicates that during exercise it is a 
rise in temperature, rather than other factors such as acidosis, that releases prolactin.  
Consequently, the work described in Chapter 6 is based on the premise that passive 
heating can mimic the effects of exercise, at least as far as prolactin is concerned.  It is 
quite feasible to combine passive heating with pindolol blockade and thus determine 
the extent of serotonergic and dopaminergic control of heat-induced prolactin release. 
 
While body temperature is clearly very important in regulating exercise, it is not 
necessarily the only central influence.  A range of legal and illegal substances appear 
to affect performance, of which caffeine is the most accessible drug to use for 
experimentation.  The approach used in the work described in Chapter 7 was to 
assume that caffeine interacts with the hypothalamic pathways involved in 
temperature regulation and, if this were the case, it would be expected to influence 
prolactin release.  This was found not to be the case and this finding opens up a new 
area, suggesting additional central pathways involved in fatigue, possibly involving 
the nucleus accumbens or the basal ganglia. 
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2.1 INTRODUCTION 
 
High ambient temperatures are well known to reduce exercise capacity and increase 
ratings of perceived exertion (e.g. Galloway & Maughan, 1997) but there are no 
simple explanations for this behaviour at the level of skeletal muscle metabolism or 
function. Heat exposure and exercise in the heat are associated with a host of 
responses by the regulatory systems of the body in an attempt to maintain 
homeostasis. The most obvious response to exercise in the heat is to increase heat loss 
by vasodilation and increased sweating but there are also behavioural changes that 
reduce heat gain together with a substantial release of pituitary hormones. 
 
Exercise in the heat leads to a redistribution of blood to the skin to facilitate heat loss 
and this may divert blood away from the working muscles (Fink et al., 1975) but 
during exercise at around 70%VO2max there is no evidence of a reduction in leg 
blood flow (Gonzalez-Alonso et al., 1998) or a metabolic limitation in the working 
muscles. Consequently it has been suggested that increasing body temperature may 
play a major role in the development of fatigue (Bruck & Olschewski, 1987) and it 
has been shown that there is an oesophageal temperature at which subjects fatigue that 
is not related to metabolic or cardiovascular changes affecting the skeletal muscles 
(Nielsen et al., 1997).  Thus the duration of exercise can be prolonged or shortened by 
manipulating core temperature before exercise so that it takes more, or less, time to 
reach the critical temperature (Lee & Haymes, 1995; Teller et al., 1998).  In these 
circumstances the perception of exertion is related to the initial temperature and rate 
of heat storage. 
 
Prolonged fatiguing exercise is associated with the appearance in the circulation of a 
number of hormones originating from the pituitary gland under the control of the 
hypothalamus. Among these is prolactin (PRL), the circulating level of which is 
known to increase during fatiguing exercise (Pitsiladis et al., 1998) and to be sensitive 
to changes in body temperature (Brisson et al., 1991). Passive heating has been shown 
to stimulate PRL release at rest (Mills & Robertshaw, 1981; Christensen et al., 1985) 
and PRL concentrations have been found to be linearly related to rectal temperature 
during exercise (Brisson et al., 1986; Melin et al., 1988).  PRL levels remain low and 
relatively unchanged during exercise at around 70% VO2max in cool ambient 
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temperatures, however blood PRL levels rise 4-5 fold towards the point of volitional 
fatigue during exercise in the heat, which typically occurs between 30 and 60 minutes 
in reasonably fit young subjects (Pitsiladis et al., 1998).  It has been suggested that 
one of the main stimuli for increases in PRL release during exercise is a thermal stress 
(Brisson et al., 1986) and a close relationship has been shown between rectal 
temperature and PRL release in response to exercise (Brisson et al., 1991).  While 
body temperature is clearly important, the relationship between rectal temperature and 
PRL release is modified by cooling the head and face during exercise (Brisson et al., 
1989; Marvin et al., 1999).  It remains a matter of considerable debate as to the 
mechanisms involved, whether it is due to direct cooling of the brain, of the blood 
reaching the hypothalamus or a reflex arising from skin afferents.  The stimulus for 
prolactin release provided by deep body temperature, at least when assessed by rectal 
temperature, is modulated by some other factor that must differ between exercise in 
hot and cool conditions.   
 
In a similar way, perception of exertion is modulated by a number of factors.  The 
original 15-point Borg scale is based on the relationship between heart rate and 
perceived exertion during exercise and the increased heart rate seen during exercise in 
the heat is an obvious candidate for the increase in perceived exertion. It is also likely 
that increases in body temperature contribute to perceived exertion and changes in 
blood lactate and glucose concentrations could also play a role. 
 
It is clear that environmental temperature during exercise has major effects on 
perception of exertion and development of fatigue and that it also affects the hormonal 
responses. Since the hormonal response to exercise is largely under the control of the 
hypothalamus it is of interest to know whether there is any association between 
changes in perception of exertion and the hormonal responses that could indicate a 
common underlying mechanism. To date there have been no studies in which changes 
in perception and pituitary hormones have been directly compared and, consequently, 
this was the primary purpose of the work described in the present chapter. 
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2.2 METHODS 
 
General Design 
Subjects performed two 40 minute exercise tests on a cycle ergometer at an ambient 
temperature of 15°C or 35°C during which blood samples were collected every 10 
minutes and rectal and skin temperature measured every 5 minutes.  Tests were 
randomly assigned and balanced for order. 
 
Subjects 
Eleven trained male cyclists participated in the study.  Their age, body weight and 
maximal oxygen consumption (VO2max) were 22.5±3.3 y (Mean±SD), 71.9±5.3 kg, 
and 4.55±0.50 l.min-1, respectively.  The study was approved by the Local Research 
Ethics Committee and subjects gave their informed consent in writing. 
 
Experimental Design 
 
Visit 1 
Subjects completed an incremental exercise test to exhaustion on an electrically 
braked cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands) to 
determine maximal aerobic power output (Wmax) and VO2max.  Workload was 
increased by 35 Watts every 3 minutes until volitional exhaustion. Expiratory gases 
were analysed and averaged over a 10 second period using a computerised on-line 
system (Oxycon Alpha, Jaeger, Bunnik, The Netherlands). Wmax was calculated using 
the method of (Kuipers et al., 1985): 
Wmax = Wfinal + (t x W) / T 
Where Wfinal is the power of the last completed stage, t is the time reached in the final 
uncompleted stage, T is the duration of each stage and W is the workload increment 
of each stage. 
 
Visits 2 & 3 
On the day before visit 2, subjects recorded their diet and were asked to adhere to the 
same diet on the day before visit 3. On the day of a test subjects arrived at the 
laboratory at 8am, having fasted from midnight.  A cannula was inserted into an 
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antecubital vein to obtain blood samples and was kept patent by flushing with 3ml 
saline every 10 minutes.  To ensure that subjects began each trial euhydrated they 
were given a bolus of water (8ml.kgbw-1) to consume during the 45 minutes between 
cannulation and the start of exercise, which was spent resting at an ambient 
temperature of around 18oC.  A resting blood sample was taken and subjects then 
moved into the thermal chamber and began to exercise on a stationary electrically 
braked cycle ergometer (Lode Excalibur Sport, Lode, Groningen, Netherlands).  
Exercise continued for 40 minutes at a constant work rate of 65% Wmax at an ambient 
temperature of either 15°C (50% relative humidity) or 35°C (30% relative humidity).  
Subjects were allowed fluid ad libitum during exercise and were asked to drink a 
minimum of 3ml.kgbw-1 water every 15 minutes to maintain hydration.  Heart rate 
was continuously recorded (Polar Vantage NV, Polar OY, Finland).  Venous blood 
samples (8ml) were taken every 10 minutes during exercise for determination of 
haematocrit, haemoglobin, lactate, glucose and PRL.  Whole body ratings of 
perceived exertion (RPE, Borg, 1975) were obtained every 10 minutes during 
exercise. 
 
Temperature measurements 
Rectal and skin temperatures were recorded every 5 minutes (Squirrel Meter Logger, 
Grant Instruments, Cambridge, UK), the latter using the four site formula of (Nielsen 
& Nielsen, 1984). 
 
Blood analysis 
Haematocrit was measured in triplicate by centrifugation.  Blood glucose and lactate 
were measured on plasma samples using enzyme-linked assays (Sigma Diagnostics, 
Poole UK); haemoglobin was measured using the cyanomethaemoglobin method 
(Sigma Diagnostics, Poole UK).  PRL was measured by radioimmunoassay (Skybio 
Ltd., UK).   
 
Data and Statistical Analysis 
Total hormone release was measured from the area under the curve of hormone level 
with time (AUC) calculated using the trapezoid method.  Changes in plasma volume 
were calculated using the method of Dill & Costill, (1974). All data were tested for 
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their approximation to a normal distribution.  Significant differences within trials, 
where data were normally distributed, were determined using repeated measures 
ANOVA with Bonferroni corrections for multiple comparisons. Where data were not 
normally distributed a Friedman test was used. Between trials, where data were 
normally distributed, significances were determined at matched time points using 
Student’s paired t-test. For data that were not normally distributed (PRL), 
significances were determined using Wilcoxon non-parametric tests.  Data are given 
as mean ± standard error of the mean, unless otherwise stated. 
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2.3 RESULTS 
 
All subjects managed to complete both trials although they reported that exercise in 
the heat was much more arduous.  
 
Perceived Exertion  
Ratings of perceived exertion (RPE) increased during exercise in both conditions and 
were significantly higher throughout the exercise in the hot compared to the cool 
condition (Final values 13.2±0.5 at 15°C and 15.7±0.9 at 35°C, Figure 2.1, p<0.05).   
 
 
Figure 2.1 Ratings of perceived exertion (Borg scale). ?15°C ?35°C. Data are Mean±SEM. * 
indicates a significant difference between trials;  ^ indicates a significant difference from 10 minute 
value in both trials (P<0.05). 
 
Cardiovascular and respiratory changes 
Heart rate (Figure 2.2) increased during the course of each trial (p<0.01) and was 
significantly higher during exercise in the heat (Final values 150±4 beats.min-1 at 
15°C and 164±4 beats.min-1 at 35°C, p<0.01). There was a non significant trend for 
ventilation to be higher during exercise in the heat.   
 
Oxygen uptake during exercise was consistently slightly higher in all subjects in the 
heat (~0.08 l.min-1) so the percentage of VO2max increased from 72±7% in cool 
 88
conditions to 74±6% in the heat (p=0.037).  There was no change with time in either 
exercise condition. 
 
 
Figure 2.2 Heart rate response to exercise. ?15°C ?35°C. Data are Mean±SEM * indicates a 
significant difference between trials;  ^ indicates a significant difference from 10 minute value in both 
trials (P<0.05). 
 
Body temperature responses 
Initial rectal temperatures did not differ significantly between trials (36.9±0.4°C at 
15°C and 37.1±0.5°C at 35°C).  The temperature increased significantly during both 
trials (Final values 38.4±0.1°C at 15°C and 38.9±0.2°C at 35°C, Figure 2.3a, p<0.05) 
and while the rectal temperature in the heat was always slightly greater than in the 
cool, the difference was only significant at 30 and 40 minutes (Figure 2.3a, p<0.01).  
In the cool trial, the mean rectal temperature was constant between 30 and 40 minutes, 
suggesting that a thermal equilibrium had been achieved, whilst during exercise in the 
heat, rectal temperature continued to increase at this time (p<0.05).  Mean skin 
temperature was significantly higher in the hot conditions.  There was a drift 
downwards in skin temperature during the latter part of the exercise although this was 
only significant during exercise in the cool (Figure 2.3b, p<0.01).  
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Figure 2.3a Rectal temperature responses to exercise. ?15°C ?35°C. Data are Mean±SEM. * 
indicates a significant difference between trials ^ indicates a significant difference from resting value in 
both trials (P<0.05). 
 
 
 
Figure 2.3b Mean skin temperature responses to exercise. ?15°C ?35°C. Data are Mean±SEM. * 
indicates a significant difference between trials (P<0.05). 
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a)  
b)  
Figure 2.4 Metabolic responses to exercise. a) Plasma Lactate; b) Plasma Glucose; ?15°C ?35°C. 
Data are Mean±SEM. * indicates a significant difference between trials;  ^ indicates a significant 
difference from resting value (P<0.05) but no difference between marked time points within a trial. 
 
Metabolic responses 
Blood lactate increased in the first 10 minutes of both trials and then remained 
relatively constant in all subjects, although the steady state concentrations varied 
between individuals (range after 20 minutes of exercise, 1.3mmol.l-1 to 5.9mmol.l-1 at 
15°C and 2.3mmol.l-1 to 6.9mmol.l-1 at 35°C).  After 20 minutes of exercise, lactate 
was significantly higher during exercise in the heat and remained elevated for the 
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remaining 20 minutes (final values 2.5±0.4mmol.l-1 at 15°C and 3.90±0.5 mmol.l-1 at 
35°C, Figure 2.4a, p<0.01). No change in blood glucose occurred during exercise in 
the cool whereas in the heat, values were significantly higher during exercise than at 
rest and were higher than in the cool condition for the last 20 minutes of exercise 
(Figure 2.4b, p<0.05). No differences were found between trials in either haematocrit 
or haemoglobin and calculated changes in plasma volume did not differ between trials 
(final values –0.6±2.5% at 15°C and –1.3±1.8% at 35°C) indicating that subjects 
maintained hydration during the exercise and any differences found between the two 
trials in terms of blood metabolites or PRL was not a consequence of 
haemoconcentration. 
 
Hormonal Response 
There were no differences in resting PRL between trials. PRL increased above resting 
values after 20 minutes exercise in the cool and after 10 minutes in the heat and 
continued to increase throughout both trials (Figure 2.5, Wilcoxon, p<0.05).  Prolactin 
values were significantly higher during the trial in hot conditions compared to the cool 
trial at every time point during exercise (Figure 2.5, Wilcoxon, p<0.05). 
 
Figure 2.5 Hormonal response to exercise. Plasma prolactin ?15°C ?35°C. Data are Mean±SEM. * 
indicates a significant difference between trials; ^ indicates a significant difference from resting value 
(P<0.05). 
 
Total PRL release, measured by AUC, was higher in the heat (9465 miU.min.l-1 Cool 
(IQ range, 5871-11390) v 15730 miU.min.l-1 Hot (IQ range, 10935-19319), Wilcoxon, 
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p=0.04).  The increase during exercise in the heat was 5 times greater than in the cool 
(28% (IQ range, 20-38) Cool v 151% (IQ range, 74-228) Hot), expressing the values 
as a percentage increase during exercise. 
 93
2.4 DISCUSSION 
 
The results presented here confirm the common experience that exercise at an 
elevated ambient temperature results in higher ratings of perceived exertion than when 
undertaken at cooler temperatures.  The effect of elevated temperature on perception 
was very similar to the changes in PRL, a pituitary hormone that is under the control 
of the hypothalamus.  The similarity between the two responses, especially in the 
heat, suggests that they may share common underlying neural pathways. 
 
The observation of increased perception of exertion in the heat is consistent with 
reports that endurance is reduced in the heat (e.g. Galloway & Maughan, 1997), while 
the greater response of PRL during exercise in the heat is also consistent with 
previous reports (Pitsiladis et al., 1998).   Combining the data in Figures 2.5 and 2.1 
strongly suggests that PRL and perceived exertion are influenced by the same stimuli 
during exercise and this was most evident for exercise in the heat (Figure 2.6).   
 
Figure 2.6. Perceived exertion (solid line) and plasma prolactin concentration (dashed line) response to 
exercise. ?15°C ?35°C Data are values from figures 2.1 and 2.5. 
 
Since PRL secretion is controlled by the hypothalamus it would appear likely 
therefore that similar pathways, at least in the heat, mediate the perception of exertion.  
Furthermore, heat loss mechanisms are also driven from centres in the hypothalamus 
and it would appear that the hypothalamus may act to integrate the response to heat 
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load imposed by exercise (Boulant, 1996); this includes vasodilatation and sweating, 
to increase heat loss, while increasing feelings of effort and fatigue (indicated by 
RPE) have the effect of reducing activity and thereby limiting heat gain.  The function 
of PRL release during exercise is not clear although it appears to be part of a general 
“stress” hormone response that includes growth hormone and ACTH. 
 
The stimulus for both PRL secretion and the increase in rating of perceived exertion 
during exercise is not entirely certain.  To be a likely candidate, the stimulus needs to 
increase steadily throughout the exercise and, at the same time, to be substantially 
greater in the heat compared to the cool conditions.  None of the factors examined in 
this study individually fit this profile. 
 
Heart rate:  The 15 point Borg scale is based on the heart rate response to exercise 
and although it is accepted that the scale does not represent a causal relationship 
between heart rate and perception there could be some awareness of heart rate, either 
as a result of feed-back or feed-forward, that impinges on consciousness and 
influences perception of effort. This might also apply to ventilation, which also drifted 
upwards during exercise in the heat.  Heart rate increased significantly throughout 
exercise and was different in the hot and cold conditions (Figure 2.2) and 
consequently has some of the attributes required for an effective stimulus.  However, 
the heart rate drift during exercise, even in the heat, was not large, increasing from 
approximately 150 to 160 bpm, corresponding to one point on the Borg scale, whereas 
perception of exertion increased by over three points on the scale.    It has been 
suggested that heart rate is not associated with a strong central signal of exertion 
(Robertson, 1982) and that the relationship between heart rate and RPE is not valid 
during prolonged, constant load, endurance exercise to fatigue (Garcin et al., 1998). It 
is also difficult to see how a change in heart rate per se could influence PRL secretion. 
 
Plasma lactate: Lactate has been shown to be linearly related to perceived exertion 
during incremental exercise (Borg et al., 1987). Plasma lactate might itself directly 
affect perception and the neuroendocrine response to exercise or it could be a marker 
for metabolic changes in the muscle that stimulate muscle sensory afferents.   
However in terms of fulfilling the conditions required for the stimulus either for 
increases in perceived exertion or causing PRL release, blood lactate does not meet all 
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the necessary requirements.  There was a significant difference between exercise in 
the two conditions but plasma levels were constant, or even falling, after 10 minutes 
when both PRL and RPE were increasing steadily. 
 
Plasma Glucose:  Hypoglycaemia has a major detrimental effect on performance and 
perception of exertion and infusion of glucose has been shown to reduce RPE, 
although only after prolonged exercise (~190 min) (Tabata & Kawakami, 1991). 
Glucose might, therefore, be expected to contribute to the perception of exertion 
during prolonged exercise.  In the present experiments, however, there was no 
evidence of hypoglycaemia in either exercise condition and, moreover, blood glucose 
rose significantly in the later stages of exercise in the heat at a time when the 
perception of effort was increasing. 
 
Skin Temperature:  Whilst there were major differences in skin temperature between 
the two conditions, which fit with the major differences in perception, any suggestion 
that skin temperature is a sufficient stimulus for changes in perception and PRL 
secretion must founder on the same arguments that apply to blood lactate.  Skin 
temperature remained constant, or even declined, during the course of the exercise at 
times when perception and PRL secretion were steadily increasing. 
 
Rectal temperature:  As has been discussed above, there are many indications that 
some aspect of body temperature plays a major role both in determining the 
perception of exertion and the release of PRL during exercise.  Rectal temperature 
fulfils the criterion of a steadily increasing stimulus during the course of the exercise 
(especially in the heat) but did not show a significant difference between hot and cool 
conditions, except in the last 10 minutes of exercise. 
 
It is evident that none of the variables discussed so far can, in isolation, explain the 
time course of changes in PRL and RPE together with the differences between 
exercise in hot and cool conditions.   One explanation is that a combination of stimuli 
is responsible and, if it is so, deep body temperature must be a major factor since it is 
the only variable that continuously increased during exercise in the heat.   This 
stimulus needs to be modulated by another that is substantially different in the two 
conditions and blood lactate and mean skin temperature both fulfil this requirement.  
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Of the two, skin temperature seems a more likely candidate since it is known that skin 
temperature has a major effect in modulating the action of core temperature on 
sweating responses (Boulant, 1996).  In this situation, plotting PRL against rectal 
temperature (Figure 2.7) it would be suggested that the difference between the two 
relationships is explained by a modulating effect of skin temperature. 
 
Figure 2.7. Plasma prolactin as a function of rectal temperature ?15°C ?35°C Data are Mean±SEM 
 
There is, however, an alternative explanation in that the rectal temperature we have 
measured is not a true representation of the temperature of blood perfusing the brain, 
which may be the unique stimulus for both RPE and PRL responses to exercise in the 
heat.  It is recognised that there is no one measure of core temperature and it is known 
that rectal temperature in steady state is generally slightly higher than that measured 
in the oesophagus.  Oesophageal temperature measures the temperature in the vicinity 
of the heart and thus is closer to the temperature of blood perfusing the brain than 
rectal temperature. At the start of exercise oesophageal temperature increases faster 
than rectal and will be higher than rectal but as, exercise continues and the body 
approaches thermal equilibrium, the two will approach one another with the rectal 
temperature finally becoming higher than the oesophageal n cool conditions, (Nielsen, 
1962).  In the heat, however, where thermal equilibrium is not achieved oesophageal 
temperature may rise faster and remain higher than rectal throughout the exercise 
(Nielsen, 1976).  If this were the case the rectal temperature measured in the cool 
condition might be overestimating the temperature of blood perfusing the brain, whilst 
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in the heat, rectal temperature could be an underestimate.  The effect of this on the 
relationship, shown in Figure 2.7 would be to draw the two lines together, possibly 
into a single relationship suggesting a simple stimulus, that of blood temperature 
entering the brain. 
 
Further work is clearly required to clarify this last point and experiments might be 
undertaken with the additional measurement of oesophageal temperature or even of 
the blood directly perfusing the brain and in this situation it would be of great interest 
to measure PRL flux across the brain. 
 
In summary, the work described in this chapter has shown a close relationship 
between the perception of exertion and activity of the hypothalamus, as indicated by 
the secretion of PRL.  It is suggested that the increasing sensations of fatigue and the 
desire to stop exercising is part of the thermoregulatory response to heat strain, 
constituting the behavioural response limiting the heat gain side of the equation.  The 
precise stimulus prompting this response remains unclear but must involve some 
components of body temperature.  Whether there is a modulatory effect of skin 
temperature on the responses evoked by changes in core temperature or whether the 
responses are directly determined by the temperature of blood perfusing the brain, 
remains to be elucidated. 
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Chapter 3 
 
 
BODY TEMPERATURE AS A STIMULUS FOR THE 
PITUITARY HORMONE RESPONSE TO EXERCISE 
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3.1 INTRODUCTION 
 
Exercise presents a serious challenge to the homeostasis of the body and pituitary hormones 
have an important part to play in regulating the supply of fuel, modulating inflammatory 
reactions and prompting repair of damaged tissues.  Although much is known about the 
time course and extent of hormone release in response to exercise, the nature of the 
releasing signal is far from clear.  Obvious candidates, such as increased blood lactate and 
hypoglycaemia, often show little change and remain constant during prolonged exercise 
while many hormone levels increase steadily with time. 
 
The pituitary hormone response to such exercise is often described as a “stress response” 
and, as such, implies a common mechanism to stimulate the release of several different 
hormones.   
 
Most hormones released during exercise are also increased as the result of heat exposure 
(Vigas et al., 2000) although the mechanisms of heat induced neuroendocrine activation are 
not fully understood.  The idea of a regulatory role of body temperature in the control of 
hormone release in exercise has been supported by various studies (Christensen et al., 
1984; Brisson et al., 1986; Brisson et al., 1987; Brisson et al., 1991).   
 
Prolactin release from the anterior pituitary gland has been shown to occur in response to 
raised core body temperature both as a result of exercise and passive heating (Brisson et al., 
1991).  However core temperature does not seem to offer a complete explanation since the 
relationship between core temperature and prolactin release is modified by skin 
temperature, being much reduced for the same core temperature if the skin is relatively cool 
(Brisson et al., 1986; Brisson et al., 1991; Bridge et al., 1999).  This suggests there is a 
close relationship between prolactin release and thermoregulation and it is of interest to 
know whether other pituitary hormones are regulated in a similar way.   
 
Growth hormone concentrations increase as a result of exercise and the extent of this 
release is governed by exercise intensity (Pritzlaff et al., 1999) and is linearly related to 
core temperature during exercise (Buckler, 1972; Karagiorgos et al., 1979). It has been 
suggested that this increase is the result of a direct stimulation of core thermoreceptors 
rather than cutaneous thermoreceptors (Christensen et al., 1984). Growth hormone may in 
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fact alter skin temperature, rather than respond to it, through the activation of eccrine sweat 
glands which have growth hormone receptors (Lobie et al., 1990). Additionally, the 
reduced sweat rate of growth hormone deficient patients returns to normal levels in 
response to growth hormone administration (Pedersen et al., 1989). Exercise in the heat 
often results in greater acidosis and higher blood lactate concentrations and it is possible 
that blood lactate concentration and acidosis may play some part in the exercise induced 
release of growth hormone (Luger et al., 1992). However, other studies have found no role 
for lactate in growth hormone response to exercise (Karagiorgos et al., 1979). It is also 
possible that increased sympathetic nervous activity may be an important mediator of the 
growth hormone response to exercise (Pritzlaff et al., 1999).  The mechanisms behind the 
increased release of growth hormone in hot environments are therefore not clear. 
 
Cortisol concentrations have been shown to be elevated both in exercise in the heat (Galbo 
et al., 1979; Hargreaves et al., 1996) and by passive heat exposure (Collins & Few, 1979; 
Moller et al., 1989) and thermal clamping of body temperature abolishes the exercise 
induced increase in cortisol concentrations (Cross et al., 1996).  Cortisol has been reported 
to increase during swimming in water of different temperatures only if body temperature 
increased (Galbo et al., 1979). The possible stimulus for this release is an increased core 
temperature, however an effect of increased skin temperature and cardiovascular demands 
during exercise in the heat cannot be ruled out.    There is, additionally, an element of 
psychological stress in the plasma cortisol response to exercise in the heat (Brenner et al., 
1997). Cortisol concentrations can increase in the heat as the result of increases in 
subjective feelings of discomfort (Follenius et al., 1982).  It is therefore not clear whether 
increases in core temperature, an increased skin temperature or increased psychological 
stress results in the augmented cortisol response to exercise in the heat. 
 
The roles that changes in core and skin temperature play in the augmented hormone 
secretion during exercise in the heat is not clear. We have, therefore, investigated the 
possibility that the secretion of prolactin, growth hormone and cortisol have a common 
release mechanism responding to changes in body temperature. 
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3.2 METHODS 
 
General Design 
Subjects performed two exercise tests to volitional fatigue on a cycle ergometer at ambient 
temperatures of 20°C or 35°C (relative humidity 30%) during which blood samples were 
collected every 10 min and rectal and skin temperature measured every 5 minutes.  Tests 
were randomly assigned and balanced for order. 
 
Subjects 
Thirteen recreationally active subjects participated in the study.  Their mean age, body mass 
and maximal oxygen consumption  (VO2max) were 22.5±3.3 y (Mean±SD), 71.9±5.3 kg, 
and 4.55±0.50 l.min-1, respectively. The study was approved by the Local Research Ethics 
Committee and subjects gave their informed consent in writing. 
 
Experimental Design 
Visit 1 – maximal exercise test 
Subjects completed an incremental exercise test to exhaustion on an electrically braked 
cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands) to determine 
maximal aerobic power output (Wmax) and VO2max.  Workload was increased by 35 Watts 
every 3 minutes until volitional exhaustion. Expiratory gases were collected and averaged 
over a 10 second period, using a computerised on-line system (Oxycon Alpha, Jaeger, 
Bunnik, The Netherlands). Wmax was estimated using the equation of (Kuipers et al., 1985): 
 
Wmax = Wfinal + (t x W) / T 
 
Where Wfinal (W) is the power of the last completed stage, t (s) is the time completed in the 
final stage, T (s) is the duration of each stage and W (W) is the workload increment. 
 
Visits 2 & 3 – constant load exercise tests 
On the day before visit 2, subjects recorded their diet and were then asked to adhere to the 
same diet on the day before visit 3. On the day of a test subjects arrived at the laboratory at 
either 8:00 having fasted from midnight.  A cannula was inserted into an antecubital vein to 
obtain blood samples. To ensure that subjects began each trial euhydrated they were given a 
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bolus of water (8ml.kg body weight (bw)-1) to consume during the 45 minute rest period 
between cannulation and the start of exercise.  A resting blood sample was taken and 
subjects then began to exercise on a stationary electrically braked cycle ergometer.  
Exercise continued at a constant work rate of 65% of Wmax and an ambient temperature of 
35°C, and 30% relative humidity, until volitional fatigue.  Subjects were asked to drink a 
minimum of 3ml.kg bw-1 water every 15 minutes to maintain hydration during the exercise.  
Heart rate was continuously recorded (Polar Vantage NV, Polar OY, Finland) and VE, VO2, 
and VCO2 were measured every 15 min.  Venous blood samples (8ml) were taken every 10 
minutes during exercise for determination of haematocrit, haemoglobin, lactate, glucose, 
prolactin, growth hormone and cortisol.  Whole body ratings of perceived exertion (RPE, 
Borg, 1975) were obtained every 10 minutes during exercise. 
 
Body temperature measurements 
Rectal and mean skin temperatures, the latter using the four site formula of (Ramanathan, 
1964), were recorded every 5 minutes (Squirrel Meter Logger, Grant Instruments, 
Cambridge, UK) 
 
Sweat rate 
Subjects were weighed nude immediately before the start of exercise and at the point of 
fatigue after having first towelled down.   Allowances were made for fluid ingested, 
respiratory water loss (Snellen, 1966), metabolic water loss (Mitchell et al., 1972), and 
quantity of blood drawn, to arrive at an overall sweat loss which was divided by time to 
give an average sweat rate over the entire period of exercise. 
 
Blood analysis 
Haematocrit was measured in triplicate by centrifugation.  Blood glucose and lactate were 
measured using enzyme-linked assays (Sigma Diagnostics, Poole UK); haemoglobin was 
measured using the cyanomethaemoglobin method (Sigma Diagnostics, Poole UK).  
Prolactin and growth hormone were measured using radioimmunoassays (Skybio Ltd, UK). 
Cortisol was measured by ELISA (DRG Instruments GmbH, Germany). All plasma 
samples from a single subject were assayed in the same batch.   
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Statistical Analysis 
Changes in plasma volume were calculated from haemoglobin and haematocrit values using 
the equations of Dill & Costill, (1974). Data were tested for approximation to a normal 
distribution.  Exercise data were analysed up to 40 minutes to include the maximum 
number of subjects and were analysed using repeated measures ANOVAs (SPSS 10) where 
data were normally distributed or, otherwise, a Friedman test was used. P values from the 
ANOVAs were corrected for sphericity using the Huynh-Feldt method, and significant 
differences between time points within trials were identified using tukey’s post-hoc test and 
between trials with students paired t-tests. Significance was determined using Wilcoxon 
non-parametric tests if the data were found not to be normally distributed. Total hormone 
release was measured from the area under the curve of hormone level with time (AUC) 
calculated using the trapezoid method and corrected for basal values. Data are reported as 
mean±sem unless otherwise stated. 
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3.3 RESULTS 
 
Exercise duration 
Subjects exercised at the same absolute oxygen uptake in both trials (3.04±0.13.min-1 at 
20°C; 2.99±0.13 l.min-1 at 35°C) which constituted a relative value of 73±2%VO2max.  
Exercise times at 20°C ranged from 45 minutes to just over two hours (mean, 81.2±8.2 
min) while at 35°C they ranged from 36 minutes to 98 minutes (mean, 56.8±5.4 min).  The 
time to fatigue in the heat was significantly shorter and, on average, 73±5% of the time to 
fatigue in the cool condition (p=0.002).  
 
Body temperature and sweat rate 
Rectal temperature increased in a similar fashion for the first 20 minutes when exercising in 
both the 35°C and 20°C conditions.  Thereafter, rectal temperature continued to rise in the 
hot condition while rectal temperature was significantly lower in the cool condition (Figure 
3.1a). Mean rectal temperature at the time of volitional fatigue was 38.4±0.2oC at 20°C and 
38.8±0.2oC at 35°C (p=0.008). 
 
Mean skin temperature at 35°C was higher than at 20°C, by approximately 3-4oC, 
throughout the exercise period (p=0.001).  Mean skin temperature in the heat rose 
significantly in the first 25 minutes of exercise (p<0.05, Figure 3.1b) and then remained 
constant.  At 20°C there was an initial small drop followed by a slight rise during the course 
of the exercise which resulted in a value higher than the start after 30 minutes, values at 
fatigue were 32.0±0.4°C at 20°C and 35.2±0.2°C at 35°C (Figure 3.1b). Sweat rate was 
significantly higher during exercise at 35°C than at 20°C (1.32±0.08l.h-1at 20°C v 
1.58±0.12l.h-1 at 35°C, p=0.03) 
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3.1a 
 
3.1b 
 
Figures 3.1 a & b.  Body temperature during exercise at 35°C (solid symbols) and 20°C (open symbols).  a. 
Rectal temperature; b. Mean skin temperature. * indicates difference between trials p<0.05; ^ indicates 
difference from time point 0 minutes within a trial p<0.05. At all time points mean skin temperature was 
higher in the hot trial. Data are mean±SEM. 
 
Metabolic parameters 
Blood lactate increased to steady state values after the first 10 minutes of exercise in both 
conditions (Figure 3.2a) and there were no further significant changes from 10 minutes to 
the time of volitional fatigue.  There was a tendency for steady state values to be slightly 
higher during exercise at 35°C which was reflected in blood lactate levels at fatigue of 
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4.3±0.9mM in the 20°C condition and 5.2±0.8mM at 35°C, however this was not a 
significant difference (p=0.059). 
 
3.2a 
 
 
3.2b 
 
Figure 3.2 a & b Blood metabolites during exercise at 35°C (solid symbols) and 20°C (open symbols).  a. 
lactate; b. glucose.  Bars labelled F are the values at fatigue (solid bar, hot conditions). * indicates difference 
between trials p<0.05 ^ indicates difference from time point 0 minutes within both trials p<0.05. Data are 
mean±SEM 
 
Blood glucose (Figure 3.2b) did not differ between trials or over time in the first forty 
minutes of exercise, or between 10 minutes and fatigue. There was a tendency for blood 
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glucose to fall over the more prolonged periods of exercise at 20°C and this resulted in a 
significantly lower blood glucose level at fatigue at 20°C, in comparison to exercise at 
35°C (4.97±0.30mM at 20°C; 5.97±0.40mM at 35°C, Figure 3.2b, p=0.046). 
 
Cardiovascular and respiratory parameters 
Heart rate increased during exercise in both trials and was significantly higher at all times 
during exercise at 35°C (Figure 3.3a).  At 20°C, heart rate after 10 minutes was 147±3 
beats.min-1, increasing to 159±3 beats.min-1 after 40 minutes.  The corresponding figures for 
exercise at 35°C were 154±3, beats.min-1 and 169±4 beats.min-1.  Heart rate at fatigue was 
significantly different between trials (169±3 beats.min-1 at 20°C and 174±3 beats.min-1 at 
35°C, p=0.006) but was less than maximal heart rate determined from the maximal exercise 
test. No differences in haematocrit were found between trials, haemoglobin and plasma 
volume change were significantly different between trials only at the 40 minute time point. 
At fatigue no differences were found between trials in either variable (fatigue values; 
haematocrit 44.1±1.1% at 20°C, 45.0±0.9% at 35°C; haemoglobin 14.8±0.6 g.dl-1 at 20°C 
and 15.2±0.7 g.dl-1 at 35°C; change in plasma volume –2.2±1.8% at 20°C and –3.9±1.0% at 
35°C).  
 
Minute ventilation increased significantly during exercise in the 35°C condition 
(79.2±4.9l.min-1 at 15min; 83.2±5.6l.min-1 at 30min, p<0.05, Figure 3.3b) but no such 
increase over time was noted at 20°C.  Initial values did not differ between trials, but by 30 
minutes values at 35°C were significantly higher than at 20°C (77.9±4.6l.min-1 at 20°C; 
83.2±5.6l.min-1 at 35°C, p<0.05, Figure 3.3b).  No changes were seen in respiratory 
exchange ratio during the course of exercise in either condition and there were no 
differences between trials, the mean values being 0.97±0.02 at 20°C and 0.98±0.02 at 35°C. 
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3.3a 
 
3.3b 
 
Figure 3.3 a & b Heart rate and ventilation responses to exercise at 20°C open circles and clear bars and 35°C 
closed triangles and solid bars. a heart rate, b minute ventilation. * indicates difference between trials p<0.05; 
^ indicates difference from other time points  within trials p<0.05. Data are mean±SEM. 
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Blood hormone levels. 
 
Prolactin 
Changes in circulating prolactin are shown in Figure 3.4a.  In the 20°C condition, there was 
a small increase in prolactin from 30 minutes of exercise with the values at 40 minutes and 
fatigue being significantly higher than resting levels.  At 35°C, prolactin rose progressively 
and was significantly greater than resting levels after 20 minutes and greater than at 20°C 
from 10 minutes onwards.  The differences in plasma prolactin concentrations were also 
reflected in the calculated area under the release curve, which was greater after 40 minutes 
of exercise in the hot condition (Figure 3.4a, p<0.03) 
 
Growth hormone 
Circulating growth hormone (Figure 3.4b) increased in a linear fashion with duration of 
exercise up to 30 (35°C) or 40 minutes (20°C) after which the levels begin to plateau.  
There were no differences between the two conditions either in values at time points during 
exercise or calculated area under the release curve. 
 
Cortisol 
Plasma cortisol (Figure 3.4c) changed relatively little during exercise with no differences 
between 35°C and 20°C conditions.  There was a slight (non-significant) fall in the first 10 
minutes followed by a steady, but slow, increase.  However this increase was not 
significant in the first 40 minutes of exercise. 
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3.4 DISCUSSION 
 
The present results are consistent with previous observations concerning the release of 
prolactin when exercising in hot and cool environments, indicating that ambient 
temperature has a major effect in modulating the response (Bridge et al., 1999).  The new 
observations are that while growth hormone release during the first 30-40 minutes of 
exercise shows a close relationship with rising core temperature, unlike prolactin, this 
relationship is similar in hot and cool conditions where skin temperature is very different.  
In contrast cortisol release showed very little dependence on either core or skin 
temperature.   
 
Prolonged exercise above 70%VO2max is demanding and subjectively reported as 
“stressful”.  This is especially true when carried out in warm, humid conditions when core 
temperatures can rise, sometimes, to dangerous levels (>40°C).  The pituitary hormone 
response to such exercise is often described as a “stress response” and, as such, implies a 
common mechanism to stimulate the release of several different hormones.  Possible 
stimuli arising during exercise include hypoglycaemia, acidosis and increasing body 
temperature.  In the present study it appears most unlikely that there is a direct causal 
relationship between blood lactate or hypoglycaemia and release of prolactin or growth 
hormone.  Blood glucose hardly changed with exercise duration and lactate, although 
elevated, remained constant after 10 minutes in both conditions.  Glucose feeding studies 
have shown that plasma cortisol concentration is unlikely to be affected by changes in 
blood glucose during exercise (Bishop et al., 1999; Bishop et al., 2001) and is probably 
also unaffected by blood lactate levels.  
 
There have been a number of studies investigating the release of prolactin both during 
exercise (Brisson et al., 1986; Brisson et al., 1991) and at rest (Brisson et al., 1991) and it is 
clear that changes in blood osmolality and acidosis are not responsible for stimulating 
release (Brisson et al., 1986).  There is, however, considerable evidence that rising body 
temperature, as a result of exercise or passive warming, is important and a linear 
relationship between circulating prolactin and core temperature during low-intensity 
exercise has been reported (Brisson et al., 1986; Melin et al., 1988).  Our own results tend 
to show a more biphasic relationship between rectal temperature and prolactin release 
(Figure 3.5a).  Skin temperature is also known to influence prolactin release and the present 
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results confirm our previous observations (Bridge et al., 1999) that ambient temperature has 
a major influence on prolactin release.  Blood lactate was marginally higher when subjects 
were exercising in the heat but it is unlikely that this accounts for the different responses.  
Likewise, heart rate and ventilation were higher in the heat but is seems unlikely that an 
increase of between 7 to 10 bpm should make much difference when, in the cool condition, 
heart rate had increased 2.5 times above resting with very little prolactin production.  Skin 
temperature appears to be a possible moderator of prolactin release since mean skin 
temperature was approximately 3-4oC lower when exercising at 20°C.  Prolactin secretion 
is known to be stimulated by serotonergic, and inhibited by dopaminergic activity in the 
hypothalamus and these two pathways are also involved in temperature regulation 
(Yamawaki et al., 1983).  Heat loss mechanisms are responsive to core temperature, sensed 
by receptors in the brain stem and preoptic area, but are also modulated by skin temperature 
with the integration of these signals thought to occur in the preoptic area (Boulant, 1981).  
It appears, therefore that activation of prolactin release during exercise is, in a large part, 
driven by the rise in core temperature but that central sensitivity to such changes is altered 
by signals coming from peripheral thermoreceptors. 
 
However, as mentioned in Chapter 2, there is, an alternative explanation in that the rectal 
temperature we have measured is not a true representation of the temperature of blood 
perfusing the brain, which may be the unique stimulus for both RPE and PRL responses to 
exercise in the heat.  It is recognised that there is no one measure of core temperature and it 
is known that rectal temperature is generally slightly lower than that measured in the 
oesophagus.  Oesophageal temperature measured close to the heart and aorta and thus is 
closer to the temperature of blood perfusing the brain than rectal temperature. At the start of 
exercise in cool conditions, oesophageal temperature will rise faster and become higher 
than rectal but as exercise continues and the body approaches thermal equilibrium the two 
will approach one another with the rectal temperature becoming higher than the 
oesophageal in the steady state of thermal equilibrium (Nielsen, 1962).  In the heat, 
however, where thermal equilibrium is not achieved oesophageal temperature may remain 
higher than rectal throughout the exercise (Nielsen, 1976).  If this were the case the rectal 
temperature measured in the cool condition might be overestimating the temperature of 
blood perfusing the brain, whilst in the heat, rectal temperature could be an underestimate.  
The effect of this would be to draw the two lines in figure 3.5a together suggesting a simple 
common release stimulus. 
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Further work is required to clarify the relationship between body temperatures and PRL 
release and experiments might be undertaken in which time dependent differences between 
rectal and oesophageal temperatures are removed, possibly by passive heating. Additionally 
measurements could be made of oesophageal temperature or even of the blood directly 
perfusing the brain and in this situation it would be of great interest to measure PRL flux 
across the brain. 
 
Growth hormone release from the pituitary is clearly under complex and multiple controls.  
Release associated with growth and the maintenance of bone and muscle is thought to occur 
mainly during REM sleep in a characteristic pulsatile fashion (Van Cauter et al., 1998).  
During exercise there is evidence that such a pulsatile release still occurs and increases in 
quantity of growth hormone secreted per pulse result in the rising blood concentrations that 
are seen (Pritzlaff et al., 1999).  Like prolactin, growth hormone release can be stimulated 
by the serotonergic 1A receptor agonist buspirone, implicating serotonergic and/or 
dopaminergic pathways in the release mechanism (Anderson & Cowen, 1992).  The results 
shown in Figure 3.5b indicate a very clear relationship between growth hormone release 
and rectal temperature, at least up to 30 or 40 minutes of exercise, this relationship has been 
shown before by other authors (Buckler, 1972; Karagiorgos et al., 1979; Christensen et al., 
1984).  Different ambient conditions, however, had no effect on growth hormone release 
suggesting, that if central thermoreceptors are triggering growth hormone release in 
response to heat exposure (Christensen et al., 1984), the receptors, or subsequent pathways 
involved, differ from those controlling prolactin since environmental temperature played no 
part in modulating the response.  This is in line with the suggestion of Christensen et al., 
(1984) that it is mainly the central thermoreceptors that govern the augmented growth 
hormone release in the heat. 
 
There was only a modest cortisol response to exercise (Figure 3.3c) and no suggestion that 
the release was in any way initiated or modulated by body temperature (Figure 3.5c).  This 
is at odds with previous findings that have shown an augmented cortisol release in the heat 
(Galbo et al., 1979; Cross et al., 1996; Hargreaves et al., 1996) and may be due to the lack 
of difference in core body temperature during the first 40 minutes of exercise in this study 
compared with others (38.4±0.1°C after 40 minutes at 35°C v 39.1±0.2°C after 40 minutes 
at 40°C (Hargreaves et al., 1996)) or the different ambient temperatures used. Cortisol is 
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only an indirect indicator of hypothalamic function since adrenocorticotropic hormone is 
the pituitary hormone which causes release of cortisol from the adrenal medulla.  The 
cortisol response is bound to lag behind that of adrenocorticotropic hormone and it is 
possible therefore that a temperature effect might have been seen at times after 40 minutes.  
However, core body temperature at fatigue in each condition was different in this study yet 
no difference in cortisol concentrations were found and a number of subjects exercised for 
around 2 hours in the cool and 90 minutes in the heat and no effect of ambient temperature 
was evident in their cortisol responses.  Increases in plasma prolactin concentrations are 
indicative of an increased serotonergic activity and although serotonergic receptor agonists 
are reported to release adrenocorticotropic hormone (Raap & Van de Kar, 1999), we have 
no evidence that this raised serotonergic activity results in an increased cortisol release 
through a raised adrenocorticotropic hormone concentration.  Cortisol is known to respond 
to hypoglycaemia (Nye et al., 2001) and if this is the major stimulus pathway then cortisol 
will be a relatively delayed response to the stress of exercise. 
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Our original hypothesis was that the higher pituitary hormone response to the stress of 
exercise in the heat, would have a common stimulus pathway involving the integration of 
skin and core temperature signals.  This is evidently not the case.  Although body 
temperatures probably have an important role to play in the release of both prolactin and 
growth hormone their pathways must diverge in as much as ambient temperature affects 
them differently.  Our results suggest that cortisol release appears to be controlled in a quite 
different fashion although the possibility of an effect of core temperature cannot be ruled 
out. 
 
The conclusion that different mechanisms are responsible for the release of PRL, growth 
hormone and cortisol is firm regardless of the questions raised of the roles of skin and core 
temperature in regulating PRL release as discussed in Chapter 2. 
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4.1 INTRODUCTION 
 
Alterations in central serotonergic (5-HT) activity are implicated in a wide range of psychiatric 
disorders as well as in chronic fatigue syndrome. In trying to understand the underlying causes 
of these disorders, it is valuable to have a measure of the sensitivity of the 5-HT pathways.  
Multiple 5-HT receptor subtypes are thought to regulate neuroendocrine secretion in man 
(predominantly 5-HT1A, 5-HT2A and 5-HT2C; Yatham & Steiner, (1993)) for which few truly 
selective agonists are available.  Consequently a variety of 5-HT agonists of varying degrees of 
selectivity have been investigated as probes of serotonergic function in man (Mueller et al., 
1985; Anderson et al., 1990; Lesch et al., 1990; Kalus et al., 1992; Palazidou et al., 1995).  
Recently, and mostly for reasons of safety and availability, the partial 5-HT1A agonist buspirone 
(Buspar, Bristol-Myers Squibb) has been used (Coccaro et al., 1990; Bakheit et al., 1992; 
Jakeman et al., 1994; Meltzer & Maes, 1994; Sharpe et al., 1996) with increases in the plasma 
concentration of prolactin being taken as the measure of serotonergic activity.   
 
Buspirone is an azapirone derivative with anxiolytic and antidepressant actions (Knapp, 1985; 
Robinson et al., 1990) that has been shown to have a high affinity for the 5-HT1A receptor in 
animals (Traber & Glaser, 1987) and this action may underlie its therapeutic properties in man 
(Eison & Temple, 1986).  Buspirone can stimulate prolactin release by the activation of post-
synaptic hypothalamic 5-HT1A receptors (Neuhauser et al., 1988; Yatham et al., 1989; Coccaro 
et al., 1990) but the prolactinotrophic effects of buspirone are complicated by its dopamine D2 
receptor blocking action (McMillen et al., 1983; Eison & Temple, 1986). Indeed it was 
originally thought that the prolactin releasing mechanism of buspirone was dopaminergic 
(Meltzer & Fleming, 1982).  The prolactin response to buspirone may, therefore, be due to a 
combination of hypothalamic 5-HT1A stimulation and pituitary D2 receptor blockade (Meltzer et 
al., 1983; Meltzer et al., 1991; Maskall et al., 1995). 
 
Several studies have attempted to characterise the relative involvement of serotonin and 
dopamine receptors in the release of prolactin by buspirone. Pre-treatment with the general 5-
HT antagonist compounds, metergoline (Coccaro et al., 1990; Gregory et al., 1990) and 
methysergide (Neuhauser et al., 1988) abolished the prolactin response to a buspirone challenge 
suggesting that the action of buspirone is entirely mediated by serotonergic mechanisms. 
However, both metergoline and methysergide have dopamine agonist actions and so the 
involvement of pituitary D2 receptors cannot be ruled out.  Indeed a more recent paper by 
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Maskall et al. (1995) in which buspirone was given during maximal dopaminergic blockade 
found no difference in prolactin release by buspirone or placebo.  Possible pituitary prolactin 
depletion by the dopaminergic blocker was ruled out and the authors concluded that extreme 
caution must be applied in interpreting the results of studies employing buspirone challenge test 
in terms of 5-HT sensitivity (Maskall et al., 1995). 
 
Pindolol, best known as a β-adrenoreceptor antagonist, has a high affinity for the 5-HT1A 
receptor (Hoyer, 1988).  It does not appear to possess any activity at dopamine receptors (Hjorth 
& Carlsson, 1986) and has been shown to attenuate the neuroendocrine and behavioural 
responses of selective 5-HT1A receptor agonists (Tricklebank et al., 1984; Koenig et al., 1988). 
Pindolol has been used in man to attenuate the prolactin response to fenfluramine, a general 5-
HT releasing agent (Palazidou et al., 1995), and in two studies attempting to characterise the 
involvement of 5-HT1A receptors in the prolactin response to buspirone.  Coccaro et al. (1990) 
reported a suppression of the prolactin response of between 49-90% whereas Anderson & 
Cowen (1992) found no significant difference in the total prolactin response.   Interpretation of 
these two studies is complicated by the small number of subjects studied, differences in the 
dosing regimen and the consequences of high and changing baseline prolactin as a result of the 
stress of intravenous cannulation.  
 
The objective of the present study was to reassess the effects of pindolol pre-treatment on the 
prolactin response to a buspirone challenge, using a similar dosing protocol to that employed by 
Anderson & Cowen (1992) whilst taking steps to avoid the complications of shifting baseline 
values.  
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4.2 METHODS 
 
Subjects and drug administration 
 
Thirty five healthy male volunteers (mean age 26.1 years, range 18-37 years) gave informed 
written consent to the study, which was approved by the local Ethics Committee.  Subjects were 
screened with a clinical interview to exclude any previous psychiatric history and had been free 
of any medication for at least three weeks prior to the study.  
 
The study was of a randomised two-way crossover design that was single blind to the subjects 
who all made two visits to the laboratory and received on separate occasions placebo or pindolol 
as a pre-treatment followed by buspirone as the drug treatment.  Nine subjects underwent an 
additional two trials receiving on separate occasions placebo or pindolol as a pre-treatment 
followed by a placebo.  All drugs were administered orally, encased in identical gelatine 
capsules.   
The different trials were; 
I, placebo – buspirone (n=35) 
II, pindolol – buspirone (n=35) 
III, placebo – placebo (n=9) 
IV, pindolol – placebo (n=9)  
Visits I and III were preceded by 2 days during which subjects took a placebo and visits II and 
IV by 2 days in which they took pindolol (10mg twice daily). This dosing regimen was chosen 
from the literature so that maximal post-synaptic receptor blockade would be achieved. It has 
previously been shown that a 20mg dose of Pindolol, without a priming dose, results in 46% 
post-synaptic 5-HT1A receptor occupancy (Rabiner et al., 2000). Whilst this is by no means a 
total blockade of post-synaptic receptors, the results also show that the occupancy is dose 
dependant (Rabiner et al., 2000).  It is therefore likely that with the priming dose given on the 
two days before the buspirone challenge and the relatively high dose given an hour before the 
buspirone (37±5mg, 0.5mg.kg-1 body mass) in this study, that a higher 5-HT1A receptor 
occupancy has been achieved.  Indeed Rabiner et al. (2000) suggest that a 30mg dose would be 
enough to fully block the functional responses to Buspirone.   
 
 127
Neuroendocrine challenge 
Subjects arrived at the laboratory at 8am following an overnight fast, although water was 
allowed ad libitum both during the fast and throughout the experiment. Following a 15 min rest 
a 21G cannula was inserted into a superficial forearm vein and kept patent with saline (Baxter 
0.9%). After a further 45 min rest, a baseline blood sample (3ml) was taken and the subject 
ingested either placebo for treatment I and III, or pindolol (0.5 mg·kgbw-1) for treatments II and 
IV.  Serial blood samples were then taken at 15 min intervals for one hour.  Following ingestion 
of either placebo or buspirone (0.5 mg·kgbw-1; Bristol-Myers Squibb) at this time, further blood 
samples were withdrawn every 15 min for the next 150min. Subjects were asked to report side-
effects on a scale of 1-10 with 5 being normal lower than 5 ‘less than normal’ and higher than 5 
‘more than normal’. Categories were Light-headed, Nausea, Dizzy, Hot, Cold, Sleepy, Fatigued, 
Clammy skin, Sweaty and Aches; there was additional space for other comments. Subjects 
rested in a semi-supine position throughout the experiment but were not allowed to sleep.  This 
protocol was repeated at weekly intervals with subjects receiving a different treatment regimen 
on each visit.  Treatments were randomised and balanced for order.  Venous blood samples were 
left to clot for 20 minutes and serum was separated by centrifugation, stored at -70°C and 
analysed within 3 months for serum PRL using a radioimmunoassay (Chelsea Kits, 
Hammersmith Hospital, London).  Average inter- and intra-assay coefficients of variation over 
the whole range were 5.9% and 2.7% respectively.  All plasma samples from one subject were 
assayed in the same batch by one of the authors who was blinded to the study conditions.  
 
Data and Statistical Analysis 
The hormone data at each time point approximated a normal distribution and are presented as 
means and SEM in the figures.  The prolactin response was calculated as the area under the 
curve (AUC) using the trapezoid method with subtraction of the baseline area.  The area under 
the curve was not normally distributed and these data are therefore reported as median and inter-
quartile range. Significance was determined using Wilcoxon matched-pairs, signed rank test. 
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4.3 RESULTS 
 
Effects of pindolol on basal prolactin 
In all nine subjects treatment IV pindolol - placebo (10mg twice daily for 2 days, 0.5mg.kgbw-1 
on test day) resulted in a reduction in the mean serum prolactin compared to treatment III 
placebo – placebo at all time points after the 0.5 mg·kgbw-1 dose was taken (Figure 4.1).  The 
area under the curve reduced from a median of 27798 to 22840 miu.min.l-1 which constituted a 
median reduction of 15% (IQ Range 12-23%, p<0.01, two-tail).  There was a gradual decline in 
prolactin over time with both treatments but the rate of decline following pindolol was double 
that following placebo (26 miu.l-1.hr-1 and 13 miu.l-1.hr-1 respectively for pindolol and placebo) 
and this was particularly evident in the first 90 minutes after pindolol was administered.  
 
 
Figure 4.1 The effect of pindolol treatment on tonic prolactin release. Serum prolactin response to treatments III 
(placebo-placebo, ▲) and IV (pindolol-placebo, ?).  Pindolol or placebo were given at -60 min and placebo at 0 
min.   Data are mean ± s.e.m. 
 
Prolactin response to a buspirone challenge  
Treatment I (placebo – buspirone) gave a robust prolactin response (Figure 4.2). The peak 
prolactin concentration occurred 75 min (60-90 min) after drug administration and reached 
317% (IQ Range 213-522%) of the basal level.  Prolactin returned to basal levels within about 
2.5 hours after buspirone administration.  Prolactin area under the curve, following buspirone 
treatment, and after subtraction of the baseline, was 33267 miu.min.l-1 (IQ Range 17228-60690). 
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Figure 4.2 The effect of pindolol treatment on the prolactin response to buspirone. Serum Prolactin response to 
treatment I (placebo-buspirone, ●) and II (pindolol-buspirone, ○). Pindolol or placebo were given at -60 min and 
buspirone or placebo at 0 min.   Data are given as mean ± s.e.m. 
 
 
Figure 4.3  Subject side-effects to buspirone. Subject negative side-effects (light-headed, nausea, dizzy, sleepy, 
fatigued) after correction for basal responses, a positive score reflects a negative feeling. Pindolol – buspirone ○, 
and placebo - buspirone ●.  Data are given as mean. 
 
Oral buspirone was generally well tolerated by the subjects.  The most commonly reported side-
effect was a light-headed or dizzy feeling typically 45-60 minutes after administration but this 
was generally not reported as unpleasant.  These feelings were often accompanied by nausea.  
An average of negative side-effects (light-headed, nausea, dizzy, sleepy, fatigued) after 
correction for basal values is reported in Figure 4.3. When looking at Figures 4.2 and 4.3 
together it can be seen that subject reporting of side-effects mirrored the change in prolactin in 
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the blood.  However the magnitude of these side-effects varied from subject to subject and those 
with the highest blood prolactin levels did not necessarily report the worst side-effects.   
 
Effects of pindolol pre-treatment on the buspirone challenge 
Pindolol treatment attenuated the prolactin response to the buspirone challenge (treatment II, 
pindolol – buspirone, Figure 4.2) in all subjects and to varying extents.  Peak values were 
reduced by about 50% and the area under the curve was reduced by a median value of 52%, with 
an IQ Range of 22-82%.  
 
 
Figure 4.4  The components of the prolactin response to buspirone. The total response (pindolol-sensitive and 
pindolol-insensitive, shaded bar) and non 5-HT1A (pindolol-insensitive, open bar) components of the buspirone 
response. Data for the pindolol-insensitive components were obtained by subtracting the baseline corrected area 
under the curve of treatment II from that of treatment I.  Values shown are medians and interquartile ranges. 
 
Subtracting the prolactin response to buspirone in the presence of pindolol from the response to 
buspirone alone, as shown in Figure 4.2, gives the component of the buspirone-mediated 
prolactin response that was not attributable to its 5-HT1A agonist action (i.e. the pindolol-
insensitive component). The two components (pindolol- sensitive and -insensitive) are shown in 
Figure 4.4.  The pindolol-insensitive component of the prolactin response was later in onset 
with, on average, a peak at 105 min (IQ Range 75-130min, p<0.05) compared to the derived 
pindolol-sensitive component, which peaked at 105 min (IQ Range 70-130min).  The pindolol-
insensitive component peaked significantly later than the pindolol-sensitive component 
(p<0.05), the time to peak varied considerably and in eight subjects the order of the peaks was 
reversed. There were no obvious relationships between the magnitude of the total prolactin 
response (buspirone alone) and the proportions of the two components or the timing of the 
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peaks.  No adverse effects were reported of the pindolol treatment alone. Pindolol treatment 
resulted in a lower severity of side-effects reported in the majority of subjects (Figure 4.3) 
whilst the reporting of side-effects still mirrored the change in prolactin in the blood.  No 
subject exercised their right to withdraw from the study. 
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4.4 DISCUSSION 
The investigations described here demonstrate the dual control of prolactin secretion.  While the 
tonic prolactin levels were found to be predominantly (~82%) under the control of non 5-HT1A 
pathways, the response to a buspirone challenge was, on average, attributable in equal measure 
to the two pathways. 
 
The prolactin response to buspirone administration (0.5mg.kg-1 body mass) was clear and robust 
in all subjects as has been reported in a number of other human studies (e.g. Meltzer et al., 1983; 
Coccaro et al., 1990; Dinan et al., 1990; Anderson & Cowen, 1992).  Although all subjects 
demonstrated a prolactin response to buspirone, there was considerable inter-subject variation in 
terms of both magnitude and time to peak. Reasons for this variability are not clear, but 
buspirone undergoes extensive first-pass metabolism (Gammans et al., 1986) which could differ 
between subjects, alternatively the variable responses might reflect genuine differences in 
central serotonergic sensitivity. 
 
The prolactin response to a buspirone challenge has been used as an index of central 
serotonergic activity (e.g. Bakheit et al., 1992; Jakeman et al., 1994; Sharpe et al., 1996) but it 
is clear that this ignores the complex actions of the drug.  In addition to its 5-HT1A agonist 
properties, buspirone is known to influence dopamine pathways (McMillen et al., 1983; Eison & 
Temple, 1986) and is metabolised to 1-(2-pryrimidinyl)-piperazine, an α2-adrenoceptor 
antagonist (Gammans et al., 1986; Bianchi & Garattini, 1988).  Pindolol treatment is one way of 
dissecting out the 5-HT1A actions of buspirone from those mediated by other pathways.   
 
The interpretation of the results presented here rests first on the selectivity and potency of the 5-
HT1A antagonist action of pindolol and secondly on the lack of any complicating actions. 
Pindolol has been shown to have a high affinity for 5-HT1A receptors (Hoyer, 1988) and does 
not appear to possess any activity at dopamine receptors (Hjorth & Carlsson, 1986).  
Additionally PET scanning has shown that a 20mg dose of Pindolol, without a priming dose, 
resulted in 46% post-synaptic 5-HT1A receptor occupancy (Rabiner et al., 2000).  Whilst this is 
by no means a total blockade of post-synaptic receptors, the results also show that the 
occupancy is dose dependant (Rabiner et al., 2000).  It is therefore likely that with the priming 
dose given on the two days before the buspirone challenge and the relatively high dose given an 
hour before the buspirone (37±5mg, 0.5mg.kg-1 body mass) in this study, that a higher 5-HT1A 
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receptor occupancy had been achieved.  Indeed Rabiner et al. (2000) suggest that a 30mg dose 
would be enough to fully block the functional responses to Buspirone.   
 
Pindolol is probably best known for its β-adrenoceptor antagonist action (Aellig, 1976) and the 
β-adrenoceptor antagonist propanolol has been reported to increase the prolactin responses to 
pharmacological challenges (Laakmann et al., 1986). It is possible that pindolol may have a 
similar action but since pindolol has been found to consistently reduce prolactin levels, any 
stimulatory action will have led to an underestimation of the size of the 5-HT1A component 
rather than falsely attributing this component to serotonergic activity. Pindolol, however, does 
have some intrinsic sympathomimetic activity (Aellig, 1976) and it is conceivable that pindolol 
could act in part, and/or in some individuals, as a β-adrenoceptor agonist which could lead to a 
reduction in prolactin release via this mechanism. This partial β-adrenoceptor agonist action of 
pindolol can not be ruled out when offering an explanation of the effects of pindolol on basal 
prolactin release although the β-adrenoceptor antagonist actions of pindolol are more likely to 
dominate (Aellig, 1976).  
 
The observed reduction in prolactin release in both tonic and stimulated conditions after 
pindolol pre-treatment is consistent with previous findings (Park & Cowen, 1995; Meltzer & 
Maes, 1996) and supports the involvement of 5-HT1A receptors in the release of prolactin.  
However, the relatively small pindolol-induced reduction of the basal levels (18%, Figure 1) 
suggests that tonic release of prolactin has only a small serotonergic stimulated component.  
Anderson and Cowen (1992) reported no reduction in tonic prolactin release following pindolol 
pre-treatment but only 3 baseline samples were taken following intravenous cannulation and it is 
possible that the elevated and changing baseline as a consequence of cannulation may have 
masked a small reduction in tonic prolactin as a result of pindolol treatment.  
 
Pindolol pre-treatment reduced the prolactin response to the buspirone challenge in all subjects 
confirming the involvement of post-synaptic hypothalamic 5-HT1A receptors in this 
neuroendocrine challenge.  The prolactin response to the buspirone challenge that was not 
sensitive to pindolol can, in part, be attributed to the antagonist actions of buspirone at pituitary 
D2 receptors (Meltzer & Fleming, 1982; Anderson & Cowen, 1992; Meltzer et al., 1992; 
Maskall et al., 1995) although other 5-HT receptor subtypes, for which pindolol has little 
affinity, have also been implicated in the control of basal prolactin secretion (Falaschi et al., 
1991).   
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The reporting of side-effects in response to buspirone administration mirrored the rise and fall in 
blood prolactin concentration in treatments I and II. With prior pindolol administration the 
severity of side-effects was reduced roughly in proportion to the reduced prolactin. This 
reduction after pindolol administration has not, to our knowledge, been reported before but 
would be expected if serotonergic pathways are involved.  It is though difficult to draw any 
conclusions at to the cause of the reduction. 
 
The present results suggest that approximately half the total prolactin response to buspirone 
could be attributed to 5-HT1A agonist actions and the other half non 5-HT1A agonist actions 
including putative D2 antagonist activity. Coccaro et al. (1990) found a significant blunting of 
the prolactin response to buspirone by pindolol pre-treatment (5-20mg) in three subjects but the 
study lacked placebo control and led Meltzer et al. (1992) to conduct a further study using pre-
treatment with 30 mg pindolol and a challenge with 30mg buspirone.  These authors found no 
significant difference between the prolactin response to buspirone with or without pindolol pre-
treatment, although the data showed a delay in the onset and peak after pindolol pre-treatment.  
The difference between these results and the present work may be due, in part, to the relatively 
low dose of buspirone and problems with the raised baseline, as mentioned before.  In our 
experience, and from the work of others, 30mg buspirone produces only a modest prolactin 
response in healthy male subjects. 
 
There was a large inter-subject variation in the extent to which pindolol blocked the prolactin 
response to buspirone in the current study. The most obvious explanation is that the relative 
importance of serotonergic and dopaminergic pathways controlling prolactin release differs 
between individuals and may depend on factors such as receptor density and sensitivity. Another 
possible explanation is a pharmacokinetic interaction between pindolol and buspirone, such that 
pindolol may lower plasma buspirone levels.  We were not able to measure plasma buspirone 
concentrations in the present study and therefore cannot exclude this possible mechanism. 
 
It is notable that, with several exceptions, the peak of prolactin release due to the non 5-HT1A 
agonist actions of buspirone occurred later than that due to the 5-HT1A agonist action this 
confirms the findings of Anderson & Cowen (1992). This could be due to an action of pindolol 
slowing the absorption of buspirone, which in turn may lead to its increased metabolism. It can 
therefore not be ruled out that with pindolol pre-treatment there may be a greater prolactin 
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release caused by the Buspirone’s principle active metabolite 1-(2-pyrimidinyl)-piperazine 
(1PP) which results in the later peak on the release curve.  
 
In conclusion, it would appear that the results of a challenge with buspirone alone must be 
interpreted with considerable care since a substantial, and variable, part of the prolactin response 
is due to pathways other than those mediated by 5-HT1A receptors.  However, two challenges, 
one with buspirone alone, the other in the presence of pindolol, provides information about the 
relative sensitivities of both 5-HT1A and non-5-HT1A components and thus adds another 
dimension to the neuroendocrine challenge.  It is possible that, in addition to differences in the 
absolute activity of the hypothalamic pathways, there may be changes in the relative importance 
of various pathways in different disorders or as a result of training or adaptation to changing 
environments. 
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Chapter 5 
 
 
RESPONSES TO EXERCISE IN THE HEAT 
RELATED TO MEASURES OF NEUROENDOCRINE 
FUNCTION 
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5.1 INTRODUCTION 
 
The ability to undertake strenuous physical work at high ambient temperatures is an 
important attribute in many occupations as well as in sport and leisure activities.  Heat 
tolerance varies between individuals and there is considerable practical importance in being 
able to detect individuals who may be heat intolerant, either as a result of an abnormal 
tolerance of increased body temperature, or due to impaired heat loss mechanisms. 
 
As core temperature rises there is an increasing reluctance of subjects to continue working 
and this is thought to be a reflex inhibition (Bruck & Olschewski, 1987), probably arising 
in the hypothalamus or brain stem, and may involve serotonergic (5-HT) pathways that 
project to higher centres.  Increasing core temperature, either passively through exposure to 
high ambient temperature at rest, or actively through exercise, increases central 5-HT 
activity (Hori & Harada, 1976b, a; Bridge et al., 1999).  Hypothalamic 5-HT and 
dopaminergic activity have both been implicated in the control of thermoregulation (Cox et 
al., 1980) and are thought to thermoregulatory responses such as vasodilatation (Cox et al., 
1980). Additionally, activity of these pathways results in an increased release of 
neuroendocrine hormones (Meltzer et al., 1983) and possibly behavioural changes that 
result in a loss of motivation to continue exercise.  Differences in heat tolerance between 
individuals could be due to intrinsic differences of function of these hypothalamic 
pathways, through differences in the sensitivity (receptor density) or activity 
(neurotransmitter release for a given stimulus), giving rise to different thermoregulatory 
and/or behavioural responses to a given thermal load. 
 
Hypothalamic activity cannot be assessed directly in man but the release of prolactin, which 
is stimulated by 5-HT receptors and inhibited by dopaminergic D2 receptors, is often taken 
as an indirect measure.  Drugs that directly, or indirectly, produce activation of 5-HT 
receptors increase plasma concentrations of prolactin.  Data from a range of human and 
animal studies suggests that the serotonergic neurones of the dorsal raphe nucleus project to 
hypothalamic sites to stimulate prolactin secretion through activation of 5-HT receptors 
(Van de Kar et al., 1996). Changes in prolactin levels in the blood therefore provide a 
useful marker for changes in central 5-HT activity as 5-HT is a prominent excitatory 
neurotransmitter for prolactin release (Struder & Weicker, 2001) 
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Circulating plasma prolactin concentrations rise during fatiguing exercise, largely in 
response to increases in core and skin temperature (Brisson et al., 1986; Brisson et al., 
1991; Bridge et al., 1999).  A common technique used to assess hypothalamic 5-HT 
sensitivity in healthy subjects, is to measure the blood prolactin response to a 
neuroendocrine challenge with buspirone (Meltzer et al., 1983; Anderson & Cowen, 1992; 
Bakheit et al., 1992; Jakeman et al., 1994; Sharpe et al., 1996; Bridge et al., 2001).  
(Jakeman et al., 1994) found a reduced prolactin response to buspirone in highly trained 
endurance athletes compared to healthy controls. It has been suggested that a higher aerobic 
fitness provides an advantage during exercise in the heat with an improved ability to 
tolerate a high core temperature at exhaustion (Selkirk & McLellan, 2001).  It is interesting 
therefore to investigate if a reduced prolactin response to buspirone is associated with an 
improved exercise tolerance in the heat. 
 
Buspirone is primarily used as a 5-HT1A receptor agonist but it also has D2 antagonist 
activity and thus causes the release of prolactin through these two actions (Eison & Temple, 
1986).  We have recently shown that it is possible to separate these actions by comparing 
the response to buspirone in the presence and absence of pindolol (Bridge et al., 2001).  
Pindolol blocks 5-HT1A receptors and thus the prolactin response to buspirone in the 
presence of pindolol gives a measure of non-5-HT1A activation which is mainly due to D2 
receptor antagonism (Eison & Temple, 1986).   
 
There is considerable evidence from animal studies to support a role for dopamine in the 
control of body temperature and regulation of heat loss (see Lee et al., 1985 for review) and 
there has been a recent report of increased dopamine in the preoptic area and anterior 
hypothalamus of rats in response to raised body temperature (Hasegawa et al., 2000).  If 
hypothalamic activity is important in determining heat loss and therefore work capacity in 
the heat, it might be possible to predict exercise tolerance in the heat from a test of 
hypothalamic neuroendocrine function.  The main purpose of this study was to evaluate this 
possibility. 
 
We have assessed exercise tolerance at a high ambient temperature compared to the 
response to a neuroendocrine challenge with buspirone with and without pindolol. Our 
hypothesis was that sensitivity of 5-HT and dopaminergic pathways in the hypothalamus, 
 142
as assessed by a neuroendocrine challenge, are predictors of exercise tolerance when 
working in the heat. 
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5.2 METHODS 
 
General Design 
Subjects performed an exercise test to volitional fatigue on a cycle ergometer at an ambient 
temperature of 35°C (relative humidity, 30%) during which blood samples were collected 
every 10 min and rectal and skin temperatures measured every 5 minutes.  The exercise 
tests were followed (on separate occasions) by two neuroendocrine challenges with 
buspirone, one of which was given in the presence of pindolol to block 5-HT1A activity.  
 
Subjects 
Twelve recreationally active and healthy subjects participated in the study.  Their mean age, 
body weight and maximal oxygen consumption  (VO2max) were, 22.9±3.6 years (Mean ± 
SD), 72.8±5.8 kg, and 4.21±0.55 l.min-1, respectively. For the neuroendocrine challenges 
subjects were screened with a clinical interview to exclude any psychiatric history and to 
ensure they had been free of any medication for at least three weeks prior to the study.  The 
study was approved by the Local Research Ethics Committee and subjects gave their 
informed consent in writing. 
 
Experimental Design 
Visit 1 
Subjects completed an incremental exercise test to exhaustion on an electrically braked 
cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands) to determine 
maximal aerobic power output (Wmax) and VO2max.  Workload was increased by 35 Watts 
(W) every 3 min until volitional fatigue. Expired gases were analysed and averaged over a 
10 second period, using a computerised on-line system (Oxycon Alpha, Jaeger, Bunnik, 
The Netherlands). Wmax was estimated using the following equation from (Kuipers et al., 
1985): 
Wmax = Wfinal + (t x W) / T 
 
Where Wfinal  is the power (W) of the last completed stage, t  is the exercise time (s) during 
the final uncompleted stage, T  is the duration (s) of each stage and W  is the workload (W) 
increment for each stage. 
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Visit 2 
Subjects arrived at the laboratory at either 08:00 hours, having fasted from midnight, or at 
13:00 hours having fasted for the previous 4 hours.  A cannula was inserted into an 
antecubital vein to obtain blood samples. To ensure that subjects began each trial 
euhydrated they were given a bolus of water (8ml.kg body weight (bw)-1) to consume 
during the 45 min rest period between cannulation and the start of exercise.  A resting 
blood sample was taken and subjects then began to exercise on the cycle ergometer.  
Exercise continued at a constant work rate of 65% of Wmax (216±11W) and an ambient 
temperature of 35°C, and 30% relative humidity, until volitional fatigue.  Subjects were 
asked to drink a minimum of 3ml.kgbw-1 water every 15 minutes to maintain hydration 
during the exercise.  Heart rate was continuously recorded (Polar Vantage NV, Polar OY, 
Finland).  Venous blood samples (5ml) were taken every 10 minutes during exercise for 
determination of haematocrit, haemoglobin, lactate and glucose.  Whole body ratings of 
perceived exertion (RPE, Borg, 1975) were obtained every 10 minutes during exercise. 
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Body temperature measurements 
Rectal and mean skin temperature, the latter calculated using the four-site formula of 
(Ramanathan, 1964), were recorded every 5 minutes (Squirrel Meter Logger, Grant 
Instruments, Cambridge, UK). 
 
Sweat rate 
Subjects were weighed nude immediately before the start of exercise and at the point of 
fatigue after having first towelled down.   Allowances were made for fluid ingested, 
respiratory water loss (Snellen, 1966), metabolic water loss (Mitchell et al., 1972) and 
quantity of blood drawn to arrive at an overall sweat loss which was divided by time to give 
an average sweat rate over the entire period of exercise. 
 
Neuroendocrine challenges visits 3 & 4 
Subjects each made two visits to the laboratory and received placebo or pindolol as the pre-
treatment followed by buspirone as the drug treatment (Challenge I and II, respectively).  
All drugs were administered orally, encased in identical gelatine capsules.  Challenge I was 
preceded by 2 days during which subjects took a placebo and for the 2 days before 
Challenge II they took pindolol (10mg twice daily).  Challenges I and II were randomised 
and balanced for order and were single-blind to the subjects in respect to pindolol.  
Subjects arrived at the laboratory at 08:00 hours following an overnight fast although water 
was allowed ad libitum during the fast and throughout the challenge. After a 15 min rest a 
21G cannula was inserted into a superficial forearm vein and kept patent with saline 
(Baxter 0.9%). After a further 45 min rest, a baseline blood sample (3ml) was taken and the 
subject ingested either placebo for Challenge I, or pindolol (0.5 mg·kgbw-1, mean dose 
37±3mg; Sandoz) for Challenge II.  Serial blood samples were then taken at 15 min 
intervals for one hour.  Subjects then took buspirone (0.5 mg·kgbw-1, mean dose 37±3mg; 
Bristol-Myers Squibb) and further blood samples were withdrawn every 15 min for the next 
150 min. Subjects rested but were not allowed to sleep in a room at an ambient temperature 
of about 22oC.  Venous blood samples were collected in EDTA tubes and plasma was 
separated by centrifugation and stored at -70°C. All samples were analysed for plasma 
prolactin concentrations (PRL) within 3 months.  
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Blood analysis 
Haematocrit was measured in triplicate by centrifugation.  Blood glucose and lactate 
concentrations were measured using enzyme-linked assays (Sigma Diagnostics, Poole UK); 
haemoglobin concentration was measured using the cyanomethaemoglobin method (Sigma 
Diagnostics, Poole UK). PRL was measured by a radioimmunoassay (Skybio Ltd, UK).  
Average inter- and intra-assay coefficients of variation of the assay were 5.9% and 2.7% 
respectively.  All plasma samples from a single subject were assayed in the same batch. 
 
Statistical Analysis 
Total hormone release in response to buspirone was measured from the area under the 
curve of hormone concentration with time (AUC) calculated using the trapezoid method 
from the time of buspirone administration and was corrected for the average resting 
concentration, from the preceding 60 minutes.  When there was no increase, or a reduction, 
in prolactin concentration after buspirone administration the area under the curve was 
calculated as zero. Plasma volume changes were calculated from haematocrit and 
haemoglobin values using the equations of Dill & Costill, (1974). Data were tested for 
approximation to a normal distribution.  Exercise data were analysed up to 40 minutes to 
include the maximum number of subjects and were tested using repeated measures 
ANOVAs (SPSS 10).  P values were corrected for sphericity using the Huynh-Feldt 
method, and significant differences between time points were identified using Tukey’s 
post-hoc test. Correlations were calculated using the Pearson’s correlation. Data are 
reported as mean ± SEM unless otherwise stated. 
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5.3 RESULTS 
 
Exercise Trials 
Exercise time and perception of exertion 
Mean VO2 was 3.06±0.13 l.min-1 during exercise which was 73±5%VO2max.  Exercise times 
ranged from 20 to 98 min (51.3±6.6 min, Table 5.1).  RPE increased during the exercise 
and was significantly higher than the initial value after 30 minutes (Figure 5.1) and values 
at fatigue were 20. 
 
 
 VO2max Exercise 
time 
Rectal 
Temperature 
at Fatigue 
Sweat 
Rate 
Area under 
curve for 
Buspirone 
Challenge 
Non- 5-HT 
component 
Plasma 
Lactate at 
10 min 
Plasma 
Lactate at
Fatigue 
 (l.min-1) (min) (°C) (l.h-1) (miU.min.l-1) % (mmol.l-1) (mmol.l-1) 
1 4.01 92.5 39.1 2.08 25943 100 2.74 5.90 
2 4.35 98.7 39.1 2.32 41273 100 3.11 8.23 
3 4.92 48.5 39.8 1.63 0 94* 8.34 11.64 
4 4.32 53.9 39.1 1.94 25579 78 3.18 5.72 
5 3.41 60.8 38.6 1.17 20145 52 3.04 4.54 
6 3.77 35.8 38.4 1.11 67481 46 5.64 3.67 
7 5.30 43.5 38.9 2.08 31183 44 4.30 6.66 
8 3.46 43.0 38.2 1.48 42379 15 3.44 3.61 
9 4.27 40.4 38.0 1.69 7838 0 1.93 2.65 
10 3.91 43.4 39.1 1.02 2970 0 6.28 8.23 
11 4.56 20.7 38.3 1.79 65138 0 4.35 3.95 
12 4.21 34.3 38.7 1.75 23438 100 3.38 4.26 
Mean 4.21 51.3 38.8 1.67 29447 49 4.14 5.40 
SD 0.55 23.0 0.5 0.41 21775 41 1.80 2.50 
 
Table 5.1 Individual subject data for maximal oxygen uptake, exercise times, prolactin response to buspirone 
and the non-5-HT component of the buspirone response. *This subject had no prolactin response above 
baseline to challenges with buspirone alone or to pindolol + buspirone and therefore a non-5-HT component 
was not calculated, as a result he is excluded from all correlations. 
 
Body temperature and sweat rate 
Rectal temperature rose steadily throughout the exercise (Figure 5.2) and was 38.8±0.1oC at 
the time of volitional fatigue.  Mean skin temperature rose significantly in the first 10 
minutes of exercise (p<0.05, Figure 5.2) and thereafter remained constant with a fatigue 
value of 34.9±0.3°C.  Sweat rate ranged from 1.02 to 2.32 l.h-1 with a mean value of 
1.67±0.12 l.h-1 (Table 5.1). 
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Figure 5.1 Rating of perceived exertion (Borg scale) during the course of the exercise.  * Indicates significant 
difference from the 10 minute time point, p<0.05; Data are Mean±SEM. 
 
 
 
Figure 5.2 Rectal (triangles) and mean skin temperatures (squares) during exercise.  * Indicates significant 
difference from time point 0, p<0.05; Data are Mean ± SEM. 
 
Blood and Metabolic parameters 
There were no changes in haematocrit or haemoglobin concentration during exercise, at 
fatigue the mean calculated change in plasma volume was 3.9±1.0%.  Blood lactate 
concentration increased during the first 10 minutes of exercise (Figure 5.3) but remained at 
this level to the time of volitional fatigue.  Plasma lactate concentration at fatigue was 5.40 
± 0.72mM.  Plasma glucose concentration did not deviate during exercise, and at fatigue 
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was 5.86 ± 0.43mM (Figure 5.3). No change was seen in the respiratory exchange ratio 
during the course of exercise indicating a consistent source of fuel throughout the exercise. 
 
 
Figure 5.3.  Plasma lactate (triangles) and glucose (circles) concentrations during exercise.  Lactate 
concentrations rose significantly in the first 10 minutes but remained constant thereafter while glucose 
showed no significant fluctuations.  * Indicates higher than time point 0 for lactate, p<0.05. Data are Mean ± 
SEM. 
 
Cardiovascular and respiratory parameters 
Heart rate increased during exercise from 153 ± 4 beats.min-1 at 5 min to 168 ± 5 beats.min-
1 after 40 min of exercise (i.e. from approximately 77% to 85% of maximum heart rate 
measured during the VO2max test).  Ventilation increased during exercise (76.8 ± 5.4 l.min-1 
at 15min compare to 82.0 ± 6.8l.min-1 at 30min, p<0.05).  
 
Neuroendocrine Challenges 
The oral administration of buspirone resulted in a robust prolactin response in all but one 
subject (Figure 5.4).  In the combined challenges, pindolol was given 60 min before the 
buspirone and during this time the resting prolactin fell, on average, by 34%.  Compared 
with buspirone alone, the prolactin response to buspirone in the presence of pindolol was 
reduced in all but two subjects, the peak response being reduced by about a third and the 
time of the peak response delayed by approximately 30 min (81 ± 10min buspirone 
compared to 113 ± 9min pindolol + buspirone, p=0.039 Figure 5.4). 
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Figure 5.4. Prolactin response to challenges with buspirone (triangles) and pindolol + buspirone (Circles). 
Pindolol was administered at the -60 minute time point and buspirone at time point 0. * Indicates significant 
difference from time point 0 in buspirone trial, p<0.05; ^ indicates significant difference from time point 0 in 
both trials, p<0.05. # Indicates significant difference between trials at that time point, p<0.05. Data are Mean 
± SEM. 
 
Subtracting the area under the curve of the pindolol + buspirone response from the area 
under the curve of the response to buspirone alone for each subject allowed the proportions 
of their serotonergic and non-serotonergic components to be calculated.  The non-
serotonergic component of the buspirone response ranged from 0 to 100% with a mean 
value of 49±12% (Table 5.1). 
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Correlations 
Correlations were sought between values derived from the neuroendocrine challenges and 
indices of performance during exercise. Statistical data are presented in Table 5.2.  
 
Variable  Area under 
curve for 
Buspirone 
Challenge 
Non 5-HT 
component 
5-HT 
component 
% Non-5-HT 
Time to fatigue  r 
p  
n 
-0.155
0.630
11
0.661
0.019*
11
-0.576
0.050
11
0.657 
0.028* 
11 
Rate of rectal 
temperature rise 
r 
p 
n 
-0.158
0.625
11
-0.616
0.033*
11
0.234
0.464
11
-0.669 
0.024* 
11 
 
Table 5.2. Pearson correlation coefficients (r), significance values (p) and number of samples (n).  * Indicates 
a significant linear correlation at the indicated p value.  
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5.4 DISCUSSION 
 
The results support the view that with exercise at about 70% VO2max the major limitation to 
performance in the heat is of central origin rather than arising in the peripheral musculature, 
the cardiovascular or respiratory systems.  Results of the neuroendocrine challenges suggest 
that activity of hypothalamic pathways, probably those involving dopamine, play an 
important role in determining such performance.  
 
The existence of central fatigue during submaximal exercise is difficult to prove since, to 
date, it can only be surmised from the absence of signs of peripheral muscle failure.  
Recently, (Nybo & Nielsen, 2001a) have shown that subjects made hyperthermic by 
exercise in the heat were unable to fully activate their quadriceps and that this effect was 
accompanied by changes in their electroencephalogram.  These observations add weight to 
the suggestion that raised core temperature itself is the signal inhibiting exercise rather than 
some consequence of the elevated temperature (Nielsen et al., 1997; Nybo et al., 2001; 
Nybo & Nielsen, 2001b, a, c), such as altered blood flow to the working muscles.   
 
In the work presented here there is evidence that fatigue was not the result of peripheral 
changes.  Blood lactate levels rose initially during the exercise but then remained constant, 
indicating that the working muscles had achieved equilibrium, with energy supply from 
oxidative metabolism matching the energy demands. Subjects remained euglycaemic, and 
RER values remained stable, indicating that there was no change in the proportion of fat 
and carbohydrate oxidisation. Heart rate and ventilation tended to increase throughout 
exercise but at no stage did they approach values that would be considered to be limiting 
for exercise. 
 
RPE increased throughout exercise in parallel with the increase in rectal temperature.  The 
end point of exercise for our subjects occurred at somewhat lower values of core 
temperature than found by Nielsen et al., (1997) and Gonzalez-Alonso et al., (1999). This 
may, in some part, reflect a difference between rectal and oesophageal sites of measurement 
or differences in the type of subjects used. In their studies, Nielsen et al., (1997) and 
Gonzalez-Alonso et al., (1999) used subjects who were endurance trained cyclists, whilst 
our subjects, although generally fit and familiar with cycling exercise, were a more 
heterogeneous group. Additionally, our results do not show such a tight relationship 
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between fatigue and final core temperature, as suggested by Nielsen et al., (1997) and 
Gonzalez-Alonso et al., (1999), since some of our subjects reached volitional fatigue at 
nearly 40oC while others were only at about 38oC (Table 5.1). It has been suggested that in 
moderately fit subjects, as used in this experiment, the cause of voluntary exhaustion during 
exercise in the heat is more a combination of core and skin temperatures, rather than the 
attainment of a high core temperature (Cheung & McLellan, 1998). 
 
The neural structures and pathways involved with central fatigue are poorly understood, but 
there has been interest in the possibility that serotonergic pathways are involved since the 
studies of Newsholme and colleagues (e.g. Newsholme et al., 1987).  Serotonergic 
pathways in the hypothalamus are involved in the control of prolactin secretion, an increase 
of which is associated with the development of fatigue (Marvin et al., 1997).  Central 
fatigue is most evident when working in the heat (Nybo & Nielsen, 2001a) and the 
hypothalamus is also the site of much of the body’s thermoregulatory control (Boulant, 
1981), suggesting that variations in activity or sensitivity of pathways in this region may 
account for some of the variations in endurance capability. The sensitivity of the 
hypothalamic pathways can be assessed by a neuroendocrine challenge with buspirone and 
patients with chronic fatigue syndrome have a very high prolactin response to this 
challenge (Bakheit et al., 1992; Sharpe et al., 1996).  Conversely a low prolactin response 
has been associated with high endurance capacity in fit, young, male subjects (Jakeman et 
al., 1994).  In the latter study, associations were found between athletic ability, based on 
VO2max data, and response to buspirone, but no direct comparison was made with actual 
endurance performance under laboratory conditions.    
 
Buspirone has a complex action in stimulating the release of prolactin since it is both a 5-
HT1A agonist and a D2 antagonist and both these actions result in the release of prolactin.  
We have recently shown (Bridge et al., 2001) that the two actions of buspirone can be 
separated by the use of pindolol and, on average, approximately half the total response can 
be ascribed to a 5-HT stimulatory mechanism (i.e. blocked by pindolol) and the remainder 
to another mechanism which, although not identified, is most likely the removal of 
dopamine inhibition. 
 
The work presented here is the first to make a direct comparison between exercise 
performance in the heat and hypothalamic sensitivity assessed by a neuroendocrine 
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challenge.   It is also the first to dissect the buspirone challenge into its component parts so 
that we have been able to directly compare endurance with the different components of the 
response to buspirone.  From the data presented in Table 5.1 it is evident that the total 
prolactin response to a buspirone challenge bears no relationship to performance in the 
heat.  Comparison of two subjects illustrates the point.  Subjects 2 and 8 had similar total 
prolactin responses (42000 and 41000 miU.min.l-1) but the endurance time for subject 2 was 
over twice that for subject 8.  Neither was there any relationship between prolactin response 
and VO2max as was implied by Jakeman et al., (1994). 
 
Separating the buspirone response in the present study into serotonergic and non-
serotonergic components (Figure 5.4) shows that, on average, the two release mechanisms 
were in very similar proportions (approximately 50%) to those reported previously (Bridge 
et al., 2001).  It is notable, however, that Table 5.1 shows a very wide variation in the 
proportions of 5-HT and non 5-HT components ranging from 100% of one, to 100% of the 
other.  This is a feature that has been commented upon previously (Bridge et al., 2001) and 
it prompts the question of whether the wide variation in neuroendocrine response is related 
to the wide variation in endurance performance seen in the heat (Table 5.1).  We therefore 
sought evidence of relationships between the separate components of the buspirone 
response and endurance exercise performance.  Table 5.2 presents the statistical data and 
while it is evident that there was no relationship between the total buspirone response and 
exercise performance, there was a high positive correlation between the non-5-HT 
component of the response and time to fatigue.  A similar high correlation was found 
between time to fatigue and the proportion of the total prolactin response to buspirone 
attributable to the non-5-HT component. In these circumstances it is not clear whether it is 
a large non-5-HT component or a small 5-HT component that is the most appropriate 
predictor of performance.  
 
Tolerance of high core temperature may be one factor determining endurance performance, 
the rate of temperature rise is clearly another key factor and it notable that while the best 
performers had the highest core temperatures at fatigue, the rate at which their temperatures 
rose was lower than for other subjects. There were strong negative correlations between the 
absolute size and the proportion of the buspirone response attributed to dopaminergic 
activity and the rate of rise of rectal temperature (non-5-HT component, Table 5.2).  
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In summary, our results show that, statistically, a substantial portion of the variation 
endurance capacity of normal subjects exercising in hot conditions may be explained by 
their differing responses neuroendocrine challenges with buspirone, coupled with pindolol 
used to block the 5-HT1A component.  It appears that a high dopaminergic component is 
associated with better exercise performance and this may be related to the absolute 
magnitude of the response or to the high ratio of dopaminergic to serotonergic activities. 
Subjects with high sensitivity of these postulated dopaminergic pathways might benefit by 
a slower rate of rise of core temperature.  
 
The neuroendocrine challenges we have described quantify the activity of hypothalamic 
pathways that appear to be involved in both thermoregulation and the perception of exertion 
and thereby the desire, or ability, to continue exercise.  Such tests may throw light on the 
fundamental mechanisms of central fatigue while they could also prove to be a way of 
identifying individuals who are well adapted to exercise in the heat.  Conversely those who 
are not well adapted may be at risk of developing heat illness since high heat tolerance but 
poor thermoregulation would be a dangerous combination.  
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Chapter 6 
 
 
PROLACTIN RESPONSE TO PASSIVE HEAT 
STRESS WITH AND WITHOUT 5-HT1A 
RECEPTOR BLOCKADE 
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6.1 INTRODUCTION 
Increasing core-temperature either passively, through exposure to high ambient 
temperatures at rest, or actively, through exercise, results in a number of physiological 
and behavioural responses.  These include vasodilatation, increased sweating, and a 
desire to move away from the heat.  Additionally, as body temperature rises there are 
increased feelings of fatigue and lethargy. These feelings probably arise from the 
limbic area, hypothalamus or brain stem and involve serotonergic neurones that 
radiate from the raphe nuclei to higher centres concerned with motivation and motor 
drive. 
 
Increased deep body temperature has been shown to increase central brain serotonin 
(5-HT) concentration in animals (Mohamed & Rahman, 1982; Sharma & Dey, 1987; 
Sharma et al., 1992; Dey et al., 1993) and is also likely to do so in man.  Central 
serotonergic activity cannot be assessed directly in human subjects but many studies 
have used the release of prolactin (PRL) as an indirect measure.  PRL is released from 
the anterior pituitary gland and its release is stimulated primarily by 5-HT receptor 
activation and inhibited by dopamine (DA) (Eison & Temple, 1986).  During passive 
heat exposure, circulating PRL has been found to rise in a linear fashion with core and 
skin temperature (Christensen et al., 1985; Brisson et al., 1991).  By measuring the 
PRL response for a given rise in temperature it may be possible to obtain an index of 
hypothalamic sensitivity.  Additionally, there is also evidence to suggest that 5-HT 
may also have an important role in the regulation of body temperature (Yamawaki et 
al., 1983). 
 
There is considerable evidence from animals to support a role for DA in the control of 
body temperature, largely regulating heat loss (see Lee et al., 1985 for review) and 
there has been a report of increased dopamine in the preoptic area and anterior 
hypothalamus in response to raised body temperature in rats (Hasegawa et al., 2000).  
To interpret the results of studies where PRL is released as core temperature is raised 
the relative contributions of both 5-HT and DA mechanisms to this release need to be 
ascertained. 
 
By administration of the 5-HT1A receptor antagonist pindolol, we have previously 
shown that approximately 82% of the basal PRL release is attributable to non-5-HT1A 
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mechanisms, most likely of a dopaminergic nature (Bridge et al., 2001), and that 
~50% of the PRL release in response to buspirone can be attributed to each of the 
mechanisms. However no such information is available about the mechanisms 
responsible for the increase in PRL with rising body temperature. 
 
Brain hypothalamic DA concentration is known to increase as a result of heat 
exposure in rats (Kao et al., 1994; Hasegawa et al., 2000), and this would be expected 
to lead to a reduced PRL secretion through a greater DA inhibition. However, in man 
increased PRL release is seen with rising body temperature, raising the possibility that 
PRL release in response to heat is entirely driven by 5-HT stimulation. This has 
important implications for exercise since it has been argued earlier (Chapters 2 & 3) 
that PRL release during exercise is primarily in response to raised core and skin 
temperature rather than any changes in circulating metabolites.  
 
To ascertain the relative contribution of 5-HT1A and non-5-HT1A (DA) mechanisms to 
PRL release in response to heat stress, we have measured plasma PRL concentration 
with and without pindolol pre-treatment.  
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6.2 METHODS 
 
General design 
Subjects underwent two passive heat exposures in a sauna maintained at 80°C to raise 
core temperature by 2.0°C. Before one of the heat exposures subjects took pindolol 
(10mg) twice daily for two days and 30mg 45 minutes before entering the sauna.  
Blood samples were taken during the heat exposures and analysed for PRL. 
 
Subjects 
Ten recreationally active non-acclimatised subjects participated in the study, which 
was of a randomised crossover design.  Their mean age, and body weight were 23.3-
±3.9 y (Mean ± SD) and 74.1±5.6 kg, respectively. Subjects were screened with a 
clinical interview to ensure that there was no previous psychiatric history and they 
had been free of any medication for at least three weeks prior to the study. The study 
was approved by the Local Research Ethics Committee and subjects gave their 
informed consent in writing. 
 
Experimental design 
Prior to the heat exposures subjects either took pindolol (10mg) or a placebo twice 
daily for two days and 45 minutes (pindolol 30mg or placebo) before entering the 
sauna.  Visits were balanced for order. Subjects arrived at the laboratory after an 
overnight fast and rested for 15 minutes before a cannula was inserted into a forearm 
vein. Subjects then drank 500ml of water to ensure adequate hydration.  After a 
further 45 minutes rest, subjects entered a sauna at an ambient temperature of 80°C 
(RH 85-90%).  Subject temperature was monitored continuously by a rectal probe 
(Grant Instruments Ltd, Cambridge, UK) and they remained in the sauna until their 
core temperature had increased by 2°C.  Blood samples (5ml) were taken after every 
0.5°C rise of core temperature.  Water was allowed ad libitum and subjects were 
encouraged to drink freely.  
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Blood analysis 
Haematocrit was measured in triplicate by centrifugation and haemoglobin was 
measured using the cyanomethaemoglobin method (Sigma Diagnostics, Poole UK).  
PRL was measured by radioimmunoassay (Skybio Ltd., UK).   
 
Statistical Analysis 
Total PRL release was measured from the area under the curve of the plasma PRL 
concentration with time (AUC) calculated using the trapezoid method and corrected 
for baseline concentrations.  Plasma volume changes were calculated using the 
equations of [Dill, 1974 #1545].  Data were tested for approximation to a normal 
distribution.  Data were analysed using repeated measures ANOVAs.  P values were 
corrected for sphericity using the Huynh-Feldt method, and significant differences 
between time points were identified using Tukey’s post-hoc test. Data are reported as 
mean ± sem. 
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6.3 RESULTS 
 
All subjects completed the two heat exposure sessions attaining a core temperature 
increase of 2.0°C in a similar time in both sessions (36.9±2.5min normal v 
32.6±1.9min pindolol, p=0.117). There were also no differences between the times 
taken to reach each 0.5°C temperature rise in each session (Figure 6.1). 
 
 
Figure 6.1. Time to increase rectal temperature by 0.5°C increments. Solid symbols show data from the 
placebo trial open symbols show data from pindolol trial. Data are mean±sem. 
 
Hormonal response 
In both heat exposures plasma PRL concentration rose and was significantly higher 
than basal levels after a 1.5°C rise in rectal temperature (394±54 baseline v 
1381±227miU.l-1 placebo and 340±39 baseline v 1128±184miU.l-1 pindolol, p<0.05, 
Figure 6.2).  No differences were found in plasma PRL concentrations between 
exposures at any increase in rectal temperature (Figure 6.2) nor was there a difference 
in plasma PRL concentration at a given rectal temperature (Figure 6.3).  Total 
prolactin release (AUC) did not differ either between sessions (97,232±14,411 normal 
v 80,986±9980miU.min.l-1 pindolol, p=0.311). 
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Figure 6.2. Plasma prolactin concentration at each 0.5°C rise in rectal temperature. Solid symbols show 
data from the placebo trial open symbols show data from pindolol trial. * indicates a significant 
difference from 0 time point for both trials. Data are mean±sem 
 
 
Figure 6.3. Plasma prolactin response to rectal temperature. Solid symbols show data from the placebo 
trial open symbols show data from pindolol trial. Data are mean±sem. 
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Figure 6.4. Changes in calculated plasma volume [Dill, 1974 #1545] during passive heat exposure. 
Solid symbols show data from the placebo trial open symbols show data from pindolol trial. Data are 
mean±sem. 
 
Blood parameters 
Whilst haemoglobin and plasma volume (Figure 6.4) remained fairly constant there 
was a significant increase in haematocrit (45.1±0.9 v 46.5±0.8%, p<0.05) after a 
1.0°C rectal temperature rise in the normal session and after a 1.5°C rise (45.4±0.7 v 
46.8±0.5%, p<0.05) in the pindolol session. No differences were found between 
sessions, at any core temperature increase, in haematocrit, haemoglobin or change in 
plasma volume. 
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6.4 DISCUSSION 
 
The results presented here are interesting, but also very puzzling. It is important to 
know how PRL is released during fatiguing exercise since the release of PRL is 
closely associated with the development of central fatigue and there may well be 
common neural pathways involved. PRL release during exercise appears to be largely 
stimulated by increases in core and skin temperature (Chapter 2 & 3) and thus passive 
heating may be a good model for this aspect of exercise. The initial conclusion, 
therefore, might be that during exercise the release of PRL is largely due to a 
withdrawal of DA inhibition rather than an increase in serotonergic stimulation. The 
result is also puzzling, partly because there is a considerable amount of work, albeit 
sometimes controversial, going back to that of Newsholme et al., (1987) suggesting 
that it is an increased serotonergic activity which is the stimulus for central fatigue. 
Secondly, the high temperature of the sauna stimulated a massive thermoregulatory 
response and this is normally associated with an increase in dopaminergic activity in 
the hypothalamus rather than a decrease implied by the present findings. 
 
The interpretation of the results presented here rests first on the selectivity and 
efficacy of the 5-HT1A antagonist action of pindolol and, secondly, on the lack of any 
complicating actions. Pindolol has been shown to have a high affinity for 5-HT1A 
receptors (Andree et al., 1999; Martinez et al., 2000; Rabiner et al., 2000a; Rabiner et 
al., 2000b; Martinez et al., 2001; Passchier et al., 2001) and does not appear to 
possess any activity at DA receptors (Hjorth & Carlsson, 1986).  Additionally PET 
scanning has shown that a 20mg dose of pindolol, without a priming dose, resulted in 
a 46% post-synaptic 5-HT1A receptor occupancy (Rabiner et al., 2000b). Whilst this is 
by no means a total blockade of post-synaptic receptors, the results also show that the 
occupancy is dose dependant (Rabiner et al., 2000b). It is therefore likely that with 
the priming dose given for two days before the heat exposure and the relatively high 
dose (30mg) given an hour a higher 5-HT1A receptor occupancy was achieved. Indeed 
Rabiner et al (Rabiner et al., 2000b) suggest that a 30mg dose would be enough to 
fully block the functional responses to the 5-HT1A agonist buspirone. 
 
Brain 5-HT concentrations have been shown to increase in animals as a result of heat 
exposure (Mohamed & Rahman, 1982; Sharma & Dey, 1987; Sharma et al., 1992; 
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Dey et al., 1993) and it is likely that this also occurs in man but it would appear that 
this does not stimulate PRL release via 5-HT1A receptors.  However, activation of 
other 5-HT receptor subtypes (e.g. 5-HT2C) has also been shown to cause PRL release 
in man although not to the same extent as 5-HT1A receptors (Barnes & Sharp, 1999). 
The possibility exists that some, probably small, part of the PRL release might have 
been due to stimulation of other 5-HT receptor subtypes. 
 
The stimulus for changes in central 5-HT and DA activity and therefore PRL release 
during heat exposure is not entirely certain but increasing core temperature and a 
higher skin temperature are both likely to be important factors (Chapters 2 & 3).  The 
main thermoregulatory control centre of the body is located in the rostral 
hypothalamus and in particular the preoptic and anterior hypothalamus (Boulant, 
1981, 2000). This area is known to contain the central brain thermoreceptors and is 
populated by temperature sensitive neurones which change their firing rates in 
response to changes in local or core temperature (Boulant, 1981, 2000).  The same 
neurones also receive afferent information from skin and spinal thermoreceptors and 
integrate this information into the appropriate thermoregulatory response to a given 
heat load or cold stress (Boulant, 1981, 2000).  There is good evidence that some of 
these temperature sensitive neurones are dopaminergic (Cox et al., 1980) and that 
serotonergic neurones, which have previously been shown also to be temperature 
sensitive (Dickenson, 1977), project into the preoptic area from the dorsal raphe 
nuclei (Cox et al., 1980).  It is possible therefore that activation of these temperature 
sensitive neurones will result in an increase in activity of one and or both 5-HT and 
DA pathways.   
 
It would be expected that hypothalamic DA concentrations would have increased in 
our subjects as a result of heat exposure. Evidence for this comes from animal studies 
that have shown hypothalamic DA concentrations to increase with heat exposure (Kao 
et al., 1994; Hasegawa et al., 2000) and that DA has an important role in heat 
dissipation (Cox et al., 1980; Lin et al., 1982; Lee et al., 1985; Kendrick et al., 1989; 
Canini & Bourdon, 1998).  It is difficult to reconcile this with the present finding 
which suggests that PRL release is due to the withdrawal of DA inhibition. One 
explanation for this is that the pathways controlling PRL release and those affecting 
heat loss mechanisms are separate and distinct from each other, and that an increase in 
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the activity of one of these pathways may be accompanied by a decrease in the other, 
the different DA receptor subtypes may have some part to play in this behaviour.  DA 
control of PRL secretion from the pituitary gland is largely governed by the D2 type 
receptor (Chang et al., 1997) whilst the both D1 & D2 receptor types control the 
hypothalamic heat loss mechanisms (Salmi et al., 1993; Verma & Kulkarni, 1993), 
although they are unequal in effect (Verma & Kulkarni, 1993; Salmi, 1998) working 
through separate pathways (Salmi, 1998). 
 
Pindolol may not provide complete blockade of all 5-HT1A receptors and some 
component of PRL release may be stimulated by 5-HT receptors other than 5-HT1A. 
Nevertheless, we have previously shown pindolol to block the 5-HT1A agonist activity 
of buspirone (Bridge et al., 2001) and it is clearly an effective drug acting on 
serotonergic pathways in the hypothalamus. Consequently if there was a component 
of PRL release which was 5-HT1A dependent, some reduction in PRL release with 
pindolol would have been seen. This was not the case and the final conclusion must 
be that there is no evidence of 5-HT1A stimulation being involved in the heat-induced 
release of prolactin during passive heating. This raises doubts as to whether the 
release of prolactin during hyperthermia in exercise involves 5-HT pathways and in 
turn the role of 5-HT in central fatigue in the heat.  
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Chapter 7 
 
 
EFFECT OF CAFFEINE CONSUMPTION AND 
THE ROLE OF HYPOTHALAMIC PATHWAYS 
ON ENDURANCE PERFORMANCE AT 
DIFFERENT AMBIENT TEMPERATURES 
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7.1 INTRODUCTION 
 
Caffeine, 1,3,7-trimethylxanthine, is one of the most widely taken drugs in the world 
and is believed to improve exercise capacity (Pasman et al., 1995; Spriet, 1995; 
Graham & Spriet, 1996).  There are reports of caffeine reducing perceived exertion 
during exercise (Rodrigues et al., 1990; Alves et al., 1995; Cole et al., 1996) and it 
also has many positive subjective effects including increased feelings of well-being, 
energy, alertness, concentration and motivation (Griffiths et al., 1990). 
 
Despite this range of apparently beneficial effects, there is little information about the 
mechanism of action of caffeine.  One possible peripheral mechanism might be to 
increase circulating free fatty acids which could stimulate fatty acid oxidation, sparing 
carbohydrate stores, and thus prolong exercise (Costill et al., 1978; Erickson et al., 
1987; Graham & Spriet, 1991) and caffeine has been reported to reduce the rate of 
glycolysis in the first 15 minutes of exercise (Spriet et al., 1992). However, more 
recent studies have failed to demonstrate a glycogen sparing effect either in the first 
few minutes of exercise (Graham et al., 2000) or over the entire exercise period 
(Chesley et al., 1995; Jackman et al., 1996; Graham et al., 2000; Laurent et al., 2000).  
Additionally, caffeine has been found to raise blood lactate levels during exercise, 
indicating an increased muscle glcyogenolysis (Graham & Spriet, 1995; Jackman et 
al., 1996; Laurent et al., 2000) rather than glycogen sparing.   Other investigators 
have found an elevation of circulating free fatty acids but without any indication of an 
increase in fat metabolism (Tarnopolsky, 1994; Graham et al., 1998; Graham et al., 
2000).  Jacobson et al. (2001) examined the action of caffeine taken together with fat 
or carbohydrate supplements on endurance exercise and found no effect on metabolic 
parameters while ratings of perceived exertion were consistently lowered. 
 
Since there is no good evidence for a peripheral action of caffeine, attention has 
turned to possible central neural mechanisms during prolonged endurance exercise 
where the inability to continue exercising may be due to a loss of central drive or 
motivation (Newsholme et al., 1987).   Increasing feelings of effort and, eventually, 
fatigue are associated with a rise in blood levels of prolactin (PRL) (Marvin et al., 
1997) which is secreted from the anterior pituitary under the control of serotonergic 
and dopaminergic pathways in the hypothalamus (Struder & Weicker, 2001). It is 
 176
therefore possible that these pathways are also involved with the development of 
central fatigue.  Endurance is reduced and perceived exertion increased when exercise 
is undertaken in hot environments, largely through an effect of raised body and skin 
temperature reducing central drive (Nybo & Nielsen, 2001a, b).  Since the 
hypothalamus is intimately involved in both temperature regulation and 
neuroendocrine responses it has been suggested that the hypothalamus plays a role in 
integrating temperature regulation and the neuroendocrine response with the 
behavioural response (a disinclination to continue working, i.e. volitional fatigue) to 
prolonged exercise (Chapters 2 & 3).   Studies with rodents have shown that caffeine 
can alter brain serotonin (5-HT) and dopamine (DA) concentrations, synthesis and 
turnover (Hadfield & Milio, 1989; Kirch et al., 1990; Nehlig et al., 1992), and it has 
been suggested that serotonin plays an important role in the mechanism of action of 
caffeine on the central nervous system (Hirsh, 1984). If, therefore caffeine acts 
through a central mechanism it could well do so by affecting hypothalamic 5-HT and 
DA pathways and it would be expected to be most effective in conditions where 
central fatigue is most evident, namely during exercise at high ambient temperatures. 
 
Data from a range of studies suggests that serotonergic neurones of the dorsal raphe 
nuclei project to hypothalamic sites to stimulate PRL secretion through activation of 
central 5-HT receptors (Van de Kar et al., 1996). Changes in PRL levels in the blood 
therefore provide a useful marker for changes in central 5-HT activity as 5-HT is a 
prominent excitatory neurotransmitter for PRL release (Struder & Weicker, 2001). 
However 5-HT does not have exclusive control of PRL secretion. Prolactin is also 
under a tonic inhibitory control by the hypothalamus, through DA secreted by the 
tuberohypophyseal pathway (Ben-Jonathan & Hnasko, 2001). 
 
Although circulating PRL has often been measured as an indicator of central changes 
with fatiguing endurance exercise there are no reports of the action of caffeine on 
PRL release.  Neither is there a substantial body of literature concerning the action of 
caffeine on exercise at high ambient temperatures.   Cohen et al. (1996) found no 
effect of two doses of caffeine during competitive road races in hot and humid 
conditions, which runs counter to the prediction that caffeine would be more effective 
in hot conditions.  However, exercise in a cool environment was not included in this 
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investigation and, to date, no direct comparison has been made of the effects of 
caffeine at high and low ambient temperatures.  
 
The results presented here are from two separate experiments investigating the 
ergogenic action of caffeine, one carried out at a high ambient temperature and the 
other in a cooler environment.  The first hypothesis tested was that the central action 
of caffeine is mediated by an action on hypothalamic 5-HT and DA pathways and this 
would be evident as a decrease in the PRL response to fatiguing exercise.  This 
hypothesis was addressed in each of the two studies.    The second hypothesis was 
that caffeine acts on pathways sensitive to body temperature and would thus be most 
effective during exercise at high ambient temperatures.  This hypothesis was 
addressed by comparing the results of the two experiments one in the hot and the 
other in the cool conditions. 
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7.2 METHODS 
 
General Design 
Subjects performed two exercise tests to volitional fatigue on a cycle ergometer after 
ingestion of caffeine (5mg.kgbw-1) or placebo capsules.  Tests were balanced for order 
and carried out double blind. The work reported here consists of two such 
experiments, the first at an ambient temperature of 18±0.3oC (relative humidity 57%) 
and the second at 35±0.3oC (relative humidity 29%).    
 
Subjects 
Seven trained male subjects participated in the first study; their mean age, body 
weight and VO2max were 24±4 yrs (Mean±SD), 75.5±4.8 kg, and 4.52±0.44 l.min-1, 
respectively.   Four of these subjects also participated in the second experiment 
which, in all, involved eight male subjects of 23±1 yrs, 70.5±1.8 kg, and 4.45±0.15 
l.min-1.  All subjects were familiar with the experimental protocols and were non heat 
acclimatised. Daily caffeine consumption of the subjects ranged from none to high (0- 
450mg.day-1) with similar ranges in both studies.  The study was approved by the 
Local Research Ethics Committee and subjects gave their written informed consent. 
 
Experimental Design 
 
Visit 1 
On their first visit to the laboratory subjects undertook an incremental exercise test to 
exhaustion on an electrically braked cycle ergometer (Lode Excalibur Sport, 
Groningen, The Netherlands) to determine maximal power output and VO2max.  
Workload was increased by 35 Watts every 3 minutes until volitional exhaustion.  
 
Visits 2 & 3 
Subjects abstained from caffeine for three days before each visit.  Subjects recorded 
their diet the day before visit 2 and were asked to adhere to the same diet on the day 
before visit 3.  On the morning of a test subjects arrived at the laboratory at 8am, 
having fasted from midnight, or at 1pm, having fasted for the previous 4 hours.  Each 
subject carried out their two tests at the same time of day.  Rectal temperature was 
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measured in both trials and in the trial at 35oC mean skin temperature was determined 
from measurements at four sites (Ramanathan, 1964).  A cannula was inserted into an 
antecubital vein and subjects then rested for 30 minutes before a blood sample (5ml) 
was taken and subjects ingested either caffeine (5mg.kgbw-1, Roche) or placebo 
capsules.  Subjects were given a bolus of water (8ml.kgbw-1) with their tablets to 
ensure that they began each trial fully hydrated.  After a further 60 minutes rest at 
room temperature (approx 18oC), subjects voided any urine and their body weight was 
recorded to the nearest 10g.   They then began to exercise on an electrically braked 
cycle ergometer until volitional fatigue, or for 90 minutes (whichever was the 
shorter), at a constant work rate calculated to elicited 70% VO2max from visit 1.  To 
maintain hydration during the exercise subjects were asked to drink a minimum of 
2ml.kgbw-1 at 18oC or 3ml.kgbw-1 at 35oC water every 15 minutes, although they were 
free to drink more. 
 
Ratings of perceived exertion (RPE; Borg, 1971) were obtained every 10 min during 
exercise.   Heart rate was recorded continuously (Polar Vantage NV, Polar OY, 
Finland) during the exercise period.  Rectal (and when measured mean skin) 
temperature was recorded every 5 min (Squirrel Meter Logger, Grant Instruments, 
UK) and VE, VO2, and VCO2 were measured every 15 min.  Venous blood samples 
(5ml) were obtained before, every 10 minutes during exercise and at the point of 
fatigue for determination of haematocrit, lactate, glucose, free fatty acids and PRL.  
Body weight was recorded immediately at the end of exercise after sweat was 
towelled off the skin.  Sweat loss was calculated as the difference in body mass 
between the start and end of the trials after correction for respiratory and metabolic 
water loss, fluid intake and the blood samples taken.  Data are expressed as sweat rate 
by dividing sweat loss by the exercise time to give an average value in litres per hour.  
 
Blood Analysis 
Haematocrit was measured in triplicate by centrifugation.  Blood glucose, lactate 
(Sigma Diagnostics, Poole UK) and free fatty acids (Wako Chemicals GmbH, 
Germany) were measured using enzyme-linked assays and haemoglobin using the 
cyanomethaemoglobin method (Sigma Diagnostics, Poole UK).  Plasma PRL 
concentration was measured by a radioimmunoassay (Skybio Ltd, UK).  Average 
inter- and intra-assay coefficients of variation of the assay were 5.9% and 2.7% 
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respectively.  All plasma samples from a single subject were assayed in the same 
batch.  Caffeine was measured in plasma samples using an ELISA method with an 
Olympus 600 analyser. 
 
Statistical Analysis 
All data was tested for approximation to a normal distribution.  Significant differences 
within trials were determined using repeated measures ANOVA with Bonferroni 
corrections for multiple comparisons where data were normally distributed or, 
otherwise, a Friedman test was used.  Between trials, where data were normally 
distributed, significance was determined at matched time points using Student’s 
paired t-test. Significance was determined using Wilcoxon non-parametric tests if the 
data were found not to be normally distributed.  Data are presented as mean±sem 
unless otherwise stated. 
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7.3 RESULTS 
 
Experiment 1: ambient temperature 18oC 
Exercise capacity and perceived exertion 
Exercise intensity was the same in both trials (73±4% VO2max for the placebo trial v 
76±2% with caffeine, p=0.3). Two subjects were stopped after 90 minutes of exercise 
in the placebo trial and three in the caffeine trail. One of these subjects was stopped 
after 90 minutes in both trials and one subject cycled for longer on the placebo (90 
minutes) compared to caffeine.  However the remainder all exercised for longer in the 
caffeine trial  (Figure 7.1). 
 
 
Figure 7.1.  Exercise times for individual subjects during the placebo and caffeine trials at 18°C. 
 
Excluding the subject who was stopped at 90 minutes on both occasions, the exercise 
time was 68.3±6.6 min for the placebo trial and 81.4±4.8 min for the caffeine trial, an 
average improvement of 23%.   The subject who exercised for longer on placebo had 
the highest habitual caffeine intake but, otherwise, there was no relationship between 
habitual caffeine intake and performance in the caffeine trial.   Irrespective of the 
effects on performance time, all subjects reported lower RPE scores during the 
caffeine trial, these being significantly lower from 20 minutes onwards (Figure 7.2, 
p<0.05). 
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Figure 7.2.  Perceived exertion during exercise at 18°C.  Data are mean ± sem placebo - triangles. 
caffeine –circles. * indicates significant difference between trials ^  indicates significant increase from 
resting value in placebo trial # indicates significant increase from resting value in both trials (P<0.05). 
 
 
Figure 7.3.  Rectal temperature during exercise at 18°C.  Data are mean ± sem E – end of exercise.  
Placebo trial – triangles.  Caffeine trial –circles. * indicates significant difference between trials ^ 
indicates significant increase from resting value in placebo trial # indicates significant increase from 
resting value in both trials (P<0.05). 
 
Body temperature and sweating responses 
Body temperature before exercise was the same with and without caffeine and there 
were no differences in rectal temperature between trials at identical time points up to 
45 minutes (Figure 7.3).  Rectal temperature at volitional fatigue was significantly 
higher in the caffeine trial (40.5±0.3°C) than with the placebo (39.8±0.3°C) (Figure 
7.3, p<0.05).  There was a tendency for sweat rate to be lower in the caffeine trial 
(0.88±0.14 l.hr-1, compared to 1.05±0.07 l.hr-1) although there was no statistically 
significant difference between trials. 
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Respiratory and Cardiovascular responses 
There were no differences in any of the respiratory variables between trials (VO2, 
VCO2, VE and RER, Table 7.1) which demonstrates that the energy consumption, 
gross efficiency and relative rates of carbohydrate and fat oxidation were not altered 
by taking caffeine.  . Whilst heart rate increased during the exercise, values were 
similar for each trial with no differences found between trials in maximum (175±4 
beats.min-1 placebo v 175±3 beats.min-1 caffeine) and average heart rate(157±4 
beats.min-1 placebo v 156±3 beats.min-1 caffeine) before or at any time during 
exercise.  
 
18°C 35°C  
Placebo Caffeine Placebo Caffeine 
VO2 (l.min-1) 3.56±0.15 3.43±0.23 3.18±0.10 3.21±0.13 
VCO2 (l.min-1) 3.19±0.17 3.12±0.21 3.09±0.13 3.16±0.13 
RER 0.89±0.05 0.91±0.01 0.97±0.01 0.99±0.01 
 
Table 7.1. Mean respiratory parameters for each trial at both temperatures. Data are mean±sem. 
 
Blood metabolites 
Blood caffeine levels were 8.2±0.7mg.l-1 60 minutes after caffeine ingestion at the 
start of exercise and were undetectable in the placebo trial. Blood glucose 
concentrations remained stable throughout exercise with no change from rest to 
fatigue (6.1±0.7 v 6.4±0.7mmol.l-1 for the placebo trial and 6.0±0.6 v 5.6±0.4mmol.l-1 
with caffeine). Blood lactate concentration increased in both trials in the first 10 
minutes of exercise and then remained stable throughout exercise with no difference 
between levels at 10 minutes and fatigue (6.1±0.6 v 6.4±0.7mmol.l-1 for the placebo 
trial and 5.9±0.6 v 5.5±0.8mmol.l-1 with caffeine).  Serum FFA concentrations were 
significantly higher in the trial with caffeine after 10 minutes of exercise and 
remained elevated above the concentrations in the placebo trial, however there were 
no significant differences between trials at the time of fatigue (Figure 7.4).  There 
were no differences in haematocrit or haemoglobin between or within trials at any 
time point. 
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Figure 7.4  Plasma free fatty acid concentration (FFA) during exercise at 18°C.  Data are mean ± sem. 
E – end of exercise.  Placebo trial – triangles.  Caffeine trial –circles. * indicates significant difference 
between trials ^ significant difference between time points (P<0.05). 
 
Hormonal Responses 
Plasma PRL levels rose although not significantly during the first 40 minutes of 
exercise in both trials and reached maximum values, which were higher than at rest 
(159 (147-177) v 443 (315-715) miU.l-1 placebo trial and 163 (119-194) v 405 (345-
498) miU.l-1 caffeine trial, median (IQ range) p<0.05) at the time of fatigue.  No 
differences were found between caffeine and placebo trials in terms of the values at 
given time points (Figure 7.5). 
 
 
Figure 7.5  Plasma prolactin in response to exercise at 18°C.   Data are mean ± sem. E – end of 
exercise. Placebo trial – triangles, open bar.  Caffeine trial –circles, solid bar. * indicates significantly 
difference from 0 minute time point, p<0.05. 
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Experiment 2: Ambient temperature 35oC 
 
Exercise duration and perceived exertion 
Endurance was approximately halved at the higher ambient temperature compared to 
exercise at 18oC, although the comparison is not strictly valid since only half the 
subjects participated in both trials.  Exercise intensity was identical between trials 
(72±2%VO2max in the placebo trial v 72±3% VO2max with caffeine, p=0.7) and 
caffeine improved performance in all but one subject who rode for the same time in 
both trials.  One subject was stopped at 90 minutes when on the caffeine trial.  
Ignoring the one subject who was stopped at 90 minutes in both trials, the times to 
volitional fatigue were 40:25±7:09 min for the placebo trial and 47:22±7:58 min with 
caffeine, the improvement in endurance on the caffeine trial being 18%, (Figure 7.6).  
Ratings of perceived exertion were significantly lower in the caffeine trial at all times 
during the exercise (Figure 7.7). 
 
 
Figure 7.6.  Exercise times for individual subjects during the placebo and caffeine trials at 35°C. 
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Figure 7.7  Perceived exertion during exercise at 35°C. Data are mean ± sem. Overall indicates subject 
rating of whole exercise period.  Placebo trial – triangles, open bar.  Caffeine trial –circles, solid bar. * 
indicates significant difference between trials ^ indicates significant increase from 10 minute value in 
both trials (P<0.05). 
 
Body temperature and sweating responses 
Rectal temperature increased throughout exercise, rising significantly above initial 
values after 25 minutes in the placebo trial and after 20 minutes in the caffeine trial.  
Rectal temperature was higher in the caffeine trial compared to placebo after 15 
minutes of exercise and remained higher throughout the remainder of the exercise.  At 
volitional fatigue rectal temperatures were 38.5±0.3°C for the placebo trial and 
38.9±0.3°C for the caffeine trial (p<0.05; Figure 7.8).  Sweat rates were not different 
between trials, 1.01±0.72 l.h-1 for the placebo trial and 1.23±0.82 l.h-1 for the caffeine 
trial.  Mean skin temperature was the same in both trials, being 33.4±0.1oC during the 
placebo trial and 33.3±0.2oC for the caffeine trial and in neither case was there any 
change during exercise.   
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Figure 7.8  Rectal temperature during exercise at 35°C.  Data are mean ± sem. F – indicates fatigue 
time point. Placebo trial – triangles.  Caffeine trial –circles. * indicates significant difference between 
trials ^ indicates significant increase from resting value in caffeine trial # indicates significant increase 
from resting value in both trials (P<0.05). 
 
Respiratory and cardiovascular responses 
There were no differences in any of the respiratory variables (VO2, VCO2, VE and 
RER, Table 7.1) between trials which demonstrates that the energy consumption, 
gross efficiency and relative rates of carbohydrate and fat oxidation were not altered 
by taking caffeine. Whilst heart rate increased during the exercise, values were similar 
for each trial with no differences found between trials in maximum (179±4 beats.min-1 
placebo v 181±5 beats.min-1 caffeine) and average heart rate(163±4 beats.min-1 
placebo v 165±4 beats.min-1 caffeine), before or at any time during exercise. No 
differences were found between trials in RER (0.99±0.0 caffeine v 0.97±0.0 placebo).  
 
Blood metabolites 
Blood caffeine levels were 7.9±0.8mg.l-1 60 minutes after caffeine ingestion at the 
start of exercise and were undetectable in the placebo trial.  Blood lactate rose in the 
first 10 minutes of each trial to a level significantly higher than at the start of exercise 
(Figure 7.9).  Although there was a tendency for lactate to continue to rise there were 
no statistically significant differences between values after 10 minutes of exercise and 
those at fatigue.  Blood lactate was significantly higher at all time points during 
exercise with caffeine compared to the placebo trial (Figure 7.9, p<0.05).  There were 
no changes in blood glucose concentrations during the first 20 minutes of exercise in 
either trial.  Thereafter concentrations tended to rise so that at fatigue the 
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concentrations were higher than after 10 minutes exercise in the placebo trial (5.0±0.3 
v 6.3±0.2mmol.l-1, p<0.05), or after 20 minutes in the caffeine trial (5.9±0.4 v 
7.1±0.6mmol.l-1, p<0.05). 
 
Figure 7.9  Plasma lactate during exercise at 35°C.  Data are mean ± sem. F – indicates fatigue time 
point.  Placebo trial – triangles.  Caffeine trial –circles. * indicates significant difference between trials 
(P<0.05);  ^ indicates significant increase between time points in both trials P<0.05. 
 
 
Figure 7.10  Plasma free fatty acid (FFA) during exercise at 35°C.  Data are mean ± sem. F – indicates 
fatigue time point.  Placebo trial – triangles.  Caffeine trial –circles. * indicates significant difference 
between time points in placebo trial ^ indicates significant difference between time points in caffeine 
trial (P<0.05). 
 
In the placebo trial FFA levels were higher at fatigue than at 10 and 20 minutes 
(Figure 7.10) in the caffeine trial FFA levels decreased in the first 10 minutes of 
exercise but were not significantly different from resting levels at fatigue (Figure 
7.10).  No statistically significant differences were seen between trials at any time 
point during the exercise. Haematocrit and haemoglobin did not change during 
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exercise and no differences were found between trials at any times.  This was 
reflected in changes in plasma volume which were not different between trails, or at 
fatigue (-4.5±3.8% in the placebo trial v -4.2±2.0% with caffeine). 
 
Hormonal Responses 
The PRL response to exercise was more pronounced in the heat (Figure 7.11) than 
when exercising at 18oC although the pattern of response, with little change in the 
early stages and then increasing rapidly to the point of fatigue, was similar in the two 
conditions (Compare Figures 7.5 and 7.11). 
 
 
Figure 7.11 Plasma prolactin response to exercise at 35°C.  Data are mean ± sem. F – indicates fatigue 
time point. Placebo trial – triangles.  Caffeine trial –circles. * indicates significant difference from 0 
time point within both trials  (P<0.05). 
 
During exercise at 35oC, PRL increased in both placebo and caffeine trials and was 
significantly higher than resting values after 10 minutes of exercise (p<0.05, 
Friedman).  No differences were found at individual time points between the caffeine 
and placebo trials (Figure 7.11). 
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7.4 DISCUSSION 
 
The results reported here confirm that caffeine reduces the subjective sensations of 
exertion and prolongs endurance when exercising at about 70% VO2max and strongly 
support previous suggestions of a possible central nervous system mechanism rather 
than a peripheral action on substrate metabolism or the metabolic cost of exercise.  
The results do not, however, support our initial hypothesis that the effects are 
mediated through hypothalamic pathways nor does caffeine appear to influence 
pathways that are sensitive to body temperature.  We postulate, therefore, that there 
are pathways leading to central fatigue in addition to those which are sensitive to core 
and skin temperature. 
 
Despite its widespread use and the general belief in the efficacy of caffeine as an 
ergogenic aid, there is relatively little quantitative information about the benefits to be 
expected, let alone its mechanism of action.  Our observation of a ~20% improvement 
in exercise duration is similar to previous reports when exercising at a similar 
intensity (Costill et al., 1978; Graham & Spriet, 1991, 1995; Pasman et al., 1995).  It 
is likely that maximal benefits of caffeine will be seen with exercise of around 70-
80% maximal aerobic capacity. Depletion of muscle glycogen is likely to be the 
limiting factor with exercise below this intensity while at higher intensities 
cardiovascular limitations and peripheral muscle fatigue will predominate.  While 
improvements with caffeine administration have been reported in these latter 
conditions, they are not always significant (Spriet, 1995).  
 
There was no evidence in the present study that caffeine altered substrate metabolism 
in any way that would lead to greater endurance.   During exercise at 18°C, and in the 
early stages of exercise at 35°C, there were significant increases in circulating free 
fatty acids which might be expected to be oxidised in working muscles and thus spare 
glycogen.  However, there were no changes in oxygen uptake or RER indicating that 
the mobilised fatty acids were not oxidised.  Previous investigations (Tarnopolsky, 
1994; Graham et al., 1998) have made similar observations which raise interesting 
questions about the control of fat metabolism in working muscles, although these are 
outside the scope of the present study.  With exercise in the heat there were 
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consistently raised blood lactate levels in the caffeine, as compared to the placebo trial 
(Figure 7.8) as has been found by others (Graham & Spriet, 1995; Jackman et al., 
1996; Laurent et al., 2000) indicating, if anything, an increased muscle 
glcyogenolysis rather than glycogen sparing.   
 
The end point of exercise for our subjects in the second experiment at 35°C occurred 
at somewhat lower values of core temperature than found by Nielsen et al. (1997) and 
Gonzalez-Alonso et al. (1999b). This may, in some part, reflect a difference between 
rectal and oesophageal sites of measurement or differences in the type of subjects 
used. In their studies, Nielsen et al. (1997) and Gonzalez-Alonso et al. (1999b) used 
subjects who were endurance trained cyclists, whilst our subjects, although generally 
fit and familiar with cycling exercise, were a more heterogeneous group.  
 
The higher core temperatures at fatigue during the caffeine trials  (Figures 7.3 & 7.7) 
were partly a function of the longer exercise duration but there is also a suggestion 
that core temperature was slightly higher throughout the exercise while taking 
caffeine.  This raises the possibility that caffeine may affect thermoregulation.  
Caffeine consumption is known to raise plasma catecholamines (Graham & Spriet, 
1995; Jackman et al., 1996; Van Soeren & Graham, 1998; Laurent et al., 2000) and 
adrenaline infusion during exercise has been shown to cause vasoconstriction in the 
skin and increase oesophageal temperature (Mora-Rodriguez et al., 1996).  Limiting 
circulation to the skin might confer some benefits in that the central blood pool would 
be preserved and the working muscles might be better perfused with oxygenated 
blood.  However it is unlikely that this explains the action of caffeine in our 
experiments since caffeine was associated with higher blood lactates which are more a 
feature of anaerobic metabolism.    
 
Exercise at 35°C in the second experiment may have lead to dehydration resulting in a 
reduction in muscle blood flow (Gonzalez-Alonso et al., 1998) and consequently 
fatigue.  This is unlikely since lactate concentrations remained stable during exercise 
and did not increase at fatigue indicating that the working muscles were not in 
metabolic crisis.  Additionally it has been shown that hyperthermia, rather than any 
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reduction of muscle blood flow, is the most important factor determining fatigue at 
high ambient temperatures (Gonzalez-Alonso et al., 1999a) 
 
The increase of circulating PRL during exercise is associated with increasing 
perceptions of exertion and it reaches its highest levels at the point of fatigue 
(Pitsiladis et al., 1998).  PRL secretion from the anterior pituitary gland is controlled 
by serotonergic and dopaminergic pathways in the hypothalamus and increases in 
blood levels are an indication of changes in hypothalamic activity (Van de Kar et al., 
1996).  Activation of hypothalamic pathways with a 5-HT agonist or reuptake 
inhibitor increases the perception of exertion and causes premature fatigue (Wilson & 
Maughan, 1992; Marvin et al., 1997).  In the former case, where PRL was measured, 
the levels were raised in parallel with the reduced exercise tolerance.  One 
physiological stimulus for PRL release appears to be an increase in core temperature 
and thus, presumably, the temperature of blood perfusing the brain, and this is also a 
powerful signal giving rise to central fatigue (Nybo & Nielsen, 2001a, b,; Chapters 2 
& 3).  However the effects of raised core temperature both on central fatigue and PRL 
secretion are modulated by skin temperature so that, for the same core temperature, 
not only does the exercise feel easier but circulating PRL is reduced when the skin 
temperature is lower (Chapters 2 & 3).   The possibility was therefore considered that 
caffeine might have similar effects on PRL release and performance to those resulting 
from skin cooling. 
 
Our first hypothesis was that the beneficial effect of caffeine are mediated by an 
action on 5-HT and DA in the hypothalamus and that this would be evident as a 
decrease in the secretion of PRL, possibly changing the relationship between PRL and 
core temperature, as is seen with exercise in cool ambient conditions (Chapters 2 & 
3).   The data (Figures 7.5 & 7.11) are quite clear, however, that although caffeine 
improved exercise performance it did not reduce the release of PRL in response to 
exercise in either the cool or hot conditions.  If anything, PRL release tended to be 
higher with caffeine.  The implication of this finding is that caffeine does not act by 
affecting the function of pathways in the hypothalamus which regulate the release of 
PRL from the anterior pituitary. 
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Our second hypothesis arose from the observations that body temperature is a major 
factor causing central fatigue.  We argued that the action of caffeine would be most 
apparent during exercise in the heat where central fatigue is most pronounced.  The 
action of caffeine might be to modify the pathways which are involved in sensing 
body temperature. However, again, the data clearly contradict our hypothesis.  The 
improvement with caffeine was 23% with exercise in the cool environment and 18% 
when working in the heat.   Time to fatigue is not an ideal measure and there were 
several instances where subjects were stopped at 90 minutes before they reached the 
point of volitional fatigue.  It is possible that, had these subjects been allowed to 
continue to exhaustion, slightly different values would have been obtained for the 
effects of caffeine. However, it is most unlikely that it would alter the general 
conclusion that the effects of caffeine on exercise performance are no greater at high 
as compared with low ambient temperatures.   
 
The negative findings in this study lead to an important conclusion.  If caffeine does 
not act to improve performance by an action on hypothalamic pathways which 
respond to core and skin temperature, then there must be at least one other mechanism 
that is activated during exercise and leads to a decrease in the desire or ability to 
continue exercising. Clues as to the nature of this, or these, pathways come from the 
pharmacological action of caffeine in the central nervous system.  Caffeine is a 
purinergic antagonist competing with adenosine at A2A receptors in the brain (Garrett 
& Griffiths, 1997).  Adenosine inhibits the release of dopamine and caffeine therefore 
enhances its release and, in this respect, has a similar effects to those of amphetamine 
and cocaine, although these latter agents act as re-uptake inhibitors.  Amphetamine 
and cocaine are widely thought to improve work capacity, although there is very little 
published evidence to substantiate this belief, and their principle mode of action is to 
increase dopamine release in the nucleus accumbens thereby providing a reward 
stimulus.   In addition to the nucleus accumbens, A2A receptors are also present in the 
striatum (Ferre et al., 1997) and it is possible therefore that caffeine may have an 
action on the basal ganglia. Caffeine has been shown to have a major protective effect 
against the development of Parkinson’s symptoms in human populations and in 
experimental animal models (Ross & Petrovitch, 2001).   A2A receptors are 
particularly abundant in the nucleus accumbens and striatum and it is possible that 
caffeine may act by providing a reward stimulus at the nucleus accumbens or by 
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facilitating activity of the basal ganglia.  These considerations point to a new direction 
for investigations of central fatigue. 
 
In summary, the results presented show that caffeine has a significant effect both on 
performance and the perception of effort during exercise and this appears not to be the 
result of a change in substrate utilisation. The lack of effect on PRL release suggests 
that caffeine is not acting via hypothalamic pathways sensitive to core or skin 
temperature.  The refutation of our two hypotheses raises the possibility of a 
mechanism of central fatigue which is in addition to those involving hypothalamic 
pathways and it is suggested that pathways involving the nucleus accumbens or basal 
ganglia warrant further investigation. 
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Chapter 8 
 
 
GENERAL DISCUSSION 
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The experiments presented within the body of this thesis confirm the findings of 
Nielsen et al. (Nielsen et al., 1999; Nielsen et al., 2001; Nybo & Nielsen, 2001) and 
Pitsiladis et al. (Pitsiladis et al., 2002) that fatigue in the heat is largely a central 
process. The new aspects of the work have been to demonstrate that the perception of 
exertion is related to the release of prolactin, implicating the hypothalamus in the 
central mechanism and this is most clearly seen in the experiments at different 
ambient temperatures.  While Brisson et al. (Brisson et al., 1987; Brisson et al., 1989) 
were the first to show the influence of skin temperature on prolactin secretion, the 
work in this thesis has shown that a cool environment has similar effects on 
perception and endurance.  
 
The results discussed in Chapter 2 show that the increased perception of exertion 
during exercise in the heat is not only related to the increased heart rate, which is a 
consequence of thermoregulatory adjustments, but also to increases in skin and core 
temperature. These temperature signals are most likely integrated at the level of the 
brain stem and feed in to hypothalamic control of thermoregulatory responses.  The 
release of the pituitary hormone PRL into the blood seems also to be under the 
influence of an integration of temperature signals, possibly in the hypothalamus and 
under the control of 5-HT and DA pathways.  It is interesting to find that growth 
hormone and cortisol, other hormones under the control of the hypothalamus, are not 
subject to the same integrative effect of skin and core temperature. 
 
There is little doubt that 5-HT and DA are involved in thermoregulation and the 
control of prolactin release and it is most likely that these neurotransmitters are also 
involved with pathways concerned with the perception of exertion and exercise 
endurance.  Further work needs to be carried out in this area, possibly using PET or f-
MRI scanning, to clarify the role of 5-HT in thermoregulation and to look at the 
changes in brain 5-HT and DA concentrations in response to heat exposure in 
humans. A large part of the work described here has been to determine the relative 
contributions of serotonergic and dopaminergic pathways in the control of prolactin 
release.  
 
Studies in the past have looked at the control of prolactin release by use of 
neuroendocrine challenges with pharmacological agents such as buspirone and 
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measuring the PRL response in the blood. However, the work described in Chapter 4 
shows that the response to buspirone is confused by the PRL releasing action of 
buspirone being on average only ~50% 5-HT1A with the remainder attributable to 
non-5-HT1A mechanisms, probably of a dopaminergic nature.  The inter-individual 
variation in the proportion of the prolactin response attributed to serotonergic 
stimulation is considerable. Use of the 5-HT1A antagonist, pindolol, may be of use in 
obtaining a clearer picture of individual differences in 5-HT and DA sensitivity. The 
prolactin release in response to passive heat exposure seems to be more the result of a 
withdrawal of DA inhibition than a stimulation of 5-HT activity (Chapter 6). 
 
Further work looking at the roles of 5-HT and DA mechanisms controlling prolactin 
release is needed to confirm the findings of Chapters 4 and 6, although we are 
currently limited by the selectivity of pharmacological tools and an inability to easily 
measure central changes in brain 5-HT and DA concentrations directly. 
 
Chapter 5, in which the combination of buspirone and pindolol was used to assess the 
separate sensitivity of the 5-HT and DA pathways and to relate this to exercise 
capacity in the heat provides an insight into the importance of these neurotransmitters 
in fatigue during exercise in the heat.  There was wide inter-subject variation in the 
prolactin response to buspirone and in the size of the separate 5-HT and DA 
components.  The DA component strongly correlated both with exercise duration and 
rate of rise of core temperature suggesting that high activity of the dopaminergic 
pathways in the hypothalamus is a good predictor of exercise tolerance in the heat, 
possibly as the result of more effective heat loss. Further support for this notion 
comes from work in animals that has shown increases in brain DA to be involved in 
thermoregulatory heat loss mechanisms. This has implications for both athletes and 
individuals in hot environments as the ability to tolerate a high core temperature 
coupled with poor thermoregulation may result in individuals being at risk of 
exertional heat illness. 
 
In terms of 5-HT and DA mechanisms and pathways concerned with fatigue in the 
heat, exercise may be an overly complicated and inefficient way of raising body 
temperature and all the other factors associated with prolonged exercise (e.g. pain, 
boredom etc) that affect performance are likely to increase the variance of the results 
 202
and reduce the power of the experiment. In this respect the use of passive heating may 
provide a clearer method to investigate the pathways involved. Chapter 6 produced 
unexpected results in that it appears the PRL release associated with heat stress has 
virtually no 5-HT component and may be the result of a withdrawal of DA inhibition 
at a time when brain DA would be expected to increase.  This may to some extent be 
explained by differential pre and post-synaptic actions of pindolol. 
 
The dosing regimen used for pindolol in this thesis results in a roughly ~44% 
occupancy at post-synaptic 5-HT1A receptors (Rabiner et al., 2000). This is by no 
means a total blockade of post-synaptic receptors and a higher pre-synaptic receptor 
autoreceptor occupation (64%) at this dose has recently been reported (Martinez et al., 
2001).  The ~44% occupancy at the post-synaptic receptors that mediate PRL release 
suggests that a 5-HT1A PRL releasing mechanism may still be functioning. A 
significant pre-synaptic 5-HT1A autoreceptor occupancy would result in an enhanced 
5-HT neurotransmission (Rabiner et al., 2000). The result of this enhanced synaptic 
release of 5-HT and the relatively small post-synaptic antagonist action of pindolol 
(accounting for only a ~44% receptor occupancy) may account for the lack of change 
seen in the PRL response to heat exposure. Nevertheless, we have shown pindolol to 
be effective in blocking the 5-HT1A agonist action of buspirone and it would be a 
remarkable situation if the pre and post-synaptic actions during passive heating were 
to cancel each other out exactly. 
 
Caffeine has a significant action potentiating the release of DA in the brain through 
removal of an inhibitory action of purinergic 2A receptors on DA release.  Results in 
Chapter 7 show that caffeine improves exercise capacity in both normal and hot 
environments without any peripheral changes that would indicate the existence of a 
peripheral ergogenic mechanism. However, the measurement of blood PRL showed 
no indication of changes in central 5-HT or DA activity in response to caffeine.  It is 
possible, therefore, that caffeine acts in a totally different area of the brain to the 
hypothalamus. It may act in a similar way to cocaine and amphetamine by providing a 
reward stimulus at the nucleus accumbens or by facilitating motor output through 
actions on the nigrostriatal pathway of the basal ganglia.  Certainly both of these 
suggestions would be in line with the observed reduction in perception of exertion 
after caffeine ingestion. 
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The increases in perceived exertion with prolonged exercise may be the result of 
reductions in voluntary muscle activation as the result of a central inhibition of motor 
output.  Increases in motor output from the cortex required to overcome this inhibition 
probably result in the increases in perceived exertion seen during exercise, especially 
during exercise in the heat. The basal ganglia ‘gates’ motor output from the brain for 
tasks requiring coordination of different muscle groups and may therefore be involved 
in these feelings of increased exertion and fatigue. 
 
The basal ganglia is thought to influence not only motor control, but also several other 
cognitive and limbic functions (Middleton & Strick, 2000).  Indeed Nauta, (1986) 
suggests that the basal ganglia provide ‘part of the neural substrate by which 
interoceptive or motivational influences can be channelled in to the motor system’.  
The same author proposed that specific pathways exist linking the limbic system and 
motor interaction in the basal ganglia in which dopaminergic and ascending 
serotonergic pathways were of prime importance. 
 
The limbic system of the brain is associated with feelings of motivation and fatigue 
(Jacobs & Azmitha, 1992) and it is possible that through pathways linking it with the 
basal ganglia, motor output is modulated by motivation (Nauta, 1986).  Evidence of 
this is seen in patients who have bilateral lesions of the basal ganglia separating it 
from the limbic system. In one case report, a patient when asked why he stayed in bed 
for half an hour with an unlit cigarette in his mouth, replied ‘I am waiting for a light’ 
(Ali-Cherif et al., 1984), for him there was no motivation to perform the movement to 
light his cigarette.  This limbic-to-motor link within the basal ganglia involving a 
neurotransmitter (e.g. dopamine and/or serotonin) is further supported by clinical 
observations in Parkinsonian patients and depressives (Chaudhuri & Behan, 2000).  In 
these conditions a disturbance to dopamine or serotonin in the brain is usually 
manifested as a disinclination to move (Chaudhuri & Behan, 2000). 
 
It is generally accepted that the limbic system functions to control and regulate 
emotional states, motivation, learning and memory.  Behaviours such as feeding, 
drinking, sexual activity, sleep are all coded in the limbic system and another 
important behaviour is that of keeping warm and avoiding extreme temperatures. 
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Alongside this behavioural coding are those for experiences of pleasure and 
punishment both of which are associated with motivation. An example is obtaining 
warmth in a cold environment which is pleasurable as is being cooled in a hot 
environment. We tend to perform behaviours because we are rewarded by them i.e. 
they make us feel better and as a result we are motivated to do them.  It is possible 
that the eventual reason why we cease exercising is the reward that is gained through 
stopping (i.e. heat production drops, we can move to a cooler environment). 
  
5-HT and DA are only two of a number of neurotransmitters in the brain that are 
involved in controlling movement, thermoregulation and other autonomic responses. 
A major inhibitory neurotransmitter in the brain is γ–aminobutyric acid (GABA) and 
the importance of this neurotransmitter within the mammalian brain is unquestionable 
(Malcangio & Bowery, 1996).  Studies that have assessed central fatigue using 
double-pulse TMS found reduced intracortical facilitation after fatiguing exercise 
(Tergau et al., 2000). Extensive pharmacological studies have suggested that 
intracortical inhibition and facilitation are mainly controlled by GABAergic 
mechanisms (Ziemann et al., 1996) and it is likely that the change in intracortical 
facilitation seen at fatigue is the result of changes in these GABAergic mechanisms 
(Tergau et al., 2000).  Other glutamaminergic agents as well as dopaminergic and 
antidopaminergic drugs are also through to affect motor cortex neurones through 
GABAergic mechanisms (Ziemann et al., 1997; Ziemann et al., 1998).  It is 
interesting to note that dopamine agonists were found to increase intracortical 
inhibition (Ziemann et al., 1997).  Motor cortical excitability is also affected by the 5-
HT1B/1D receptor agonist zolmitriptan which has been found to reduce excitability as 
assessed by TMS (Werhahn et al., 1998).  GABA is one of a number of other 
neurotransmitters that may form an integrated fatigue mechanism involving 5-HT and 
DA. As easier and quicker techniques are developed for investigating in vivo changes 
within the human brain during exercise and heat exposure a clearer picture of central 
fatigue mechanisms will undoubtedly evolve probably involving a combination of 
neurotransmitters and neuronal pathways. 
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8.1 Future work 
 
At the end of any series of experiments there are always further questions to be 
answered or new avenues to explore, outlined below are areas for further work and 
new research.  
 
• The results of Chapter 5 could be expanded upon by the use of DA antagonists 
and agonists to further explore the relationships between function of the DA 
pathways and exercise tolerance in the heat. 
 
• Whilst several training studies have looked at relatively short-term training 
effects on the function of the 5-HT system, no studies have yet looked at any 
possibly changes that may occur in the DA system in either short or long-term 
training.  
 
• It is possibly that the adaptations seen with heat acclimation may be related to 
changes in 5-HT and DA function within the hypothalamus and this is an 
important area to be looked at using the buspirone challenge in conjunction 
with pindolol. 
 
• The precise roles of DA and 5-HT in prolactin release during exercise and in 
passive heating experiments need further investigation.  Whether DA agonists 
block the prolactin response to heat is of great interest as is any subsequent 
effect on thermoregulation and perception. 
 
• Does passive heating really mimic exercise in terms of changes in perception 
of exertion, EEG and ability to voluntarily activate muscle during fatiguing 
contractions? 
 
• The finding that caffeine does not alter hypothalamic 5-HT or DA function 
opens up another possible range of mechanisms leading to fatigue. Caffeine 
may act upon the basal ganglia to facilitate motor function or provide a reward 
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stimulus at the nucleus accumbens. In this respect a comparison with the 
effects of amphetamine and cocaine would be interesting and informative. 
 
• If there is another mechanism of central fatigue involving the basal ganglia or 
nucleus accumbens, what is the stimulus that activates this fatigue pathway? 
Potential candidates include pain and feed-forward signals for motor 
programs. Basal ganglia function may be evaluated by tests involving rapid 
and coordinated movements at rest and at fatigue. It is possible that any action 
of the nucleus accumbens may be blocked by administration of the GABA 
agonist Baclofen. 
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